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Poxviruses employ sophisticated signaling pathways that thwart cellular defense
mechanisms and simultaneously ensure viral factors are modulated properly. Yet, our
understanding of these complex signaling networks are incomplete. For example, the
vaccinia B1 kinase plays a vital role in inactivating the cellular antiviral factor BAF, and
is suggested to orchestrate other pathways. B1 is highly conserved among poxviruses and
exhibits a remarkable degree of similarity to VRKs, a family of cellular kinases,
suggesting that the viral enzyme has evolved to mimic VRK activity. Indeed, B1 and
VRKs have been demonstrated to target a shared substrate, the DNA binding protein
BAF, elucidating a signaling pathway important for mitosis and the antiviral response.
Our research further characterized the role of B1 during vaccinia infection to gain novel
insights into its regulation and integration with cellular signaling pathways.
We began by constructing and characterizing the first B1 deletion virus (ΔB1).
Then using this virus, we tested the hypothesis that cellular VRKs can complement B1
function, and discovered a VRK2 role in facilitating DNA replication in the absence of
B1. Study of the VRK2 mechanism revealed that B1 and VRK2 mediate DNA
replication via an additional pathway that is BAF independent.
We also utilized the ΔB1 virus in an experimental evolution assay to perform an
unbiased search for suppressor mutations and identify novel pathways involving B1.

Interestingly, our characterization of the adapted viruses reveals that mutations
correlating with a loss of function of the vaccinia B12 pseudokinase provide a striking
fitness enhancement to this virus. Next, B12 characterization showed a nuclear
localization, unique for poxvirus proteins, that is related to its repressive function. Our
data indicate that B12 is not a global repressor, but inhibits vaccinia replication in the
absence of the B1 kinase. The mechanism of B12 partially depends on suppression of
BAF antiviral activity. However, the parallel B12 pathway to restrict virus replication is
less clear. Together, our studies of B1 and B12 present novel evidence that a paralogous
kinase-pseudokinase pair can exhibit a unique epistatic relationship in a virus, and
orchestrate yet-to-be-discovered nuclear events during infection.
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CHAPTER 1
INTRODUCTION
This Ph.D. dissertation thesis will introduce the vaccinia virus life cycle and recurring
themes of viral mimicry of host factors and modulators of vaccinia DNA replication. The
aims addressed include 1) Determine how cellular vaccinia-related kinases (VRKs)
complement functionally for vaccinia B1 kinase and 2) Identify viral factors capable of
regulating the signaling axis of host barrier-to-autointegration factor (BAF) antiviral
activity and vaccinia B1 kinase countermeasure to affect DNA replication. Addressing
these gaps in knowledge will inform boarder themes of kinase contributions to virus
replication and host range specificity, as well as, virus countermeasures to DNA-targeting
BAF antiviral activity against virus replication.
1.1. POXVIRIDAE FAMILY
Poxviruses are large double-stranded DNA viruses, which carry out all stages of
their lifecycle in the cytoplasm of infected cells (1). Vaccinia virus, the prototypical
poxvirus, has a genome 195 kb in size, which encodes approximately 200 proteins (2).
These proteins are expressed in a temporally regulated cascade of early, intermediate, and
late stages of gene expression. Close to half of poxviral proteins are expressed early in
infection and include virally encoded DNA replication machinery and viral transcription
factors (2). Also among the early proteins are numerous viral factors capable of
interacting with host proteins and modulating host signaling cascades (3). Studies of the
host mechanisms targeted by vaccinia proteins have provided fascinating insights into
how cellular signaling can be redirected to create an environment favorable to an
infecting pathogen.
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1.1.A. History
The family Poxviridae classifies a group of cytoplasmic replicating viruses with
species specific genera in vertebrae and insect hosts. Two subfamilies include viruses that
are human pathogens; Orthopoxvirus variola and Mulluscipoxvirus molluscum
contagiosum. The variola virus is the etiological agent of smallpox. The smallpox
pathology in humans is characterized by a skin rash. However, at the time of rash
presentation the virus had already spread from the typical respiratory site of inoculation
into the blood and specific organs before epithelial presentation between 13 - 24 days
later. Ulcers form at the mucosal membranes and raised pox on the skin develops.
Resolution of the infection occurs for most, although the mortality rate is high, exceeding
30-40%. Predominantly two Orthopoxviruses, cowpox virus and vaccinia virus were used
to vaccinate against smallpox, and successful eradication was achieved by 1980
following a smallpox eradication program. Despite eradication of variola virus from
circulation, instances of zoonosis occur most commonly for monkeypox virus to humans.
Additionally, the risk of variola virus use as a bioterrorism threat supports the continued
research of poxviruses and development of better protective vaccines against poxviruses.
The historical significance of poxviruses is also attributed to the discovery of
vaccinia virus and use of this virus, in conjunction with cowpox virus, for vaccination
against smallpox and inform insights into the research of mammalian viruses. Vaccinia
virus was the first animal virus seen microscopically, grown in tissue culture, quantified
via titration and chemically analyzed. This virus has been used as the prototypical
poxvirus and contributed to our understanding of the poxvirus life cycle and many
themes including, but not limited to, host-pathogen interaction at the cellular and
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molecular levels. Furthermore, use of vaccinia virus and relative, myxoma virus as
genetically engineered oncolytic virotherapeutics has immense promise (4). Specifically,
myxoma virus has a limited host range that restricts replication in human cells, although
permits replication in many cancer cell lines (5) likely due to compromised innate
signaling. Attenuated viruses have been generated with a variety of trans genes, yet the
most promising direction is the combination of virotherapy and immunotherapy for
cancer treatment. Specifically, viruses can be used to deliver a transgene directly to
cancer cells and create an immunogenic environment via cell lysis and activation of the
immune response cancer cell antigens. Transitioning into the molecular mechanism of
host-pathogen interaction, the intracellular signaling pathways that occur during poxvirus
infection can be used to inform vaccine and virotherapy design through the study of
intracellular pathways that can be manipulated to improve activation of immune cells and
antigen presentation.
1.1.B. Genome
The vaccinia virus genome is 195 KB in size, which is considered a large DNA
virus. The double-stranded DNA genome is composed of two linear strands of DNA that
are joined by AT-rich tandem repeat sequence, termed inverted terminal repeats (ITRs).
The ITRs form a loop structure at the terminus of each linear DNA strand, aligning and
connecting the two DNA strands and forming a closed loop lacking exposed DNA ends.
These ITRs base pair due to the repeat sequence, although there are a number of single or
double unpaired bases within this region. It is possible that having unpaired bases in the
ITRs contributes to DNA condensation and alternatively a nick DNA site for initiation of
DNA replication.
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Another contributor of DNA compaction is the percentage of guanine and
cytosine base pairs over adenine and thymine pairing, using three or two hydrogen bonds
respectively. The human genome has a large range of average GC content between 35%
and 60% in a 100 KB fragment (6). The herpes simplex virus dsDNA genome has a
relatively high GC content. Lower GC content was identified in intergenic regions and
corresponded with enrichment of retrotranspostition events, suggesting that a high GC
content may protect viral genes from invasion by mobile genetic elements (7). Viruses
within the Poxviridae family range in GC content between ~18% and 64% (8).
Orthopoxvirus genus have about 36% GC richness, while Parapoxvirus genus have about
64% genome GC content (8). It is unclear why such a variation in GC content exists for
poxviruses or how viral and cellular factors contributing to gene expression and
replication may select for higher or lower GC content. To speculate briefly, there is a
curious correlation between high GC content in poxviruses and the absence of viral B1
kinase known to regulate DNA condensation factor, BAF. Specifically, B1 may allow for
a AT-rich genome, which is favorable for recombination or invading transposons. While
poxviruses do differ by much more than solely the presence or absence of the B1 kinase
for low and high GC containing viruses, the question of if B1 contributes to a flexible
genome and enhanced DNA fragment scavenging is quite a compelling idea.
The coding capacity of poxviruses is quite extensive. The cowpox virus genome
includes the core poxvirus genes in addition to all the variable genes in other
Orthopoxviruses. For this reason, the cowpox virus is thought to be the closest genetic
match to the ancestor poxvirus for this genus. The other Orthopoxviruses have smaller
genomes than cowpox (Fig 1.1) and these genomes are marked with single nucleotide
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Fig 1.1. Orthopoxvirus genome length. The genome size for a few Orthopoxviruses is
illustrated to emphasize that cowpox virus contains all conserved core genes and less
conserved genes present in all other Orthopoxviruses. This indicates that loss of coding
sequence has resulted for the other Orthopoxviruses, which aligns with preliminary data
supporting gene loss as a poxvirus adaptation scheme. The genome sequence lengths
were taken from NCBκGenome database.
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polymorphisms (SNPs) and gene fragmentations likely caused by insertion/ deletion
(indel) mutations and gene deletions (9). Interestingly, ectermelia and camelpox viruses
have between 8-10% base pair loss as compared to coxpox virus (Fig 1.1). Taterpox,
monkeypox, and vaccinia are reduced by 13-15% coding sequence, while the variola
virus genome has 18.6% fewer base pairs than cowpox virus (Fig 1.1). It is tantalizing to
ponder why gene loss is observed. Possibly to overcome changes in immune factors
between species or utilize cellular factors more efficiently due to initial gene loss events?
Gene loss as an adaptive mechanism for poxviruses is indeed supported (9, 10), and begs
the question, are poxviruses limited by this adaptation mechanism to a single host with
improbable cross species infection?
To argue against restrictive outcome of gene loss adaptation scheme, suppression
of growth defective phenotypes for other vaccinia mutants occurs via rapid poxviral gene
amplification and gain of function mutations (11, 12). These examples illustrate gene loss
or amplification as dynamic mechanisms of poxvirus adaptation, yet the consistent
reduction of coding sequence for other Orthopoxviruses as compared to cowpox virus
could hint at a higher frequency of gene loss over gene amplification adaptation.
1.1.C. Vaccinia virus life cycle
Being the prototypical poxvirus, vaccinia virus life cycle has been well
characterized, while gaps in knowledge continue to be studied. Such areas of uncertainty
will be indicated throughout this section on the viral life cycle. To begin, the vaccinia
virus virion entry into the cell occurs by endocytosis or via a binding and fusion
mechanism (Fig 1.2-1) between entry-fusion proteins located on the mature virion
membrane and cellular glycosaminoglycans on the plasma membrane. The specific
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binding receptors on the cell are not known. However, viral entry does not require tested
glycosaminoglycans, suggesting entry mechanisms independent of fusogenic properties
exist. Endosomal acidification (13) in combination with actin and ezrin-containing
protrusions (14) facilitate entry, indicating an endocytosis mechanism is employed as an
alternative entry method. Following entry, the viral core along with viral proteins
packaged into the lateral bodies situated on either side of the viral core are released into
the cytosol. The core changes in conformation (Fig 1.2-2) and is trafficked along the
microtubules of the cell near to the endoplasmic reticulum (15). The core contains the
viral genome, a DNA-dependent RNA polymerase, early transcription factors, and other
proteins required for transcription. Furthermore, packaging of these proteins is critical,
due to early transcription occurring within the viral cores (Fig 1.2-3). These early
transcripts, capped and polyadenylated by viral proteins to resemble eukaryotic mRNA,
are extruded from the core for translation by the cellular ribosome and translational
machinery in the cytoplasm.
Next, the proteins that compose the core are degraded (Fig 1.2-4) in a process
referred to as uncoating, which describes the exposure of the viral genome from its
protective compartment. Importantly, the uncoating process requires the synthesis of
early proteins and coincides with the end of early transcription. Specifically, the core
proteins fail to be degraded without early proteins. In addition to uncoating functions,
early proteins participate in replication of the viral DNA (16), restriction of immune
signaling (17, 18), and transcription of intermediate genes (19). The regulation of gene
expression is coordinated by different promoter sequences and
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Fig 1.2. Vaccinia virus life cycle. Vaccinia virus entry into a host cell occurs via a
binding and fusion action [1]. The core released into the cytoplasm is trafficked along
microtubules and undergoes a conformational change [2]. Following this step, early gene
expression occurs within the core [3], leading to expression of gene required for
uncoating [4]. At this time, the viral genome near ER membranes is incorporated into
replication factories. These replication factories are sites of DNA replication [5],
intermediate gene expression [6] and late gene expression [7]. Following these stages, the
virion is assembled [8], undergoes morphogenesis [9] into a mature virion, which can exit
the cell via cell lysis. Alternatively, wrapping of the mature virions in the trans Golgi
membrane [10] produces an enveloped mature virion that can bud from the cell [11].
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transcription factors, which are synthesized just prior to the requirement for the specific
stage of gene expression. Furthermore, rapid mRNA turnover (20, 21) enhances the
impact of these specific transcription factors, assisting in the coordinated transition to the
next stage of gene expression.
The step following uncoating orients the viral DNA into replication factories near
or consisting of ER membranes. Within these replication factories, DNA replication (Fig
1.2-5), intermediate gene expression (Fig 1.2-6), and late gene expression (Fig 1.2-7)
occurs. The replication of viral DNA is predicted to initiate at a nick in the DNA, which
allows strand displacement DNA replication. However, evidence of smaller DNA-RNA
fragments is suggestive of lagging strand synthesis. Recent discoveries of a viral primase
(22) and cellular ligase that can complement for viral ligase activity (23) support this
alternative lagging strand replication or recombination-dependent mechanism of DNA
synthesis. As replication proceeds, concatemeric structures are formed where the
synthesized DNA is linked to another DNA strand by a repeat sequence of DNA
discussed above as ITRs. The DNA concatemers must be resolved into genome unit
molecules to generate progeny virus, but this occurs at a later step.
Transcription of intermediate genes has a less specific promoter sequence than
early genes. Alternatively, the late gene promoter region is characterized by an A/T rich
core followed by a longer initiator sequence which is unique for late genes. Intermediate
genes encode a variety of proteins including late gene transcription factors, and late genes
encode proteins important for capsid formation and factors packaged into the virion to
support early transcription within the viral core (1).
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The membrane that makes the immature virion was shown to be derived from the
ER (24-27). Formation of crescent membranes has been observed (Fig 1.2-8) with a
dense nucleoprotein mass entering it to form immature virions. Interestingly before the
virions change morphologically into mature virions, the concatemeric replicated DNA
must be resolved into single genome units (28). At a point following this step, the
immature virion undergoes an alteration in morphology from a sphere to a barrel-shaped
particle (Fig 1.2-9). Morphogenesis is also characterized by the addition of membrane
proteins to the virion exterior and internal core protein processing and reorganization. At
this stage the virus can lyse the cell for release or be enveloped (Fig 1.2-10) by the trans
Gogli membrane (29, 30) and then bud from the cell (Fig 1.2-11). The budding of an
enveloped virion results in a single additional membrane for the enveloped virion as
compared to the mature virion. Furthermore, an important step in subsequent infection of
mature versus enveloped virions seems to be the removal of the single membrane
envelope before association of the virus to the cell membrane. Specifically, proteins that
reside on the mature virion membrane must be available to interact with the cell plasma
membrane for entry. Overall, the general vaccinia virus life cycle is known. However, the
molecular mechanisms to carry out this intricate process are still being revealed. The
further study of non-essential genes and identification of cellular complementary proteins
aids our discovery of essential or necessary viral protein functions.
1.1.D. Innate immunity
Poxviruses encode a number of proteins to facilitate innate and adaptive immune evasion.
This section will specifically address mechanisms of innate immunity evasion.
Poxviruses encode homologs of innate immune countermeasures, while also utilizing
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alternative mechanisms to evade the host response. The divergence in countermeasures
for poxviruses is likely due to adaptation in the various hosts.
The host detects viral DNA, RNA and responds to poxvirus infection through
multiple pattern recognition receptors (PRRs). The vaccinia virus counters signaling by
toll-like receptors (TLRs) via Bcl-2 like structured proteins (31). Other poxviruses
encode homologs to these proteins (32) and likely function to counter innate immune
signaling through TLRs as well. Sensing of viral nucleic acid through AIM2
inflammasome (33) and RNA polymerase III (34) intracellular proteins and the latter of
the two is restricted by vaccinia E3 protein. Therefore, despite providing pathogen
associated molecular patterns (PAMPs), poxviruses counter detection or signaling
through TLRs.
Downstream of TLRs, the NF-κB transcription factor complex activates in
response to sensed viral infection and coordinates expression of inflammatory genes (35).
Poxvirus infection activates NF-κB during infection as shown during infection with a
modified vaccinia Ankara virus (36). In contrast to this attenuated virus, wild-type (WT)
vaccinia virus expresses proteins that target PKR (37, 38), extracellular signal regulated
kinase 2 (ERK2) (39), and TLR adaptor proteins which are upstream viral sensors that
activate the NF-κB signaling pathway. The viral countermeasures target multiple proteins
of the signaling cascade from the TLR initiating signal. Specifically, a vaccinia virus Bcl2-like protein prevents TLRs TRAF6 and IRAK2 signaling (40-42), which is upstream of
NF-κB activation. Similarly, vaccinia virus and ORFV each express one or more viral
proteins that binds directly to IKK, which restricts NF-κB activation (43, 44).
Alternatively, molluscum contagiosum encodes a protein the increases IKK degradation
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in order to restrict NF-κB activation. Additionally, Ankryin-repeat proteins encoded by
vaccinia virus and many Orthopoxviruses interact with NF-κB, blocking NF-κB
phosphorylation and nuclear translocation. Interestingly, ORFV and myxoma virus both
express a protein that mediates this same function, although these proteins lack homology
to the Orthopoxvirus ankryin-repeat proteins.
Poxviruses also express proteins that coordinate restriction of host apoptosis
signaling. This section will highlight both extrinsic and intrinsic apoptotic pathways. The
extrinsic pathway began by ligand binding to death receptor on the plasma membrane,
signaling cascade to activate caspase 8, and subsequent caspase 3 activation. The intrinsic
pathway is mediated by changes in the mitochondria in response to a number of different
stimuli including cell cycle dysregulation, DNA damage, pathogen sensing, and hypoxia.
The signaling cascade occurs to activate caspase 9, which in turn signals for caspase 3
activation. The execution pathway follows caspase 3 activation and results in the
activation of endonuclease and protease activity, cytomorphological changes, and
formation of apoptotic bodies as reviewed (45).
The death receptors of the extrinsic apoptosis signaling pathway are inhibited by
vaccinia cytokine response modifier A (CrmA) or SPI-2 (46), a viral protein with
homology to cellular serine protease inhibitor (SPI) superfamily. Orthopoxvirus
CrmA/SPI-2 also has a restrictive function on caspase 8 activation (47, 48), downstream
of the death receptor signaling. The molluscum contagium virus encodes two proteins
with death-effector domains (DEDs), one of which can interact with FADD and caspases
(49). Interestingly, despite having restrictive properties on apoptosis, the DED domains
were not required for apoptosis restriction (50). Alternatively, interaction with the
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inhibitor of κB kinase (IKK) was discovered (51), yet confirmation of this interaction as
essential for repressing apoptosis has not been published.
The intrinsic pathway of apoptosis signaling is targeted by viral factors as well.
Signaling of apoptosis through the mitochondria includes cytochrome C release from the
mitochondria to activate caspase 9. The Orthopoxvirus Bcl-2-like proteins discussed in
NF-κB countermeasures are also able to restrict cytochrome release in addition to prevent
activation of pro-apoptotic proteins, Bak and Bax. Separate from the Bcl-2-like proteins,
vaccinia expresses a multifunctional anti-apoptotic protein that can restrict caspase 9
activation and a recent discovery uncovered a role of vaccinia protein to repress the
apoptosome and prevent caspase 9 activation (52). Other poxvirus proteins have been
shown to restrict induction of apoptosis through both extrinsic and intrinsic pathways,
although the specific molecular mechanism is uncharacterized.
Poxviruses, incite proteins from their viral repertoire to counteract host anti-viral
signaling through PRRs, NK-κB, apoptosis, and others not summarized here. The
interplay between host-virus interactions has fostered evolution of immune response
factors and viral countermeasures. Specifically, poxviruses often have redundant
countermeasures to antiviral host defense measures as shown by many of these proteins
being non-essential when deleted signally and evidence of multiple proteins targeting the
same signaling pathway. Furthermore, co-evolution is apparent between virus and host,
as poxviruses often mimic host factors in order to bind and restrict host antiviral
signaling.
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1.1.E. Viral mimicry elicited for counteracting innate immunity
The examples of viral mimicry are most apparent for viral factors that counter the
host anti-viral response, although other examples exist. A well characterized group of
virus mimics is the Bcl-2 like proteins that modulate apoptosis signaling as recently
reviewed (31, 32). Multiple poxviruses encode Bcl-2 like proteins that are not always
similar in the amino acid sequence to the mammalian Bcl-2 proteins, however share
structurally similar protein folds and conserved domains (53). These Bcl-2 like proteins
bind to mammalian Bcl-2 proteins to restrict cell death signaling by pro-apoptotic
proteins (54-57). Alternatively, other viral Bcl-2 like proteins restrict signaling through
TLRs to activate NF-κB (40, 41, 58-62). This is a clear example of how viral homologs
of cellular factors are strategically used to disassemble the host innate immune response
to poxvirus infection.
A more recent finding was the molecular mimicry of the cellular inhibitor of κB
(IκB)α by a vaccinia virus protein (63). The impact of the viral IκBα mimic is the
restricted binding of the cellular factor to the E3 ubiquitin ligase for ubiquitination and
degradation. The blocked degradation of IκBα allows for the IκBα-NFκB interaction to
be maintained, resulting in retention of NFκB in the cytoplasm and the absence of
inflammatory gene expression through NFκB. This viral mimic therefore competes with
the cellular homolog for binding to a shared substrate as a countermeasure to the host
anti-viral signaling.
Together these viral mimics illustrate how the virus can manipulate the host
antiviral response. Specifically, viral proteins with structural or sequence homology and
conserved interaction domains as compared to host proteins allows for sequestering of
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pro-apoptotic proteins or competition between factors to mediate restricted host
responses. Therefore, viral mimicry is a useful mechanism of evading the host immune
response.
1.2. VACCINIA B1 KINASE VIRUS MIMICRY OF HOST VACCINIARELATED KINASES
Protein kinases regulate the function of a large fraction of cellular proteins,
governing numerous molecular processes (64-66). However, much remains unknown
about how this class of proteins is regulated and what evolutionary mechanisms may
have driven their conservation in all kingdoms of life as well as viruses. Investigation of
B1 and F10 kinases and H1 phosphatase encoded by poxviruses has provided fascinating
insights into how these factors dysregulate host signaling pathways and orchestrate viral
protein function. Expressed early during infection, the product of the vaccinia B1R gene
encodes the B1 Ser/Thr kinase vital for productive infection with a clear role in impairing
at least one facet of the host antiviral response (67-69). B1 homologs are highly
conserved within the members of the Poxviridae family that infect mammals, with the
only exceptions being the Molluscipoxvirus and Parapoxvirus genera (Fig 1.3).
Interestingly, a group of eukaryotic kinases have homology (~40% amino acid identity)
to the vaccinia B1 protein (70-73). These proteins are named vaccinia related kinases
(VRKs) and have been found to share at least one common substrate with B1,
demonstrating that the B1/VRK enzymes represent an intersection of viral and host
signaling pathways and an example of viral mimicry of a cellular factor.
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Fig 1.3. Conservation of B1 kinase and B12 pseudokinase in Poxviridae family. The
conservation of the B1R (red) and B12R (blue) genes is overlaid on the Poxviridae family
phylogenetic tree generated in Hughes et al (74). A dotted black line is depicted for the
variola virus B12R gene to illustrate that the 5’ end of the gene is present in the virus,
despite the 3’ end being truncated and not predicted to express a protein.
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1.2.A. Vaccinia virus B1 kinase
The vaccinia B1 protein kinase is essential for productive infection and has a clear
role in restricting at least one intrinsic immune factor. Much of what we know regarding
the function of B1 is based on studies of temperature-sensitive mutant viruses (Cts2 and
Cts25) with point mutations in the B1 locus (67, 68). Biochemical and genetic analyses
of these mutant viruses and kinases indicates that during infection the altered proteins are
expressed, but are considerably more labile than wild-type B1, and have severely reduced
catalytic activity (75). Phenotypically, progeny of these B1-deficient viruses are
markedly reduced in number during infection at non-permissive temperatures, due to
critical defects in viral DNA replication (67, 75). B1 known signaling is summarized
(Fig 1.4). Importantly, while wild-type B1 is vital to productive infection in all cell lines
tested to date, the severity of the Cts2 virus phenotype is cell type dependent (68, 76, 77).
This suggests that functional activity of the mutant B1 protein and/or its substrates may
be impacted by host enzymes, which may partially complement for B1 in some cell types.
Furthermore, to ensure replication of the vaccinia genome, it is critical that B1
phosphorylate the cellular protein BAF, encoded by the BANF1 gene. BAF is a highly
conserved DNA-binding protein with essential cellular functions related to maintaining
genomic integrity via diverse pathways (78). For example, BAF is capable of
intercepting cytoplasmic DNA and assembling higher-order DNA-protein assemblies (79,
80). This allows BAF to strongly inhibit vaccinia virus DNA replication (69) and
intermediate transcription (81). Importantly, this host defense activity of BAF against
vaccinia virus is dependent on its DNA-binding property, which can be blocked through
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Fig 1.4. Signaling pathways of VRK1, VRK2 and B1 kinases. The signaling pathways
for the cellular vaccinia-related kinase 1 and 2 are compared to the vaccinia virus B1
homolog. The VRK1 signaling image was borrowed from a VRK1 review article (82).
The VRK2 and B1 signaling pathways were generated from primary literature as
referenced specifically in the body of the text.
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phosphorylation mediated by B1 (69, 83), thus allowing poxvirus DNA replication to
proceed.
Although BAF phosphorylation by B1 clearly enhances viral fitness, genetic and
biochemical studies indicate that B1 likely contributes to poxviral replication via other
pathways as well. For example, RACK1 (receptor for activated C kinase) is
phosphorylated in a B1 dependent manner, triggering a selective advantage for translation
of viral RNAs that is postulated to enhance viral fitness late in infection (84). Some other
known substrates of the B1 kinase include the ribosomal Sa and S2 proteins (85) as well
as the viral H5 multi-functional protein (86, 87), each of which can be directly
phosphorylated by B1 in vitro and is modified in a B1-dependent manner in infected
cells. However, although it has been known for some time that these proteins are
substrates of B1, whether their phosphorylation by B1 is beneficial during the poxvirus
lifecycle remains unclear.
1.2.B. Cellular vaccinia-related kinases (VRKs)
The casein family of kinases includes the vaccinia virus related kinases (VRKs)
VRK1, VRK2, and VRK3, which are highly conserved in vertebrates and a single VRK
protein in Drosophila melanogaster and Caenorhabditis elegans (88, 89). The discovery
that this group of eukaryotic Ser/Thr kinases have homology (~40% identity) to the
vaccinia B1 gene led them to be named vaccinia virus-related kinases (VRKs) (70-72).
These kinases are constitutively expressed in a range of cell types (90) and have high
sequence conservation between mouse and human homologs (72). These are typical
criteria of essential and/or impactful cellular factors as indicated by selected conservation
despite changing evolutionary pressures. Furthermore, these kinases have clear sequence
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conservation within the domains required for kinase activity (72), potentially indicative
of overlapping substrates. Other regions of the VRKs are unique and are responsible for
directing distinct subcellular localizations and functions. For example, VRK1 is
predominantly located in the nucleus while the major isoform of VRK2 is associated with
the endoplasmic reticulum and nuclear envelope (72, 91). Importantly, the divergence of
these kinases to localize in separate compartments will also impact the regulation of
shared substrates.
The majority of research has focused on the role of VRK1 in the nucleus to
regulate factors contributing to cell cycle progression and mediate upstream signaling to
inhibit apoptosis as summarized (Fig 1.4). However, there is less known about the role of
VRK2 in the cytoplasmic compartment. The signaling pathways regulated by VRK2 are
summarized in Fig 1.4. Both VRK1 and VRK2 transcripts were associated with fetalspecific genes upregulated in high proliferative cells (70), indicative of kinase functions
during embryonic development. Furthermore, our attempts to deplete VRK1 from a
VRK2 knockout cell line resulted in cell death, and single VRK1 knockouts result in
infertility (88, 92). Together, research of the VRKs support critical roles for cell growth
and organism procreation. Interestingly, both VRK1 and VRK2 possess strong catalytic
activity found to modulate cellular processes including mitosis and apoptosis via multiple
substrates (89, 93-95). It has also been demonstrated that VRK2 limits cell death during
Epstein-Barr Virus (EBV) infection (96) and delays myxoma replication in a breast
cancer cell line (97), thus providing other examples that VRKs may regulate pathways
important during viral infection.
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Importantly, these findings support the model that B1 activity may be
complemented in some cells by these host enzymes. Indeed, functional conservation of
these viral and cellular kinases has been demonstrated by (i) evidence that VRK1 can
rescue the Cts2 viral DNA replication defect when expressed from the Cts2 virus genome
under a viral promoter (73), and (ii) the discovery that B1 and VRK1 share the same
cellular substrate, BAF (98). Together, the study of VRKs can inform the function of the
vaccinia B1 kinase and vice versa to contribute to our interpretation of VRK roles in the
host.
1.2.C. Cellular barrier-to-autointegration factor (BAF) substrate
The most well characterized substrate of both B1 and the VRKs is BAF, a highly
conserved DNA-binding protein with essential cellular functions. BAF expression is
needed for survival and differentiation of both human and mouse embryonic stem cells,
and the depletion or knockout of BAF in Caenorhabditis elegans and Drosophila
melanogaster is embryonically lethal (80, 99). BAF has also been implicated in human
disease; a point mutation within the BAF-coding region has been identified in two
patients presenting with a hereditary progeroid disease called Nestor-Guillermo progeria
syndrome (100). The molecular underpinnings of these defects are likely multifactorial
(101), as BAF functions during mitosis and other processes integral to maintaining
genomic integrity. In addition to these cellular functions, BAF is also capable of strongly
inhibiting vaccinia virus DNA replication (69, 83) and intermediate transcription (81).
The host defense activity of BAF against vaccinia virus is dependent on its DNA-binding
property (Fig 1.5A), where BAF interacts with the phosphate backbone of the virus
dsDNA minor groove. A key interaction that is blocked by B1-
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Fig 1.5. Barrier-to-autointegration factor crystal structure with DNA. (A) The threedimensional crystal structure of BAF bound to DNA is a solved structure. (B)
Interactions between multiple residues of a basic region of the BAF molecule interact
with the minor groove phosphate backbone of the DNA structure. This interaction
includes the Ser4 (yellow) that is shown to be phosphorylated by cellular VRKs and
vaccinia B1 kinase, and disrupts BAF-DNA interactions. Images for this figure were
borrowed from Bradley et al (79).
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mediated phosphorylation is the Ser4 site (Fig 1.5B), which has a direct interaction with
the DNA (69, 102). Therefore, the characterization of the B1-BAF signaling axis
supports the importance of B1 expression to counteract the cellular BAF antiviral activity
during poxvirus DNA replication.
1.3. ENZYME / PSEUDOENZYME MODELS
The discovery of proteins with sequence similarity to enzymes, despite lacking
residues required for catalysis was made possible in the age of sequence databases and
combined knowledge of bioinformatics, protein structures, and enzyme kinetics.
Intriguingly, screening sequence data revealed that most enzyme families contain a
catalytic-null protein (103-105), necessitating the characterization of these potential
pseudoenzymes. These enzyme families include kinases, phosphatases, proteases, E2
ubiquitin ligases, and phospholipases. The classification of an active protein kinase was
first described by Eyers and Murphy, and was based on the characterization of domains
required for phosphotransferase activity (106). The requirement of ATP binding was
more generally applied to all enzymes for classification as a catalytically active form
(107). These transferase-null proteins are referred to as pseudoenzymes or pseudokinases
for phosphotrasferase-null proteins. The function of these pseudoenzymes can be
appreciated as pseudo-transducers or pseudo-signalers in which the former has an
immediate, limited impact while the later has a broader impact on the system (108).
1.3.A. Viral pseudoenzymes and virus required cellular pseudoenzymes
The research on viral pseudoenzymes and viral factors that interact with cellular
pseudoenzymes is limited. To explicate what is known about this group of
pseudoenzymes and the relationship with virus life cycle modulation, we describe a
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specific example of virus hijacking of an enzyme/pseudoenzyme pair, a herpesvirus
encoded pseudoenzyme that recruits a cellular paralog, and psuedoenzymes encoded by
vaccinia that lack an essential function. Together the primary literature supports virus
modulation of host enzyme/pseudoenzyme pairs and provide examples were viruses
encoding a catalytic-null protein that is essential for viral function or less clear roles for
non-essential psuedoenzymes.
First, an example of virus hijacking a pseduoenzyme/enzyme pair of the host was
recently elucidated. The initial discovery of the non-enveloped dsDNA polyomavirus
(PyV) requirement of a host catalytic-null protein for the trafficking the virus particle
across the ER membrane was quite interesting, especially because this unique mechanism
was thought to occur without virion disassembly or budding events. The ER resident
protein 29 (ERp29) is an inactive protein disulfide isomerase (PDI). The active PDIs
participate in quality control of folding of proteins in the ER lumen via catalysis of
disulfide bonds between cysteine residues. The catalytic-null ERp29 is implicated in ER
to Golgi apparatus and ER to cytoplasm trafficking. Interestingly, the ERp29 contributes
to PyV conformational change that occurs in the ER lumen (109). The cellular
pseudoenzyme mediates extension of the VP1 C-terminal arm, which increases the PyV
particle binding to the luminal surface of the ER membrane. The PyV particle is then
thought to transit through the ER membrane and into the cytosol. Importantly, interaction
of the PyV particle with the ER lumen membrane does not occur in the absence of the
ERp29. Furthermore, two active proteins from the PDI family also engage and contribute
to PyV infection. Intriguingly, the catalytically active ERp57 cooperates with the
pseudoenzyme to facilitate VP1 conformational change via a mechanism requiring
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catalysis that is not complemented by the other active PDI (110). Therefore, PyV hijacks
both cellular pseudoenzyme and catalytic competent PDI for unique transit across the ER
membrane and into the cytoplasm without a budding step. Further studies are needed to
elucidate the mechanism of virus capture and modulation of this host protein pair.
Second, only one example from the literature was identified for a virus encoding a
pseudoenzyme with a characterized essential function during virus infection. Specifically,
during gammaherpesvirus infection, the capture of the cellular
phosphoribosylformylglycinamidine synthetase (PFAS) occurs via expression of a
paralogous, catalytic-null protein, viral glutamine aminotransferase (vGAT), which binds
directly to the active enzyme to coordinate function (111). The PFAS-vGAT interaction
enables the recruitment of the cellular enzyme and subsequent deamination of RIG-I
corresponding to restriction of cytokine production. Therefore, this example illustrates
that viruses encoding a pseudoenzyme can be used to manipulate the cellular paralog to
evade host immune response.
Third, there are two pseudoenzymes encoded by vaccinia virus that have been
studied, but lack a known function during infection. The first is a Ser/Thr catalytic-null
B12 (112, 113) encoded by B12R under an early promoter (114). This protein has no
impact on growth in vitro and in vivo of a virus as determined by growth studies of a B12
deletion virus (114, 115). Similarly, the serine recombinase predicted catalytic-null F16
protein encoded by the early F16L gene was deemed non-essential by unchanged growth
kinetics of F16L deletion vaccinia virus (116). Despite the conclusion that both B12R and
F16L are non-essential, the B12R gene is conserved in all Orthopoxviruses (Fig 1.3) and
F16L predicted catalytic-null is conserved in the Chordopoxvirinae subfamily with the
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exception of avipoxviruses and catalytic competent paralog in crocodile poxvirus.
Therefore, it is possible that these viral proteins retain function despite a loss of catalytic
activity in order for their maintenance throughout evolution, which was shown for
vaccinia uracil DNA glycosylase D4R. This protein is essential for DNA replication,
although via a catalytic-independent function (117). The importance of these catalyticnull proteins may stem from the presence of viral mimicry of host proteins. It is possible
that the requirement of catalytic activity is not required for viral proteins if an active
enzyme is expressed by the host. Instead, psedoenzymes may represent a mechanism of
modulation of host signaling pathways to enhance virus replication. Additionally, the
coding capacity of viruses may impact how viruses utilize pseudoenzymes during
infection.
1.3.B. Mechanisms of cellular pseudokinases
From the human kinome, 10% of these proteins are predicted to be catalytically
inactive pseudokinases (64) in the canonical sense, but does not account for noncanonical phosphotransferase activity despite mutations predicted to cripple kinase
function. Further, the identification of catalytic-null proteins was first described for
kinase-like proteins and later applied to other inactive enzymes. To address the
mechanisms of pseudoenzymes in cells, we draw from pseudokinase / pseudophosphatase
models due to multiple known examples. The molecular mechanisms of pseudokinases
and pseudophosphatases have been divided into four categories: modulator, signal
integrator, anchor, and competitor (Fig 1.6). Thus far, the characterization of these
pseudoenzymes has been linked to one or more of these functional categories (118). Yet,
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Fig 1.6. Pseudokinase/ pseudophosphatase signaling models. Pseudokinases and
pseudophosphatases are categorized functionally into the following groups: modulator,
signal integrator, anchor, and competitor. These roles require either direct interaction of
the pseudoenzyme with the active enzyme or between the pseudoenzyme and a substrate
shared with the enzyme. This illustration was modified from the original graphic in
Reiterer et al (118).
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as this is a growing area of research alternative mechanisms may exist outside the four
models referenced here.
To begin, the modulator function of the catalytic null counterpart ‘modulates’
catalysis of the active kinase or phosphatase. Examples demonstrate that dimerization of
active and catalytic-null proteins can positively regulate catalysis by enhancing binding
to specific substrates and/or modify signaling outcomes (119-121). Interestingly, the
catalytic dead protein does not completely inhibit catalytic activity of the bound enzyme
in these known interactions.
Next, proteins lacking catalytic activity can also behave as scaffolds used to
integrate signaling via two or more proteins and are termed ‘signal integrators.’
Participating as another layer of regulation, these scaffolds can be required for a specific
signal to occur (122). Additional pseudoenzymes are predicted to function as scaffolds,
however further elucidation of a molecular mechanism is required.
The last two categories include the presence of a shared substrate between a
catalytically active and inactive protein. Furthermore, signaling can be modulated by the
restriction of a substrate to transit to a different subcellular compartment carrying out the
action of a substrate ‘anchor’ (123). Alternatively, if both proteins reside in the same
compartment, a shared binding domain of a substrate can lead to a binding competition
between the catalytic active and null proteins (118). It is possible that catalytic dead
proteins locked in an open conformation, similar to the open conformation of an active
enzyme may participate as efficient competitors for substrate binding. In this example,
the pseudoenzyme attenuates the signaling impact of the active enzyme via subcellular
localization or occupation of substrate binding site.
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These models exemplified by pseudokinase and pseudophosphatases can likely be
applied to other pseudoenzymes as the themes of conserved substrate domains and signal
transduction can be applied to other transferase activities. Furthermore, the biological
relevance of these pseudoenzymes applies to significant cellular processes including, but
not limited to, biosynthetic processes, cell migration, innate and adaptive immune
signaling, proliferation, differentiation, vesicle transport, and proteasomal signaling (64).
1.4. Aim 1: Determine how cellular VRKs complement functionally for vaccinia B1
kinase.
Despite the fact that the vaccinia B1 kinase and the cellular VRK proteins share
similar kinase domains and can all target BAF, it remains to be determined whether the
VRK proteins expressed by the cell can regulate BAF antiviral activity or if B1 and the
VRKs may share other substrates important for poxviral infection. The purpose of the
studies completed in chapters 3 and 4 was to address these and other knowledge gaps in
B1 / VRK signal transduction. Herein, we describe the construction and characterization
of the first recombinant vaccinia virus in which the entire B1 coding sequence has been
deleted (chapter 3). This was achieved using a complementing cell line expressing the
B1 protein and allowed us to thoroughly examine the role of B1 independent of any
residual hypomorphic activity present for the B1 temperature sensitive mutant proteins.
Next, we determined that B1-mediated phosphorylation of BAF is not enhanced by other
viral factors, nor does BAF hyperphosphorylation occur during infection in the absence
of B1 (chapter 3). Transcriptional analysis of B1 expressing cells also yielded numerous
pathways of interest that require validation, but support additional functions for B1 in
metabolism, proteolysis, and vesicle transport (chapter 4). Furthermore, using the B1
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deletion virus we present evidence that VRK2 and, to a lesser degree, VRK1 can
complement for the absence of B1 (chapter 4). Intriguingly, the complementation of the
B1 deletion virus by VRK2 appears to occur via a mechanism that is largely independent
of BAF (chapter 4), thus indicating that B1 and VRK2 share a novel signaling pathway
capable of significantly regulating the poxvirus life cycle. In an effort to understand how
poxviruses lacking a B1 kinase replicate, we infected cells deleted of either VRK1 or
VRK2 with ORF virus which lacks a B1 kinase (chapter 4).
With no attenuation of viral yield, the ORF virus either uses VRK1 and VRK2
interchangeably or has evolved alternative mechanisms to regulate pathways impacted by
B1 during vaccinia virus infection.
1.5. Aim 2: Identify viral factors capable of regulating the B1-BAF signaling axis.
To address this second research aim, in chapter 5 we utilized experimental
evolution of the B1 deletion virus to search for novel pathways through which B1
functions. This approach leverages the natural errors that occur during vaccinia DNA
replication to introduce variants that can suppress the fitness defect caused by a deleted
gene. Whole genome sequencing and analysis of the rescued, adapted B1 deletion
viruses revealed an insertion and deletion mutation (indel) within the B12R gene (chapter
5). The indel mutation introduced frameshifts into the coding region that led to a
truncation of the B12 protein (chapter 5). Previous publications had characterized B12 as
a pseudokinase with 36% amino acid similarity to B1 kinase (124, 125). In chapter 5, we
present multiple lines of evidence demonstrating that expression of wild-type B12 leads
to a striking reduction in fitness of viruses with a defect in B1. Importantly, while
mutation or depletion of B12 can rescue the B1 defect in viral DNA replication in
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multiple cell types, altering the levels of B12 had no apparent impact on wild-type virus
or other mutant viruses. From these data we infer that the inhibitory mechanism executed
by B12 is repressed by the B1 kinase.
Additional investigation in search of a mechanism of action for B12 revealed that
wild-type B12 primarily localizes to the nucleus, while B12 mutants are diffuse within
cells (chapter 6). Together, this indicates that B12 C-terminus is necessary for retention
in the nucleus and important for its repressive function on vaccinia DNA replication.
Furthermore, the adapted virus containing a B12 mutation exhibits reduced sensitivity to
BAF overexpression (chapter 6), suggesting that B12 may function, at least partly, via a
BAF dependent mechanism.
The interpretation of how B12-BAF signaling axis modulates DNA replication
was aided by the discovery that B12 constitutively colocalizes with chromatin throughout
mitosis (chapter 6). BAF also exhibits colocalization with the chromatin, which would
place B12 and BAF in close proximity during mitosis. Furthermore, we discovered a
B12-VRK1 interaction during infection (chapter 6). When linked with our data that B12
regulates BAF indirectly and previous work characterizing direct VRK1-mediated BAF
phosphorylation, a B12-VRK1 interaction may indicate that B12 represses VRK1
phosphorylation of BAF during vaccinia infection. Coming full circle, we showed that
when the B1-B12 pair is absent during infection, the cellular VRK1 but not VRK2
contributes to virus replication (chapter 6). This indicates that without the B1-B12 pair,
VRK1 plays a more significant role than VRK2 for vaccinia propagation. Therefore, the
study of the ΔB1mutB12 virus in cells lacking VRK1 will reveal novel B1/VRK1
signaling pathways necessary for vaccinia replication.
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CHAPTER 2
MATERIALS & METHODS
2.1. Reagents. Unless otherwise noted, chemicals were obtained from Sigma Aldrich.
Primers were obtained from Integrated DNA Technologies. The complete summary of
primers and siRNAs used can be found in table 2.1. The list of antibodies used for
experiments is detailed in table 2.2.
Table 2.1 Probes, primers and siRNAs
Name
Sequence
mCherry R Primer (Sanger Seq) 5'-CGCATGAACTCCTTGATGATGGC-3'
mCherry F Primer (Sanger Seq) 5'-GAAGCTGAAGGACGGCGGC-3'
A57 F Primer
5'-GATATGGATGAGGCCAACGAAGC-3'
B2 R Primer
5'-CTCAAACATAGGCAGCAGTGCTCC-3'
B1 ORF R Primer
5'-CTTAGTCCATGGCAAGATACCTCCC-3'
B11R F Primer
5’-TGCTTACTACTAACATGGATACAGA-3’
B13R R Pimer
5’-TCAATACTGACGAGATTGAC-3’
B12R F Primer (Sanger Seq)
5’-CCAGATCTGTATGGAATTGGAGAAACCG-3’
B12R R Primer (Sanger Seq)
5’-CCTCGGTTCTATTTTTCCATGGG-3’
Total VACV DNA (HA) F Primer 5’-CATCATCTGGAATTGTCACTACTAAA-3’
Total VACV DNA (HA) R Primer 5’-ACGGCCGACAATTATAATTAATGC-3’
B1R F Primer (qPCR)
5’-GTGCAAGGCATTTGGTCTATAC-3’
B1R R Primer (qPCR)
5’-CAACATCACCGACCTTTTTGG-3’
B12R Probe
5’-/56-FAM/TTGGAGCAA/ZEN/CAGTTTCAA-3’
B12R F Primer (qPCR)
5’-ACTCACATATAGATTACAACGAGGAC-3’
B12R R Primer (qPCR)
5’-ACCGAACCATTCTATCATGCA-3’
B13R.1 Probe
5’-/56-FAM/AGCTGTTCA/ZEN/GCAGTGGAT-3’
B13R.1 F Primer (qPCR)
5’-CAGCGTCAATCTCGTCAGTAT-3’
B13R.1 R Primer (qPCR)
5’-CCTTATCCATGTTCTCCTCCTTT-3’
B13R.2 Probe
5’-/56-FAM/ACAGAGGTG/ZEN/TTCGGTTCA-3’
B13R.2 F Primer (qPCR)
5’-GGCTCGTATAATCTGGTGGATAC-3’
B13R.2 R Primer (qPCR)
5’-CGTCGACACTCACATCTGAATTA-3’
BamHI-Kozak-HA-B12 F Primer 5'-GAGAGAGGATCCGCCACCATGTATCCCTACGACG-3'
BamHI-Kozak-B12 F Primer
5'-GAGAGAGGATCCGCCACCATGGAAAGCTTCAAGTACTG-3'
B12-BamHI R Primer
5'-GAGAGAGGATCCTTAGTCCTGGATGAACAGCTTCCGC-3'
XhoI-Kozak-HA-B12R F Primer 5'-ATTATCTCGAGGCCACCATGTACCCTTATGATGTGCCAGACTATGCTATGGAATCCTTCAAGTATTGTTTTGATAACG-3'
B12R-NheI R Primer
5'-GACTAGCTAGCTCAATCTTGTATAAACAGTTTACGTAGTC-3'
TK-locus L Primer
5'-GGGACTATGGACGCATGATAAG-3'
TK-locus R Primer
5'-ACACTTTCTACACACCGATTGA-3'
TK L Primer
5'-ATACGGAACGGGACTATGGA-3'
B12R F Primer
5'-ACAGTTTCAAGACGAGGAGATTTA-3'
NheI-Kozak-HA-eGFP F Primer 5'-ATTATGCTAGCGCCACCATGTACCCTTATGATGTGCCTGATTATGCAATGGTGAGCAAGGGCGAGG-3'
eGFP-XhoI R Primer
5'-TCACACTCGAGTTACTTGTACAGCTCGTCC-3'
siCtrl (Scramble)
5’-CAGUCGCGUUUGCGACUGGUU-3’
siVRK2 #1
5’ -CACAAUAGGUUAAUCGAAAUU- 3’
siVRK2 #2
5’ -ACGUUCAGAUCCUCUAUU- 3’
siB12 (siB12-1)
5’-GGUAUAAAGUAUUUGGCUAUU-3’
siB12-2
5’-CAUGAUAACUUCAGGAAAUUU-3’
siB12-3
5’-GGAUAUUGCAUGAUAGAAUUU-3’
siB12-4
5’-UGAUAACGAUGGCAAGAAAUU-3’
siB13-1
5’-AGACAAGAUUGAUGGAUUAUU-3’
siB13-2
5’-GGAUAAGGUUAGCGCUCAAUU-3’
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Table 2.2 Antibodies and dilutions
Antibody
αBAF (total) (rabbit)
αphospho-BAF (N-terminus phospho-specific) (rabbit)
αGAPDH (mouse)
αHA.11 (mouse)
αI3 (rabbit)
αlaminA/C (mouse)
αmyc (mouse)
αtubulin (mouse)
αVRK1 (mouse)
αVRK2 (mouse)
αF18 (rabbit)
Goat αmouse
Goat αrabbit
Fluor 594 OR 488 conjugated goat αmouse
Fluor 594 OR 488 conjugated goat αrabbit

Company
custom
custom
Santa Cruz Biotechnology
BioLegend
custom
Cell Signaling
Cell Signaling
Sigma Aldrich
Santa Cruz Biotechnology
Santa Cruz Biotechnology
custom
BioRad
BioRad
Life Technologies
Life Technologies

Clone
Assay/Dilution
Jamin et al. 2014 IB(1:3,000)
Jamin et al. 2014 IB(1:1,000)
IB(1:200)
16B12
IFA(1:400) / IB(1:1,000)
IFA(1:300)
IB(1:2,000)
9B11
IFA(1:100) / IB(1:1,000)
T7816
IB(1:10,000)
E-3: sc-390809 IB(1:500)
H-5: sc-365199 IB(1:500)
IB(1:6,000)
IB(1:20,000)
IB(1:20,000)
IFA(1:400)
IFA(1:400)

2.2. Cell Culture. African green monkey kidney CV1 cells were obtained from
Invitrogen life technologies. African green monkey BSC40, mouse fibroblast L929,
human cervix epithelial adenocarcinoma HeLa, human lung epithelial carcinoma A549,
and human thymidine kinase-negative 143B osteosarcoma TK(-) cells were purchased
and obtained directly from ATCC. These cell lines except A549 cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum (FBS; Atlanta Biologicals) and penicillin-streptomycin in 5% CO2 at 37˚C. A549
cells were maintained in DME/ Ham’s F-12 Nutrient Mixture (1:1) media supplemented
with 10% FBS and penicillin-streptomycin in conditions stated above. Human nearhaploid fibroblast HAP1 parental, vaccinia-related kinase 1 (VRK1) knockout
(VRK1KO), and VRK2KO cells were obtained from Horizon Genomics and maintained
in Iscove’s Modified Dulbecco’s Medium (IMDM; Fisher Scientific) with 10% FBS and
penicillin-streptomycin at incubation conditions as stated above. VRK1KO cells (cat#
HZGHC000073c014) contain an 11 base pair (bp) deletion in VRK1 exon 5 introduced
by CRISPR/Cas9 gene editing and VRK2KO cells (cat# HZGHC000403c006) contain a
7bp deletion in VRK2 exon 2.
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Primary ovine fetal turbinate (OFTu) cells were obtained by aseptically removing
turbinate tissues from ovine fetuses and were minced in presence of PBS and antibiotics,
washed several times with PBS, digested with 0.2% Trypsin at RT for 1-2hr, and gauzefiltered. The cell suspension was centrifuged and pellets were washed twice with PBS
and once with growth medium. Cells were maintained in minimal essential medium
(MEM) supplemented with 10% fetal bovine serum (FBS), 2 mM of L-glutamine, and 50
μg/mL of gentamicin.
2.3. Generation of stably transduced cell lines. The pHAGE-HYG-MCS-B1myc
construct was produced by amplifying a codon optimized myc-tagged B1 ORF using
BamHI-Kozak-B1 (5’-AGCAGGATCCGCCACCATGAACTTC-3’) forward primer and
B1-BamHI (5’-GGCGGATCCTTACAGGTCCTCTTCAG-3’) reverse primer set and
cloning the product into the BamHI site of the multiple cloning site of the pHAGE-HYGMCS vector (94). The lentiviruses encapsidating pHAGE-HYG-MCS (126) (control),
pHAGE-HYG-B1myc (127), and pHAGE-HYG-3XFlag-BAF (plasmid was generously
provided by Dr. Paula Traktman) were produced in 293T cells following transfection
with pHAGE-HYG-MCS-B1myc or pHAGE-HYG-MCS (empty vector) in combination
with pVSVG, pTat, pREV, and pGag/Pol. Alternatively, a two plasmid helper system
was also used to generate lentiviruses encapsidating pHAGE-HYG-MCS (control) or
pHAGE-HYG-B1myc. The two plasmid helper system included pVSVG and psPAX2, a
gift from Didier Trono (Addgene plasmid # 12260), was combined with the transfer
plasmid for transfection of 293T cells. At 15.5hr post transfection, fresh media with 5mM
sodium butyrate (EMD Millipore Corp.) was added to cells. At 24hr post transfection,
fresh media with 10mM HEPES (Fisher Scientific) was added to cells. At 48hr post
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transfection recombinant virus was harvested, polybrene (Fisher Scientific) was added at
10 µg/mL, and stocks were aliquoted for storage at -80˚C. These lentiviruses were used
to transduce CV1 cells the day following cell seeding at 3x105 cells in a 35mm well.
B1myc and control CV1 cells were selected with 200 µg/mL hygromycin B (Invitrogen)
and B1myc expression confirmed with immunoblot using mouse αmyc (Myc-Tag (9B11)
Mouse mAb #2276 Cell Signaling) antibody or plaque assay rescue of ΔB1 virus on
B1myc expressing CV1 cells.
Lentiviruses expressing BAF-specific short hairpin RNA (shRNA) or control
(scrambled) shRNA have been described previously (69), and were used for stable
depletion of BAF in CV1 cells and HAP1 VRK2KO cells. Those transduced cells were
selected with 10 µg/mL and 500ng/mL of puromycin respectively prior to use in
experiments. Lentiviral vector pLenti-C-Myc-DDK expressing myc-tagged human
VRK2 (isoform VRK2A, #RC206522L1 OriGene) was used to generate lentivirus as
described above.
The lentivirus generation and stable expression of HA-tagged and untagged B12
cells used the pHAGE-HYG-MCS-HA-B12 or pHAGE-HYG-MCS-B12 construct which
were produced by PCR amplifying a codon-optimized HA-B12 ORF in the pcDNA3.1
vector purchased from GeneArt (Fig 2.1). The primers used for PCR amplification are
found in Table 2.1. HA-B12 or B12 ORF was then cloned into the BamHI site within the
pHAGE-HYG-MCS multiple cloning site. Lentivirus generation used the four plasmid
helper system (pVSVG, pTat, pREV, pGag/Pol), following the same protocol
summarized above for transduction of CV1 cells.
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Fig 2.1. Sequence for vaccinia B12R codon optimized for expression in mammalian
cells. A vaccinia B12R gene codon optimized for expression in mammalian cells was
generated by GeneArt.

2.4. Transcriptome analysis. L929 control or B1myc stably expressing cells were
transfected with plasmid DNA and harvested 6h post transfection for RNA extraction.
Prior to use in RNA sequencing experiments all RNA samples were analyzed with
respect to purity and potential degradation. A260/280 ratios were determined using a
Nanodrop instrument. Potential degradation was assessed by analysis of 200 ng of the
RNA with an Advanced Analytical Technical Instruments (AATI) Fragment Analyzer by
the University of Nebraska Medical Center (UNMC) Next Generation Sequencing Core
(NGS) Facility. 12 sequencing libraries were generated by the UNMC NGS Core
beginning with 1 ug of total RNA from each sample using the TruSeq V2 RNA
sequencing library kit from Illumina following recommended procedures. Multiplexed
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libraries were sequenced on the HiSeq 2500 (Illumina) and a total of approximately 27
million 50 bp single reads were generated for each sample. Approximately 96 % of the
bases >Q30 were achieved with a mean quality score for each sample of Q37. Following
sequencing FASTQ files were provided.
The transcriptome analysis was conducted using customized analysis pipeline
based on TOPHAT 2.0.13 and CUFFLINKS 2.2.1. The reference genome index and
annotation (NCBI build 37.2) were downloaded from Illumina's iGenomes project. The
top differentially regulated genes were identified, and the genes were visualized with
clustering on both genes and treatments using a R script based on heatmap2 package.
Genes differential expressed at a Log2(fold change) > 1.9 and P-value <0.05 were
analyzed in heat map (Fig 4.1B). The transcriptome data was also analyzed for regulation
of signaling pathways. First, the transcriptome raw count data was converted to gene
symbols. Second, data was analyzed using GSEA program and available gene sets to
identify regulated pathways each comparison: B1 with control (Fig 4.2.A), B1/plasmid
with control/plasmid (Fig 4.2.B), B1/plasmid with control (Fig 4.3.A), and
control/plasmid with control (Fig 4.3.B).
2.5. B1 deletion recombinant virus generation. The B1 deletion recombinant vaccinia
virus ΔB1 was generated by infecting B1myc expressing CV1 cells with WT virus
(MOI=0.03) and co-transfecting the linear DNA fragment upB1-P11-mCherry-downB1
(Integrated DNA Technologies). This DNA fragment was synthesized to contain the
mCherry ORF under the control of the vaccinia p11 promoter (128), and flanked by
sequence homologous to the 250bp immediately upstream and downstream of the B1
ORF, thus it was constructed to replace the B1 ORF with p11mCherry upon homologous
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recombination. The infected/transfected cells were incubated for 48hr, harvested and
titrated on B1 expressing CV1 cells for isolation of individual plaques. Virus expressing
mCherry was purified by serial plaque purification on CV1-B1myc cells until no nonfluorescent plaques (out of 100 plaques) were observed. The ΔB1 virus was plaque
purified 6 additional times before being expanded on B1myc expressing CV1 cells and
purified using a sucrose cushion. Replacement of the B1 ORF was verified by DNA
sequencing and PCR analysis (Table 2.1).
2.6. Serial passage of ΔB1 on CV1 cells for adapted virus generation. The
ΔB1mutB12-A1, -A2, -A3 viruses were generated by infecting CV1 cells at a MOI of 0.1
in three independent 10cm plates. Virus was propagated in cells two days at 37˚C before
cell harvest. Cells were pelleted and resuspended in 1ml PBS. 100µl cells in PBS were
saved for DNA purification and remaining cells were pelleted and resuspended in 900µl
10mM Tris pH 9.0 for virus titration. After freeze/thawing three times, the three
independent virus stocks were titrated on B1myc expressing CV1 cells. Using these titers
for passage 1 viruses, 10cm plates of CV1 cells were infected at a MOI of 0.1 and
allowed to propagate on cells for days at 37˚C. Serial passage of viruses in CV1 cells at a
MOI of 0.1 was completed for 7 total passages with either two or three days of
propagation before cell harvest. Each passage of virus was titered on complementing,
B1myc expressing CV1 cells.
2.7. WT/HA-B12 recombinant virus generation. The recombinant WT/HA-B12 virus
expresses an additional vaccinia B12R gene with a 5’ HA epitope sequence from the
nonessential, thymidine kinase (TK) locus. This virus was generated by homologous
recombination using standard protocols and pJS4 variant kindly shared by Paula
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Traktman laboratory (69). Briefly, the HA-B12 sequence from the virus was amplified
using F and R primers containing XhoI or NheI restriction sites respectively (Table 2.1)
and cloned into a pJS4 variant (129) flanking it with regions homologous to the vaccinia
TK gene. Next, CV1-B1myc cells were infected with WT virus at MOI = 0.03 followed
by transfection 3hpi with 3 µg linear pJS4-HA-B12 per 35mm well. Cells were harvested
48hpi, freeze/thawed three times, and used for virus titrations on CV1-B1myc cells.
Recombinant viruses went through two rounds of purification by infecting 143B TK()/B1myc cells (lacking cellular expression of thymidine kinase) and treatment with 25
µg/µl bromodeoxyuridine (BrdU) to reduce productive infection of WT virus with an
intact TK locus (control infections were completed without BrdU selection). WT/HAB12 viruses were plaque purified three times and confirmed to be a pure stock using PCR
amplification of viral DNA and immunofluorescence detection of HA-B12 protein in
50/50 plaques. An expanded preparation of this virus from a freeze/thawed lysate of
infected CV1-B1myc cells was used for immunofluorescence assays.
2.8. Viruses and viral infection assays. Viruses used for experiments include the
following: wild-type (WT), B1 deletion (ΔB1) (127), orf virus (130), ΔB1mutB12-A1,
ΔB1mutB12-A2, ΔB1mutB12-A3, B1-mutant Cts2 (68), D5-mutant Cts24 (131), E9mutant Cts42 (132), and WT/HA-B12 WR strain vaccinia viruses. Parapoxvirus orf virus
(ORFV; OV-IA82 strain) was isolated, propagated and purified in OFTu cells. Genomic
DNA sequencing confirmed homogenous virus stock preparation. ORFV passaged less
than 10 times after plaque purification was used for experiments (Fig 4.8C). All other
viruses were expanded on BSC40, CV1 or CV1-B1myc cells and purified using a sucrose
cushion.
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ORFV viral yield was assayed for ORFV infection (MOI=1) of HAP1 control,
VRK1KO and VRK2KO cells. Four days post-infection cells were harvested and lysed.
Cell debris was pelleted using centrifugation and supernatants containing virus were used
to quantitate viral yield by the Spearman-Karber’s tissue culture infectious dose 50
method (TCID50/mL), using primary ovine fetal turbinate (Oftu) cells. Viral yield
experiment (Fig 4.8C) was performed in experimental duplicate.
Plaque assays were completed using either 200 or 300 plaque forming units (PFU)
per well. WT, Cts2 and ΔB1 infections were completed 39.7˚C and fixed/stained 48h post
infection. For the ΔB1 adapted virus plaque assays, control or B1myc expressing CV1
cells were infected with WT, ΔB1, or ΔB1 adapted virus A1 for passages 1 through 7.
Cells were fixed and stained at 72h post infection. The plaque assay of B12 depletion
during WT, ΔB1, and ΔB1mutB12-A3 infection was completed by infecting cells 24h
post transfection with siRNA. 72h post infection cells were fixed and stained. The plaque
assay on CV1 control or HA-B12 stably expressing cells were fixed 72h post infection
with WT or ΔB1mutB12-A3 virus.
For immunofluorescence assays, cell lines were infected with WT or ΔB1 virus at
MOI=5 at 37˚C for 7 or 18h prior to fixation with 4% PFA.
Viral growth assays were conducted in multiple cell lines. One-step 24h viral
growth assays were completed by infecting a monolayer of CV1, HeLa, A549, L929, or
transduced CV1 cells with WT, Cts2, ΔB1, ΔB1mutB12-A1, or ΔB1mutB12-A3 virus at
a MOI of 3 and incubated at 37˚C and/or at 37˚C and 39.7˚C (only for studies including
temperature sensitive (ts) mutant viruses). At 24h or indicated time post infection cells
were harvested for downstream DNA accumulation and viral yield quantification. Half of
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the cells harvested were pelleted and resuspended in PBS for DNA purification and
qPCR while the other half was resuspended in 10mM Tris pH 9.0, freeze/thawed three
times, and serially diluted for titration on CV1-B1myc cells at 37˚C or 31.5˚C (only for
experiments including ts mutant viruses). For one-step growth assays with siRNA treated
cells, CV1 cells were infected 24h post transfection with siRNA. Viral growth was also
measured at multiple time points for CV1 cells infected with WT, ΔB1, or ΔB1mutB12A3 virus. Cells were infected with a MOI of 3 and harvested at 3, 7, 16, and 24h post
infection and used for both DNA accumulation and viral yield quantification. For multistep growth curves, CV1 cells were infected at a MOI of 0.01 and harvested at 48h post
infection for viral yield measurement by titration of samples on CV1-B1myc cells. Multistep growth assay in siRNA treated cells were carried out at 24h post transfection, with
cell harvests at both 7 and 48h post infection for viral yield quantitation.
WT virus was used for infections of cells transfected with pJS4 plasmid
constructs. CV1 cells were infected at either a MOI of 3 or 5 and harvested 24h post
infection for immunoblot analysis of HA-B12wt and HA-B12ΔA690 expressed from the
pJS4 vector late viral promoter.
For detection of early gene expression, CV1 cells were infected with WT, ΔB1, or
ΔB1mutB12-A3 at a MOI of 3 and harvested 4h post infection for RNA extraction from
cells.
For immunoblotting analysis shown in Fig. 3.3A, CV1 cells were infected with
WT or ΔB1 virus at MOI=10 at 37˚C and harvested cells 6hpi. WT, ΔB1, ΔB1mutB12A1, or ΔB1mutB12-A3 viruses were used for Fig 6.4A BAF blot following the same

42

conditions. In Fig. 4.4E, HAP1 cell lines were infected with WT or ΔB1 virus at MOI=3
at 37˚C and harvested 7 and 18hpi for early and late protein detection respectively.
2.9. Sequencing. For complete genome sequencing of the WT (from the Wiebe
laboratory), ΔB1, ΔB1mutB12-A1, and ΔB1mutB12-A3 viruses 1 ng of viral DNA from
each sample was used to construct sequencing libraries. Libraries were constructed using
the Nextera XT kit from Illumina per manufacturers suggestions. An aliquot of the
resultant multiplexed library of four viral isolates was sequenced on the MiSeq V2
instrument. 150 base pair (bp) paired-end sequencing was performed. The paired reads of
150 bp (trimmed when necessary to remove adaptors and ends of reads with lower QC
scores) was provided. Next, Illumina paired-end sequence reads were filtered using the
program fastq_quality_filter from FASTX-Toolkit 0.0.14. The read pairs with at least
90% bases having quality of 30 were used to map to reference genome of Vaccinia virus
WR (reference genome NC_006998.1). Bowtie2 version 2.2.4 was used for accurate and
efficient mapping. Sequence data was uploaded to SRA database (PRJNA490542). The
estimated overall coverage of each of the samples (using only the high quality paired
reads) is between 800 and 2000x based on a genome size of 220kb.
Sequence data was analyzed for gene duplications, point mutations and insertion
or deletion (indel) mutations within protein coding regions of the genome using a selfdeveloped pipeline including samtools/bcftools. Sequence discrepancies that occurred in
<5% of the read counts for a single nucleotide call were not included in further analysis.
The mapped reads were visualized using Integrated Genome Browser (IGV 2.3.59).
Complete genome sequences were aligned for all sequenced viruses and compared to the
WT (Wiebe) virus to identify gene duplications. Point mutations were assessed by
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comparing WT (Wiebe) to WT WR (reference genome NC_006998.1) in the NCBI
database, ΔB1 to WT (Wiebe), and both ΔB1-A1 and ΔB1-A3 to ΔB1 sequenced
genome. Lastly, indel mutations were discovered by comparing the indel changes
between WT (Wiebe) and WT WR (reference sequence) with the change in indel
mutations for ΔB1, ΔB1-A1, or ΔB1-A3 and WT (Wiebe) as in figure 5.2B or by
alignment the whole genome sequence for ΔB1-A3 to the WT WR (reference sequence)
genome in figure 5.2C. Mutations in greater than 5% of the read counts at a single
nucleotide position were considered significant mutations in the mixed population of
ΔB1-A1 and ΔB1-A3 viruses.
For B12R targeted Sanger sequencing, ∆B1mutB12 virus lineages A1, A2, and A3
were plaque purified twice on CV1 cells. Virus was expanded on CV1 cells and DNA
was purified from the resultant viruses using a GeneJET whole-blood genomic DNA
purification minikit (Thermo Scientific). Purified DNA samples were subjected to Taq
based PCR using 1µM each B11R F and B13R R primers (Table 2.1). Following PCR
amplification, B11-B13 products were cleaned using a QIAquick PCR purification kit
(Qiagen). PCR products were then submitted for Sanger DNA sequencing (Table 2.1) and
analyzed for lesions within B12R.
2.10. Plasmid/siRNA/mRNA transfections. Transcriptome analysis of B1 expressing
cells with or without control plasmid transfection was completed as follows. L929 control
or B1myc stably expressing cells were transfected with 2ug control plasmid pUC-Neo
following manufacturer’s specifications for a 35mm well. Cells were harvested 6h post
transfection for downstream RNA purification. For plasmid transfection for expression of
B12 forms, CV1 cells in a 35mm well were transfected with 5µl lipofectamine2000
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(Invitrogen) for 5µg pJS4-HA-B12wt or pJS4-HA-B12ΔA690 plasmid DNA following
the manufacturer’s incubation suggestions. Cells were then infected with WT virus 6h
post transfection for expression of HA-B12wt and HA-B12ΔA690 from the pJS4 vector
under a late vaccinia virus promoter.
For the transient depletion of VRK2, B12, or B13 mRNA, cells in a 35mm well
were transfected with a mixture of 5µl Lipofectamine RNAiMAX (Invitrogen) and
100nM siRNA (Table 2.1) targeting the scramble control, VRK2, B12, or B13 mRNA
sequences. During VRK2 depletion, HeLa or A549 cells were transfected and protein
depletion was measured by immunoblot analysis at 3 days post transfection. For one-step
infections in siCtrl and siVRK2 treated cells, cells were split into a 12-well plate 3 days
post transfection and infected 4 days post transfection prior to 24hr DNA accumulation
and viral yield assays. For B12 or B13 depletion using siRNA, CV1 transfected cells
were incubated 24h at 37˚C before infection of cells for downstream experiments.
In mRNA transfections for immunofluorescence assays, in vitro synthesis of GFP
or HA-B12 mRNA was conducted following mMessage mMachineTM T7 Ultra
manufacturer’s recommendations (Invitrogen) with linearized template pcDNA3.1-GFP
or pcDNA3.1-HA-B12 (Fig 2.2). GFP was cloned into the pcDNA3.1 vector using
primers containing NheI or XhoI restriction sites (Table 2.1). CV1 or CV1-B1myc cells
were transfected with 1.5µl Lipofectamine MessengerMax (Invitrogen) and 1µg mRNA
per well of a 12-well plate following the manufacturer’s protocol. The mRNA transfected
cells were fixed or permeabilized the next day for immunofluorescence and
prepermeabilization assays.
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Fig 2.2. Sequence for vaccinia B12R codon optimized for expression in mammalian
cells. A vaccinia B12R gene codon optimized for expression in mammalian cells was
generated by GenScript.

2.11. Immunofluorescence assay. Cells were fixed with 4% paraformaldehyde (Alfa
Aesar) in 1X PBS for 15m and permeabilized with 0.2% Triton X-100 (Sigma) in 1X
PBS for 10m at room temperature (RT). Primary antibodies were incubated with cells for
2h at RT following dilutions in 1X PBS (Table 2.2). Secondary antibodies with
conjugated fluorophore (Table 2.2) were incubated with cells for 1h at RT in the dark.
The 4’,6-diamidino-2-phenylindole (DAPI) nuclear stain was added to cells at 1:1000
dilution in 1X PBS and incubated with cells for 30m at RT in the dark. All dilutions and
washes used 1X DPBS/Modified with Ca+ and Mg+ added (HyCloneTM
ThermoScientific) for figures 3.1C, 3.2B and 4.5. All other experiments used 1X PBS for
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dilutions and washes. Immunofluorescence images were taken using an EVOS® FL Auto
Cell Imaging System (Invitrogen) with dual cameras and selected excitation/emission
filters GFP (Fluor 488), TxRed (Fluor 594) and DAPI. Using ImageJ software,
composites were generated to make minor adjustments to brightness and some images
were modified using LUT settings. Images were saved as RGB.tiff or montage.tiff files.
2.12. Prepermeabilization assay. CV1 cells were transfected with HA-GFP, HA-B12 or
no mRNA following transfection protocol in section ‘Plasmid/siRNA/mRNA
transfections’. 24h post transfection with mRNA cells were fixed with 4%
paraformaldehyde (Alfa Aesar) in 1X PBS for control ‘Fix/Permeabilize Cells’ condition
or first permeabilized with 0.1% Triton X-100 (Sigma) in 1X PBS for 30s, then fixed for
‘Permeabilize/Fix/Permeabilize Cells’ condition (133, 134). The following steps were
carried out identical to those stated in ‘Immunofluorescence assay’.
2.13. Cellular fractionation assay. CV1 control cells or cells stably expressing HA-B12
were fractionated into soluble cytoplasmic (Cyto.), membrane (Memb.), nuclear (Nuc.),
chromatin-bound (Chrom.) and cytoskeletal (Cytoskel.) fractions using the Subcellular
Protein Fractionation Kit for Cultured Cells (Thermo Scientific #78840) following the
manufacturer’s instructions with the addition of phosphatase inhibitors. Lamin A/C was
used as a nuclear protein control that has soluble fractions and fractions bound to the
chromatin and cytoskeleton. GAPDH and BAF are cytosolic and membrane associated
protein controls. Additionally, the BAF control protein has a nuclear fraction that is
chromatin-bound.
2.14. Immunoblot assay. Protein expression was evaluated by harvesting cells and
resuspending cells at 1 X 104 or 5 X 103 cells/µl in a 2X SDS protein sample buffer

47

supplemented with either 10U/ml benzonase or 50 units/ml Pierce universal nuclease for
cell lysis (Thermo Scientific), trypsin serine protease inhibitor (phenylmethylsulfonyl
fluoride), protease inhibitor cocktail (Rocke), and phosphatase inhibitor cocktail (Roche).
For detection of tubulin, B1myc, VRK1, VRK2, HA epitope tagged B12 forms, lamin
A/C and GAPDH, cells were resolved on a 12% SDS-PAGE gel. Vaccinia F18, total
BAF, and phosphorylated BAF protein was detected by resolving cells on an 18% SDSPAGE gel. Transfer of the proteins to a polyvinylidene difluoride (PVDF) membrane
were carried out overnight. Membranes were blocked in 5% milk made in 1X Tris
buffer/NaCl/0.05% tween (1X TBST). Primary and secondary antibodies (Table 2.2)
added to 1% milk in 1XTBST were incubated with the membrane. Supersignal WestPico
chemiluminescent reagents (Thermo Scientific) were incubated with the membranes.
Only VRK1 and VRK2 blots were incubated with Supersignal WestFemto Maximum
Sensitivity Substrate chemiluminescent reagents (Thermo Scientific). The Bio-Rad
ImageLab software was used to quantify chemiluminescence signal. Images were made
from film or chemidoc images. Fold B12 protein levels were averaged from 5
independent experiments. Raw values were quantified for HA-B12wt, HA-B12ΔA690,
and HA-B12 G-A protein abundance using the volume tool in ImageLab for chemidoc
images. Fold values were calculated by setting a standard protein to 1 and determining
fold values for HA-B12wt, HA-B12ΔA690, and HA-B12 G-A (Fig 5.6B and C). Relative
phospho-BAF protein levels were quantified by dividing raw values for phosphorylated
BAF from ImageLab volume tool by total BAF raw values for each experiment (Fig
6.4B-D) and averaged for the three experiments (Fig 6.4E).
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2.15. DNA/RNA purification and qPCR. For fold DNA abundance quantified for total
VACV DNA and the B1R gene specifically, DNA was extracted from WT, ΔB1, ΔB1
adapted viruses A1 passages 1-7, ΔB1 adapted viruses A2 passages 1-7, and ΔB1 adapted
viruses A3 passages 1-7 infected CV1 cells (for infection details see section “Viruses and
viral infection assays”). The WT and ΔB1 control samples came from one-step infection
DNA samples in CV1 cells. DNA was purified using a GeneJET whole-blood genomic
DNA purification minikit (#K0782, Thermo Scientific). The Bio-Rad iTaq Universal
SYBR Green Supermix was used with quantitative polymerase chain reaction (qPCR) as
previously described (102) with the addition of a B1R specific primer set. In brief, the
WT purified DNA sample was serially diluted to generate a standard curve and determine
amplification efficiency of HA (total VACV DNA) and B1R primer sets (Table 2.1). For
WT and ΔB1 controls about 10ng DNA and 1µM primers were combined in a single
reaction. Variable amounts of DNA were used for ΔB1-A1, ΔB1-A2, and ΔB1-A3
passages 1-7, although the volume used was constant when combined with 1µM primers
per reaction.
The one-step 24h viral DNA accumulation samples were treated similarly to the
DNA extraction and purification above. The infection protocol is detailed under one-step
viral growth infections in methods section “Viruses and viral infection assays”. Samples
were subjected to qPCR with the HA specific primer set (Table 2.1) in triplicate to
determine relative viral DNA accumulation.
For transcriptome analysis, the RNA was extracted from L929 cells following the
suggested protocol for the RNeasy Mini Kit (Qiagen). Early viral gene expression was
determined by infecting CV1 cells as detailed in methods “Viruses and viral assays”
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section and harvested at 4h post infection. RNA was extracted from cells similar to
above, using the RNeasy Mini Kit (Qiagen). Reverse transcription of RNA into cDNA
was carried out using a high-capacity cDNA reverse transcription kit (Thermo Fisher
Scientific, Applied Biosystems). Then using probe and primer sets specific for either B12
or B13 cDNA, qPCR was used to quantify relative mRNA levels for B12 and B13. In a
10ul reaction, probes were used at 0.25nmol and primers for each probe were used at
0.5nmol per reaction (Table 2.1). The single 10ul reaction also included about 40ng
cDNA and 10ul of the 2X PrimeTime Gene Expression Master Mix (Integrated DNA
Technologies). Each sample was completed in duplicate with three experimental
replicates. The WT virus sample was used to generate a standard curved to determine
amplification efficiency of the probe/primer sets and this number was factored into the
cDNA fold values.
2.16. Statistics. Each experimental question was tested in a minimum of three
experimental replicates, unless stated otherwise, and graphed data represent the mean of
all experimental replicates. Error bars shown represent standard deviations from the
mean. The P values indicated were calculated using Excel two-tailed Students t-tests or
Prism multiple student t test.
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CHAPTER 3
GENERATION AND CHARACTERIZATION OF B1 DELETION VIRUS
3.1 Construction of a B1 complementing cell line and B1 deletion vaccinia virus
To gain further insight into the functions of the vaccinia B1 kinase, we initiated
construction of a mutant virus in which the B1R ORF is deleted. In light of the previous
observation that B1 expression is essential to the viral life cycle (73), we posited that
replication of a B1R deletion virus would require a complementing cell line expressing
the kinase. Therefore, a lentivirus system was used to stably express a myc-tagged B1
kinase (B1myc), codon optimized for expression in mammalian cells. Transduced CV1
cells were confirmed to have B1myc expression by immunoblot analysis (Fig 3.1A). To
determine whether stable expression of B1 resulted in any gross changes in cell fitness,
the morphology of the cells was closely monitored, as was their doubling rate over time.
We observed no alteration in the morphology of B1myc expressing cells over a period of
3-4 weeks (data not shown). Furthermore, CV1 cells expressing the B1myc protein did
not vary significantly from the control cells in regards to apparent doubling time (Fig
3.1B). Finally, we used an immunofluorescence assay to determine the localization of
the B1myc protein in transduced cells. We observed that the B1myc protein was present
primarily in the cytoplasmic compartment in uninfected cells (Fig 3.1C). Together this
data illustrates that we successfully produced a cell line stably expressing the B1myc
protein in the cytoplasmic compartment.
To next construct a B1 deletion virus (ΔB1), we utilized a targeting construct in
which the mCherry ORF was placed downstream of the vaccinia p11 late promoter and
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Fig 3.1. Characterization of CV1 cells stably expressing myc-tagged B1 kinase. (A)
Representative immunoblot analysis of CV1 whole-cell lysates of control cells or B1myc
expressing cells using αmyc or αtubulin primary antibodies. (B) The apparent doubling
time of CV1 control (n=2) and B1myc expressing (n=5) cells was calculated. Error bars
represent standard deviations. (C) Immunofluorescence analysis of B1myc protein
localization in uninfected CV1 control and B1myc transduced cells. The B1myc protein
was detected using αmyc primary antibody with appropriate secondary antibody and
DAPI was used to detect the cellular nucleus.
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flanked by ~250bp homologous to the sequence immediately upstream and downstream
of the B1R ORF in the vaccinia WR genome (Fig 3.2A). This targeting construct
containing the mCherry ORF was transfected into CV1-B1myc cells infected with WT
vaccinia virus, and recombinant progeny were identified using fluorescence microscopy.
Virus expressing mCherry was purified by serial plaque purification on CV1-B1myc cells
until no non-fluorescent plaques (out of 100 plaques) were observed, and then plaque
purified an additional six times. This virus was then expanded on CV1-B1myc cells and
replacement of the B1R ORF was verified by PCR using primer sets 1-3 (Fig 3.2A), and
DNA sequencing (data not shown). Upon confirmation of the sequence of the newly
purified recombinant virus, we began characterization of the B1 deletion virus in
immunofluorescence assays and comparative growth studies with the temperature
sensitive Cts2 virus detailed below. Microscopy studies using WT and ΔB1 in control
CV1 and B1myc expressing cells revealed that replication factories are similar in size and
number for WT and ΔB1 viruses in B1 complementing cell lines, but absent for ΔB1
infected control cells (Fig 3.2B, αI3 panel, white arrowheads). Additionally, B1myc
localizes to I3 during both WT and ΔB1 infection (Fig 3.2B, white arrowheads) although
dispersed in the cytoplasm in the absence of infection (Fig 3.1C). Based on these initial
results, ΔB1 behaves similarly to the WT virus in CV1-B1myc cells in relation to the
presence of replication foci and B1 recruitment to replication foci.
3.2. B1 expression in CV1 cells rescues viral growth of both Cts2 and ΔB1 to near
WT levels.
Next, we characterized ΔB1 using a plaque assay and one-step viral yield assay in
CV1 control cells and CV1-B1myc cells. For comparison, the well-characterized
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Fig 3.2. Knockout strategy and growth characteristics of ΔB1 in CV1 cells. (A) The
B1 deletion virus was generated via homologous recombination between the WT WR
vaccinia genome and a DNA fragment of the mCherry gene with 250bp homologous
sequence to the regions flanking the B1 gene, replacing the B1 gene with mCherry gene
under a late viral promoter, p11. Arrows indicate primer sets used to amplify DNA used
for sequence confirmation of recombination. (B) Immunofluorescence analyses of CV1
control and B1myc cells infected with WT or ΔB1 virus at MOI=5 for 7hr at 37˚C before
fixation. Detection of I3 (red) used αI3 primary antibody and B1myc (green) detection
used αmyc primary antibody. White arrowheads point to I3 (red) foci representative of
DNA replication factories (left panels) and B1myc (green) foci colocalizing with I3 (right
panels, B1myc cells only). The late mCherry fluorescent protein produced during ΔB1
infection was not above background levels at 7hpi (data not shown). (C) Plaque assay of
control (top row) and B1myc expressing (bottom row) CV1 cells infected with 200PFU
per well WT, Cts2, or ΔB1. Cells were incubated for 72hr at 39.7˚C prior to fixation and
staining. (D) 24hr viral yield assays were carried out at 39.7˚C for WT (black), Cts2
(grey), and ΔB1 (red) on control (left three bars) and B1myc expressing (right three bars)
CV1 cells. Virus titrations were completed on B1myc expressing cells at 31.5˚C.
Standard deviation is denoted by error bars and † indicates a p-value < 0.05.
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temperature sensitive virus, Cts2, was also included in these assays. Importantly, the
Cts2 virus is able to complete the viral life cycle and produce infectious virions at low
temperature (31.5˚C), but is inhibited at the stage of DNA replication at high temperature
(39.7˚C) (68, 75). In the Cts2 virus, the B1R gene contains a single nucleotide
substitution that results in expression of a more labile and catalytic-inert protein (75).
Therefore, we predicted that the CV1-B1myc cells will complement the Cts2 virus as
well as our new recombinant virus, ΔB1. Indeed, B1myc expression rescued the Cts2
virus at non-permissive temperature (39.7˚C) and the ΔB1 at low multiplicity of infection
(MOI) as assayed using a plaque assay (Fig 3.2C). Specifically, the number of plaques
for Cts2 and the ΔB1 increased from zero to about 200 plaques, although it is noteworthy
that the plaque morphology of both Cts2 and ΔB1 produced slightly smaller plaques as
compared to the WT virus plaques. Additionally, the WT virus plaque numbers and
morphology were not altered by the expression of B1myc in CV1 cells, demonstrating
that B1 expression from the cell does not enhance WT viral growth at low MOI.
Production of infectious virus during Cts2 and ΔB1 infection was then assessed
through a one-step 24hr infection and titration of virus. In the CV1 control cells (at
39.7˚C) both the Cts2 and ΔB1 viral yield were reduced about 32 and 53 fold respectively
in viral yield as compared to WT viral yield (Fig 3.2D). We found that this decrease in
yield could be rescued for Cts2 if the assay was done at 31.5°C, but not for the ΔB1 virus
(data not shown), thus demonstrating that ΔB1 is not temperature sensitive. Next, the
same assays were performed in CV1-B1myc cells. Expression of B1 in these cells did
not significantly alter WT viral yield from levels in control cells. However, infections of
the CV1-B1myc cells revealed a significant rescue of both the Cts2 and ΔB1 to near WT
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levels for viral yield. Specifically, B1myc expression from the cells increased Cts2 and
ΔB1 viral yield 16 and 18 fold respectively from viral yield in control cells (Fig 3.2D).
Together, these data provide evidence that deletion of B1 from the viral genome results in
a severe, temperature-independent loss in viral fitness and that B1 expression from the
cell can complement for this defect.
3.3. B1 expression in CV1 cells is necessary and sufficient to hyperphosphorylate
BAF independent of other viral factors.
Previous studies of the B1 kinase determined that this kinase is needed to directly
regulate the phosphorylation and thus the antiviral activity of BAF, a cellular DNA
binding protein. Specifically, hyperphosphorylated BAF has reduced affinity for dsDNA
and reduced homodimerization activity, both of which are required to facilitate dsDNA
condensation and inhibition of vaccinia DNA replication and intermediate transcription
(81, 98, 102, 135). Despite our growing understanding of this B1-BAF signaling axis, it
is unknown if the B1 kinase activity mediating BAF phosphorylation in cells is enhanced
by other viral factors. To address this gap in knowledge we utilized both the B1myc
expressing CV1 cells and ΔB1, to determine if B1myc expression in cells in the absence
of infection results in BAF phosphorylation to levels similar to WT infection. First,
lysates from uninfected control cells or CV1-B1myc cells were used for an immunoblot
analysis of total BAF protein levels and phospho-specific BAF protein levels. Total BAF
protein levels were similar between the CV1 control (Fig 3.3A, lane 1, top panel) and
CV1-B1myc (lane 2, top panel) transduced cells whereas phospho-specific BAF protein
levels were markedly higher in cells stably expressing the B1myc protein than EV (empty
vector) transduced cells (Fig 3.3A, compare lanes 1 and 2, bottom panel). Quantitation of
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Fig 3.3. B1 is necessary and sufficient to phosphorylate BAF in cultured cells. (A)
Whole-cell lysates were harvested from CV1 control (EV) or B1myc expressing (B1) cell
lines which were uninfected (lanes 1 and 2) or infected with ΔB1 (lanes 3 and 4, red) or
WT (lanes 5 and 6) at MOI=10 for 6hr at 37˚C. Top panel representative immunoblot
assayed for tubulin loading control and total BAF protein levels. The same lysates were
used to generate the bottom panel of tubulin loading control and phosphorylated BAF
form as detected by the phospho-specific BAF antibody. (B) Relative phospho-BAF/ total
BAF protein levels were quantified by measuring chemiluminescence using ImageLab
software (Bio-Rad) and error bars represent standard deviation (n=4). The uninfected EV
sample was set to 1. Numbers under each column correlate to numbering for immunoblot
in Fig 3A.
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relative phospho-BAF protein levels from four independent experiments are graphed and
demonstrate that on average, greater than 3-fold more phosphorylated BAF is found in
B1myc-expressing cells than in control cells (Fig 3.3B). These data support the
conclusion that B1myc alone is able to upregulate BAF phosphorylation independent of
other viral factors.
We next addressed the question of whether other viral factor(s) enhance B1
mediated BAF phosphorylation. CV1 control cells and B1myc expressing cells were
infected with either WT virus or ΔB1. Cell lysates isolated at 6hpi were used for analysis
of total BAF and phospho-BAF levels. In regard to total BAF protein, we observed
similar levels for uninfected and infected cell lysates of both EV (empty vector) and
B1myc expressing CV1 cells (Fig 3.3A, top panel). In regard to phosphorylated BAF,
ΔB1 infected control CV1 cells consistently showed phospho-BAF levels similar to those
in uninfected control CV1 cells (Fig 3.3A, compare lane 1 and 3 in lower panel). In
comparison, B1myc expression from cells during ΔB1 infection rescues phospho-BAF
levels by approximately 3-fold; similar to fold increase between uninfected CV1-B1myc
cells and WT infected control cells (Fig 3.3B, compare column 4 to 1 and 5). WT
infected CV1-B1myc cells had on average higher phospho-BAF levels, but no significant
change in plaque formation nor viral yield was observed (Fig 3.2B and C). Overall, the
findings that no difference is found between BAF phosphorylation in Fig 3.3B (columns
2 and 4) argues against another vaccinia protein enhancing B1 phosphorylation of BAF.
Together, these data support previous evidence that B1 kinase is necessary to
phosphorylate BAF in cells. Furthermore, our data provide new evidence that this
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mechanism occurs independent of other viral factors, as phosphorylation of BAF is not
enhanced in the presence of other viral proteins.
3.4. BAF depletion results in a partial rescue of ΔB1 replication.
BAF depletion strongly rescues both viral DNA replication and viral yield during
Cts2 infection (69), demonstrating that a primary function of B1 is to inactivate the
antiviral activity of BAF. Based on those data, we hypothesized that depletion of BAF
would similarly rescue the growth of ΔB1. To test this prediction, lentiviral expression
of BAF-specific shRNA was used to deplete endogenous BAF to about 20% of the total
BAF protein in CV1 cells (Fig 3.4A). A plaque assay was used to assess viral growth at
low MOI in control cells and BAF depleted cells. WT virus maintained plaque size and
number independent of BAF depletion, as expected. The Cts2 virus plaque number was
rescued by BAF depletion at non-permissive temperature, which is consistent with
previous studies utilizing this model. Although, as seen before, the Cts2 plaque size is
noticeably smaller than WT (73). Therefore, both B1myc expressing cells (Fig 3.2C) and
BAF depleted cells (Fig 3.4B) rescue Cts2 deficiency in plaque number. ΔB1, however,
was not rescued by BAF depletion at low MOI infection; no visible plaques were present
in either the control or BAF depleted CV1 cells (Fig 3.4B). These results indicate that
CV1-B1myc cells (Fig 3.2C) but not BAF depleted cells (Fig 3.4B) rescue the ΔB1
plaque numbers to WT levels at a low MOI infection.
Subsequent studies were conducted at higher MOI to determine DNA replication
and viral yield of the ΔB1 in the BAF depleted cells. WT DNA replication remained
constant independent of BAF depletion representing control conditions with a functional
B1 kinase produced by vaccinia (Fig 3.4C, columns 1 and 4). During Cts2 and ΔB1
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Fig 3.4. Impact of BAF depletion on growth of B1 mutant viruses. (A) Representative
immunoblot analysis of BAF in CV1 cells transduced to express shCtrl or shBAF.
Detection of tubulin (top panel) was used as a loading control. Total BAF (middle panel)
and phospho-BAF (bottom panel) levels were detected using primary antibodies αBAF
and αphospho-BAF, respectively. (B) Plaque assay on control (top row) and BAF
depleted (bottom row) CV1 cells infected with 200PFU of WT, Cts2, or ΔB1 per well.
Cells were incubated for 72hr at 39.7˚C prior to fixation and imaging. One-step (C) DNA
accumulation and (D) viral yield assays were completed at 39.7˚C for WT, Cts2, and ΔB1
on shCtrl and shBAF CV1 cells. The WT/CV1 shCtrl sample was set to 1 for relative
DNA accumulation. Virus titers were quantified on B1myc expressing cells at 31.5˚C
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(Fig 3.4 continued) (permissive temperature for Cts2 virus). Standard deviation is
denoted by error bars and p-values * < 0.005, ** < 0.001 (black lines drawn between
compared columns).

infections of shCtrl CV1 cells a 75% and 96% reduction of DNA accumulation,
respectively, was observed as compared to WT infection of shCtrl cells (Fig 3.4C). In
comparison, DNA accumulation during Cts2 infection of BAF depleted CV1 cells was
only reduced about 13% from WT, while DNA replication of ΔB1 remained 72%
attenuated in BAF depleted cells (Fig 3.4C). Therefore, BAF depletion rescued Cts2
DNA accumulation to near WT levels, but ΔB1 still exhibited attenuation in cells
depleted of BAF. To next examine the impact of BAF depletion on production of
infectious virus, one-step viral yield assays were undertaken. We observed that the Cts2
and ΔB1 viral yields were reduced 71 and 170 fold as compared to WT during infection
of CV1 cells expressing a control shRNA (Fig 3.4D). However, the Cts2 and ΔB1
viruses were about 6 and 23 fold less than WT, respectively, in the BAF depleted cell
infections (Fig 3.4D). Therefore, BAF depletion cannot fully rescue ΔB1 DNA
replication and viral yield to WT levels. These results revealed an enhanced deficiency of
ΔB1 DNA replication and viral yield as compared to the Cts2 virus. It appears that while
the B1 mutant protein expressed by Cts2 is highly labile and catalytic-inert at high and
low temperatures (75), it still makes a substantial contribution to the viral life cycle either
by regulating BAF or possibly through participation in additional, unknown signaling
pathways.

62

3.5. The ΔB1 displays a growth deficient phenotype in multiple cell lines.
We next examined whether ΔB1 exhibited cell-type specific variability in its replication.
Previous work using Cts2 and Cts25, another temperature sensitive B1 mutant virus,
showed reduced viral growth in the mouse L929 cells when compared to BSC40 cells at
non-permissive temperature (68, 75), suggesting that the mutant B1 and/or its substrates
may function in a cell type specific manner. If it is the substrates rather than the mutant
B1 that is cell-type dependent, then one would predict that ΔB1 would have a similar
trend as the Cts2 virus, attenuated viral growth overall and increased deficiency in the
mouse L929 cell line. Interestingly, our results showed that the DNA replication was
attenuated for the ΔB1 to a similar degree in monkey, mouse and human cell lines with
no increased deficiency in the L929 mouse cells as was previously found with Cts2 (75)
(Fig 3.5A and C). Virus production was also profoundly diminished, with the ΔB1 viral
yield was 448, 176, and 668 fold lower than WT in BSC40, CV1, and L929 cell lines
respectively (Fig 3.5B), and 650 fold lower than WT in HeLa cells (Fig 3.5D). Together,
these data demonstrate that loss of B1 results in a significantly decrease in viral fitness
that can be observed in diverse cell types.
3.6. Chapter 3 Summary
In this chapter we discussed the successful construction of a B1 complementing cell line
and B1 deletion vaccinia virus (Fig 3.1 and 3.2). Using this new system to study B1, we
determined that B1 in cell culture is sufficient to hyperphosphorylate BAF without
additional viral factors (Fig 3.3). We also characterized the phenotype of this ΔB1 virus
with the Cts2 B1 mutant virus, which led to a pivotal discovery. Although depletion of
BAF rescued the block in DNA replication for the Cts2 B1 mutant virus, only a modest
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Fig 3.5. Growth of ΔB1 in multiple cell types. One-step infections at MOI=3 for WT
(black) or ΔB1 (red) on BSC40, CV1, L929, or HeLa cells incubated at 37˚C. Cells and
virus were harvested at 24hpi. (A) DNA accumulation for BSC40, CV1, and L929 cells.
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The WT/BSC40 sample was set to 1. (B) Viral yield for infections in BSC40, CV1, and
L929 cells. Virus titrations were completed on B1myc expressing CV1 cells. HeLa cell
(C) DNA accumulation and (D) viral yield were conducted separately from other cell
lines, using an identical protocol. The WT/HeLa sample was set to 1. Viral harvest was
titered on CV1-B1myc cells. Standard deviation is denoted by error bars and p-values † <
0.05, ‡ < 0.01, ** < 0.001 (black lines drawn between compared columns).

rescue was observed for the ΔB1 virus (Fig 3.4). Furthermore, the attenuated phenotype
of B1 deletion virus was observed in monkey, human and mouse cell lines to similar
levels (Fig 3.5). At this point, we predicted that the Cts2 virus expressed a partially
functional B1 protein. Although it remained unclear if in the absence of B1, BAF is
morepotent than previously appreciated or if B1 also restricts another repressor of viral
DNA replication (Fig 3.6).
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Fig 3.6. B1 regulates DNA replication via a BAF-dependent and independent
mechanism. The vaccinia virus life cycle includes stages of early gene expression
(early), DNA replication, intermediate gene expression (intermediate), late gene
expression (late), and morphogenesis of the assembled virion into a mature virion. In
chapter 3 we have confirmed the function of B1 to restrict BAF antiviral activity against
vaccinia DNA replication. BAF was previously shown to restrict vaccinia intermediate
transcription (81). Our addition to this signaling axis of B1-BAF is a BAF-independent
function of B1 to promoted vaccinia DNA replication.
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CHAPTER 4
VACCINIA B1 KINASE COMPLEMENTATION BY CELLULAR VRK2
4.1. B1 downregulates gene sets related to immune response signaling.
The vaccinia B1 kinase has a highly promiscuous phosphorylation profile in vitro
(98), while also exhibiting conserved phosphorylation of both host (84, 85, 98) and viral
(86, 87) proteins in cell culture. Due to the signaling capability of kinases in general and
the unrestrained phosphorylation activity of the B1 kinase, we posited that expression of
B1 in cells would result in transcriptional modifications. These significantly altered
transcripts may provide insight on which pathways the B1 kinase is regulating during
infection to promote efficient vaccinia virus replication. We chose to complete our
transcriptome analysis of B1 expression in mouse L929 cells due to the available
resources to analyze mouse transcriptome changes and signaling pathways. Initially, we
assayed for B1 expression in stably transduced L929 cells using immunoblot analysis
(Fig 4.1A). Upon confirmation of B1 expression, we transfected control (Ctrl) or B1
expressing cells (B1myc) with 2ug control plasmid or lipofectamine only untransfected
with three samples per condition. Cells were harvested 6h post transfection and RNA was
extracted and purified. The RNA integrity number (RIN) score was 10, which certified
excellent RNA quality, for each sample as measured using the Advanced Analytical
Technical Instruments (AATI) Fragment Analyzer (data not shown). Importantly, RNA
quality scores below 6 have a drastic, negative impact on the confidence of differential
gene expression trends observed due to RNA degradation unrelated to experimental
conditions. Sequencing libraries for each sample were generated and followed by RNA
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Fig 4.1. Transcriptional modulation of host genes during B1 expression. (A) Control
or B1myc stably expressing L929 cell lysates were subjected to immunoblot analysis
using αTubulin and αMyc primary antibodies to detect tubulin (loading control) and
B1myc protein. (B) Transcriptome data was analyzed for the following comparisons as
presented in a heat map: L929 control/plasmid DNA to L929 control, L929 B1myc to
L929 control, and L929 B1myc/plasmid DNA to L929 control. Gene transcripts that were
reduced as compared to L929 control gene transcripts (red) and increased (green) are
included in the heat map for data (P-value <0.05). The green or red bar next to the gene
names represents >1.9 fold increase (green) or decrease (red) in transcripts for L929
B1myc comparison to L929 control cells. Asterisks and plus sign highlight genes of
interest: Ncrna00085 (green asterisk), Gm4951 (green plus sign), and [C030002C11 Rik,
miR-29b-2, miR-29c] (red asterisk).

sequencing. The RNA sequencing quality was greater than 30, with a mean core of 37.
Transcriptome analysis was completed by comparing sample RNA sequencing data with
the mouse transcriptome. Under B1 expression, transcription of 242 genes out of 28,902
total murine genes were significantly changed from control cells (P-value <0.05). A
subset of these genes had a Log2(fold change) > 1.9. Specifically, 25 genes were
upregulated (Fig 4.1B, L929 B1myc column, green line) and 19 genes were
downregulated (Fig 4.1B, L929 B1myc column, red line) as compared to L929 control
cells. Ncrna00085 also known as sperm acrosome associated 6 (SPACA6) protein mRNA
is upregulated in L929 B1myc cells with plasmid DNA but not in L929 with plasmid
DNA nor in L929 B1myc cells (Fig 4.1B, green * and Table 4.1). The SPACA6 protein
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Cellular hyperosmotic salinity response
Cellular response to amino acid stimulus
Cellular response to ethanol
Cellular response to leukemia inhibitor factor
Negative regulation of gene expression
Tissue remodeling
Cellular response to interferon-beta
Defense response

endoplasmic reticulum
membrane

N/A

N/A
N/A

Gene Ontology (Provided by Mouse Genome Informatics)
Component
Process
Function
Integral component of
Molecular function Fusion of sperm to egg plasma membrane
membrane,
involved in single fertilization
Membrane

N/A
N/A

-1.17196

-0.248089

Log2(fold change) as compared to L929 cells
L929 B1myc with pDNA
L929 B1myc
L929 with pDNA

long non-coding RNA
non-coding RNA

Gene Type
protein coding

320977
723963

non-coding RNA gene region
C030002C11Rik,
Mir29b-2,Mir29c
C030002C11Rik RIKEN cDNA A330023F24
microRNA 29b-2
Mir29b-2

Table 4.1 Transcriptome details of genes of interest
NCBI ID
Gene name
Gene
75202
Sperm acrosome associated 6
Ncrna00085

Linkage between miRNA29c and immune
response modulation to viruses.
PMID: 24953694 & 28063705

Comments
A male-infertile transgenic mouse, BART97b,
has a deletion of the Spaca6 gene which
encodes an uncharacterized Immunoglobulin
Superfamily (IgSF) protein. The murine Spaca6
encodes an evolutionary conserved IgSF
protein. PMID: 24275887
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is essential for male murine fertility, specifically in the ability of sperm to fuse with the
egg plasma membrane (136). The next gene region of interest includes the
following three genes, which were grouped together; C030002C11 Rik, miR-29b-2, and
miR-29c. This gene cluster was significantly reduced in expression particularly in L929
B1myc cells with plasmid DNA (Fig 4.1B, red * and Table 4.1). Interestingly, the miR29c is related to modulation of innate and adaptive immunity signaling in response to
viruses (137, 138). Lastly, Gm4951 transcripts were increased in all samples as compared
to L929 cells, and B1myc expression with plasmid DNA seemed to have an additive
impact on transcription levels (Fig 4.1B, green + and Table 4.1). The Gm4951 gene is
also referred to as interferon-gamma-inducible GTPase 2, which is based on functional
predictive methods based on gene sequence.
Another method was taken to analyze this data utilizing gene ontology tools. First,
the transcriptome raw count data was converted to gene symbols. Second, GSEA was
used to identify regulated pathways for B1 expression and/or plasmid DNA transfection
with L929 cell control condition. In cells expressing B1, there was a trend of low
expression values for gene sets related to immune response/ stress signaling (Fig 4.2A).
A comparison between plasmid transfected L929 and L929 B1myc cells had gene sets
with higher expression values for pathways associated with endoplasmic reticulum (ER),
Golgi apparatus, and vesicle transport signaling as well as proteolysis activity signaling,
signal transduction and immune signaling for the L929 B1myc plasmid transfected
condition (Fig 4.2B). Analysis of gene set enrichment differences between L929 cells and
L929 B1myc cells transfected with plasmid DNA showed lower gene expression for gene
set for immune response/ stress signaling, proteolysis activity signaling, ER/Golgi
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Fig 4.2. Gene ontology for cells expressing vaccinia B1 kinase. L929 transcriptome
data was used to identify signaling pathways differentially regulated under the following
conditions: (A) L929 B1myc to L929 control and (B) L929 B1myc/plasmid DNA to
L929 control/plasmid DNA. Gene symbols represent a set of genes from the GSEA
consortium. The heat map indicates gene sets denoted by a specific gene symbol with
high expression (red), low expression (blue) or no change (white) for the experimental
condition as compared to control. Gene ontology (GO) terms were color coded to
represent broad signaling categories: stress/immune response (gold), protein
activation/proteolysis (purple), vesicle trafficking (green), and intracellular/extracellular
signaling/signal transduction (black).

apparatus/vesicle transport signaling (Fig 4.3A). There were also a few gene sets with
higher gene expression for pathways involving signal transduction and cell-to-cell
communication (Fig 4.3A). Lastly, plasmid transfected cells as compared to L929
untransfected cells had lower gene set expression values for pathways related to
proteolysis activity signaling and immune/stress signaling (Fig 4.3B). Together, this
transcriptome analysis of B1 expressing cells with and without the presence of foreign
DNA identified many genes of interest, particularly miR-29c, which will require further
analysis for relevant genes of interest and functional ramifications during vaccinia virus
infection. Furthermore, the gene ontology analysis of altered pathways during B1
expression suggests a function of B1 that reduces immune and stress responses, which
would be beneficial in the context of vaccinia virus induction of immune and stress
sensors.
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Fig 4.3. Gene ontology for B1/DNA and DNA control. L929 transcriptome data was
used to identify signaling pathways differentially regulated under the following
conditions: (A) L929 B1myc/plasmid DNA to L929 control and (B) L929
control/plasmid DNA to L929 control. Gene symbols represent a set of genes from the
GSEA consortium. The heat map indicates gene sets denoted by a specific gene symbol
with high expression (red), low expression (blue) or no change (white) for the
experimental condition as compared to control. Gene ontology (GO) terms were color
coded to represent broad signaling categories: stress/immune response (gold), protein
activation/proteolysis (purple), vesicle trafficking (green), and intracellular/extracellular
signaling/signal transduction (black).

4.2. VRK2 is required in HAP1 cells for optimal DNA replication of ΔB1.
The vaccinia B1 kinase has ~40% sequence identity to a family of conserved
cellular genes called vaccinia related kinases (VRKs) from which it likely evolved (70).
VRKs have essential roles within cells, one of which is to mediate BAF regulation during
mitosis. In vivo, VRK1 regulates BAF function in the nucleus via phosphorylation (89)
and in vitro, both VRK1 and VRK2 are able to phosphorylate BAF (98).
Complementation studies for B1 kinase were completed previously, using VRK1
recombined into the Cts2 virus. In those studies, VRK1 expressed under a viral promoter
in the cytoplasmic compartment rescued viral DNA replication deficiency of the Cts2
virus to greater than WT levels, although plaque morphology was smaller for Cts2-VRK1
recombinant virus than for the WT control (73). These studies confirmed
complementation under conditions which circumvent the nuclear restriction of
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endogenous VRK1. Therefore, we hypothesized that endogenous VRKs would
compensate for the absence of the viral B1 kinase during infection. To test this
hypothesis, we used a human, near haploid (HAP1) cell line control and VRK1 or VRK2
knockout (KO) HAP1 cell lines to evaluate the requirement of VRK1 or VRK2 during
infection with the ΔB1. First, we confirmed the loss of expression of either VRK1 or
VRK2 from the knockout HAP1 cell lines by immunoblot analysis (Fig 4.4A). Second,
although VRKs are known to regulate the cell cycle (139-143), we observed no
significant variability in apparent doubling time between the control and the knockout
HAP1 cell lines (Fig 4.4B). Third, we examined viral DNA accumulation to determine
VRK1 or VRK2 complementation of B1 function. WT and ΔB1 viruses have similar
levels of relative DNA present at 3hpi in HAP1 control, VRK1KO, and VRK2KO cell
lines indicative of viral entry, but minimal if any DNA replication at this time point (Fig
4.4C, left). At 7hpi DNA accumulation increased for both viruses but showed a consistent
lag during ΔB1 infection as compared to WT virus in HAP1 control, VRK1KO, and
VRK2KO cells (Fig 4.4C, right) demonstrating the importance of B1 for DNA replication
in these cells. Interestingly, by 24hpi, the amount of ΔB1 DNA detected was similar to
WT virus in the HAP1 control cells, indicating that although ΔB1 lags at 7hpi it can
recover if given enough time (Fig 4.4D). However, ΔB1 DNA was not as abundant in the
VRK1KO or VRK2KO HAP1 cells lines at 24hpi. Infected VRK1KO cells exhibited a
52% reduction in relative DNA accumulated for ΔB1 as compared to the WT virus (Fig
4.4D). A striking difference was observed in the VRK2KO cells, which showed further
reduction in DNA accumulation during ΔB1 infection, reaching levels of only 3% DNA
accumulation as compared to WT total levels. Next, we analyzed expression of a
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Fig 4.4. VRK2, and to a lesser extent VRK1, complement B1 roles in DNA
replication and viral yield production of ΔB1. (A) HAP1 cell lysates from control,
VRK1KO, and VRK2KO cells were subjected to immunoblot analysis using αtubulin,
αVRK1, or αVRK2 primary antibody. (B) The apparent doubling time was calculated for
each HAP1 cell line. Standard deviation is denoted by error bars (n= 5). (C) DNA
accumulation for 3hpi (left of dotted line) and 7hpi (right of dotted line) for WT (black)
or ΔB1 (red) in HAP1 control, VRK1KO, or VRK2KO cells. The 3hpi WT/Ctrl sample
was set to 1. (D) DNA accumulation and (F) viral yield measured for WT (black) or ΔB1
(red) at 24hpi in HAP1 cell lines; control, VRK1KO, or VRK2KO cells. The WT/Ctrl
sample was set to 1 for DNA accumulation. Standard deviation is denoted by error bars
and p-values † < 0.05, ‡ < 0.01, * < 0.005, ** < 0.001. (E) Whole-cell lysates from
control (lanes 1 and 2), VRK1KO (lanes 3 and 4), and VRK2KO (lanes 5 and 6) were
infected with either WT (lanes 1, 3, and 5) or ΔB1 (lanes 2, 4, and 6) and harvested for
immunoblot analysis for both early gene expression (αI3) at 7hpi and late gene
expression (αF18) at 18hpi. Cell loading control, tubulin, was detected from 7hpi cell
lysates. The F18-specific blot shown at both a short (top) and long (bottom) exposure
time.
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representative early and late gene to determine if loss of B1 affected these stages of the
virus life cycle in HAP1 cells. Early gene expression, as assayed by I3 protein level at
7hpi via immunoblot analysis, was present at similar to slightly higher levels for ΔB1 as
compared to WT in HAP1 control, VRK1KO, and VRK2KO cell lines (Fig 4.4E). This
early gene expression is consistent with unaltered early transcription despite the loss of
B1. Late gene expression, as measured by detection of late protein F18 at 18hpi (Fig
4.4E), was markedly reduced during ΔB1 as compared to the WT infection in HAP1
control and VRK1KO cells lines, although a low level of expression could be detected in
these two cell lines. Importantly, no visible F18 late protein was observed for the ΔB1 in
the VRK2KO HAP1 cells. These data are consistent with a model in which the
replication of ΔB1 DNA in control and VRK1 KO cells allows for weak late gene
expression; whereas the severely impaired DNA replication in VRK2 KO cells results in
a complete block of late gene expression. Finally, we tested the effects of VRK1 and
VRK2 absence on viral yield for the ΔB1. Consistent with the late gene expression data,
the viral yield was almost 53-fold less for ΔB1 than for the WT virus in the HAP1 control
cells (Fig 4.4F). The ΔB1 viral yield during infection of VRK1KO cells exhibited a 52fold reduction as compared to WT infections, similar to the trend observed in HAP1
control cells (Fig 4.4F). As observed for the viral DNA replication data (Fig 4.4D), an
additional reduction in viral fitness occurred in the VRK2KO cells. The viral yield of the
ΔB1 in the VRK2KO cells was 550 fold lower than WT viral yield under the same
cellular conditions (Fig 4.4F). Lastly, we used an immunofluorescence assay to assess
early (I3) and late (P11mCherry) protein expression for ΔB1 in each HAP1 cell line. The
uninfected cells represent the negative controls for I3 and mCherry viral protein
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expression (Fig 4.5, panels 1 and 5). At 7hpi the I3 early protein is expressed in ΔB1
infected parental HAP1 cells and forms foci indicative of replication factories (Fig 4.5,
panel 2), which is consistent with both 7hpi I3 protein levels (Fig 4.4E) and DNA
accumulation results (Fig 4.4C). Interestingly, while I3 was expressed in VRK1KO and
VRK2KO cells, the number of concentrated foci formed by I3 decreases in the VRK1KO
cell line and are quite rare in VRK2KO cells as compared to ΔB1 infected HAP1 control
cells (Fig 4.5, top row, panels 3 and 4).
Next, late protein expression was assayed through detection of the mCherry
protein, in which gene expression is regulated by the P11 late viral promoter. mCherry
protein expression followed a similar trend as observed for ΔB1 F18 immunoblot (Fig
4.4E); almost all cells express mCherry during ΔB1 infection of HAP1 control cells,
about half in VRK1KO cells and very few VRK2KO cells express mCherry protein (Fig
4.5, panels 6-8). In summary, VRK2 absence and to a lesser extent VRK1 absence
resulted in a marked deficiency of ΔB1 DNA replication, 24hr viral yield, 7hpi
replication factory formation, and 18hpi late expression of mCherry. These data indicate
that endogenous VRK2 can partly compensate for the absence of the B1 kinase during
infection of HAP1 cells, specifically during viral DNA replication. Furthermore,
endogenous VRK1 was also able to complement B1 roles during DNA replication,
although to a much lesser degree than VRK2 in these studies.
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Fig 4.5. Characterization of ΔB1 DNA replication factory formation, and late
mCherry protein levels in HAP1 control, VRK1KO and VRK2KO cell lines.
Immunofluorescence analyses of uninfected HAP1 control cells (panels 1 and 5), and
ΔB1 infected HAP1 control (panels 2 and 6), VRK1KO (panels 3 and 7), and VRK2KO
(panels 4 and 8) at MOI=5 and incubated at 37˚C. Early I3 protein was detected using αI3
primary antibody at 7hpi (panels 2-4) and late mCherry fluorescent protein was imaged
from cells at 18hpi (panels 6-8). Uninfected HAP1 control cells were also incubated with
αI3 primary antibody and appropriate secondary antibody. All cells were incubated with
DAPI stain used to detect nuclei.
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4.3. VRK2 reconstitution in VRK2 knockout HAP1 cells rescues ΔB1 DNA
replication.
To confirm the necessity of VRK2 during ΔB1 infection we generated a lentivirus
expressing the wild type human VRK2 gene, tagged at its C-terminus with the myc
epitope. Stable expression of exogenous VRK2myc was achieved in both HAP1 control
cells and VRK2KO HAP1 cells (Fig 4.6A). Exogenous VRK2myc (gray arrow) protein
levels in the transduced VRK2KO HAP1 cells were similar to protein levels of
endogenous VRK2 (black arrow) in HAP1 control cells (Fig 4.6A, lanes 1 and 4).
Exogenous VRK2myc protein expression in the transduced HAP1 control cells was less
than exogenous VRK2myc levels in the VRK2KO HAP1 cells, although detectable at a
longer exposure (Fig 4.6A, lanes 2 and 4). Relative DNA accumulation measurements
were used to determine if addition of exogenous VRK2myc could rescue the deficiency
of the ΔB1 during infection of the VRK2KO HAP1 cell line (Fig 4.6B). Exogenous
VRK2myc expression in HAP1 control cells did not alter the WT or ΔB1 relative DNA
accumulation (Fig 4.6B, lanes 1-4). Importantly, the reconstitution of VRK2 protein in
the VRK2KO HAP1 cells resulted in a rescue of ΔB1 relative DNA accumulation 16 fold
above that in VRK2KO cells (compare bars 6 and 8). These data confirm that the ΔB1
DNA replication deficiency in the VRK2KO HAP1 cells is due to an absence of VRK2.
This is the first demonstration that VRK2 specifically complements for the loss of B1
kinase during viral DNA replication carried out in HAP1 cells.
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Fig 4.6. VRK2 reconstitution rescues ΔB1 deficiency in HAP1 VRK2KO cells. A)
HAP1 control (lanes 1 and 2) and VRK2KO (lanes 3 and 4) cells were transduced with a
lentivirus expressing human myc-tagged VRK2 to generate HAP1 control/ VRK2myc
(lane 2) and VRK2KO/ VRK2myc (lane 4) cells. Immunoblot analysis of endogenous
VRK2 (black arrow, 58kDa) and exogenous VRK2myc (grey arrow) for each transduced
cell line. B) DNA accumulation was measured after 24hr one-step infection with WT
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(Fig 4.6 continued) (black) or ΔB1 (red) in control cells (columns 1 and 2), exogenous
VRK2myc expressing control cells (columns 3 and 4), VRK2KO cells (columns 5 and 6),
and exogenous VRK2myc expressing VRK2KO cells (columns 7 and 8). The WT/Ctrl
sample was set to 1. Standard deviation is denoted by error bars and * p-value is <0.005
(black lines drawn between compared columns).

4.4. Impact of VRK2 depletion on ΔB1 DNA replication in HeLa and A549 cells.
Our above studies indicate that HAP1 cells are somewhat unique from other cell
lines tested (Fig 3.5A-D) in that vaccinia virus DNA replication is delayed during ΔB1
infection, but approaches WT levels by 24hpi (Fig 4.4C and D). Therefore, significant
reductions in DNA accumulation during ΔB1 infection of HAP1 cells can be measured
effectively, as illustrated in VRK2KO HAP1 cells (Fig 4.4C and D). To further examine
the requirement of VRK2 during vaccinia virus infection in the absence of B1 we utilized
two other human cancer cell lines, HeLa and A549, which express similar protein levels
of VRK2 to HAP1 cells (Fig 4.7A). First, we used siRNA to deplete VRK2 from either
HeLa or A549 cells, using siRNAs targeting VRK2 mRNA. HeLa cells were depleted of
VRK2 using two different siRNAs designed to target different sites on the VRK2 mRNA.
The siVRK2#1 achieved a better depletion than siVRK2#2 resulting in about 20%
remaining endogenous VRK2 (Fig 4.7B). WT 24hpi DNA accumulation was not affected
by VRK2 depletion in HeLa cells (Fig 4.7C). Notably, ΔB1 displayed a statistically
significant, although modest, decrease in DNA replication during infection of VRK2
depleted HeLa cells as compared to infection of siCtrl HeLa cells. The viral yield of WT
virus was not altered while ΔB1 was modestly reduced during infection of VRK2
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Fig 4.7. Effect of VRK2 depletion on ΔB1 growth in human HeLa and A549 cells.
(A) Immunoblot analysis of HAP1 control, HeLa, and A549 human cell lysates using
αtubulin and αVRK2 primary antibodies as shown. (B) Endogenous VRK2 was depleted
in HeLa cells by transfection of cells with two different siRNAs targeting human VRK2
mRNA. Immunoblot analysis for tubulin loading control and αhuman VRK2 protein was
completed for whole-cell lysates of untransfected HeLa cell control (lane 1), siRNA
scrambled as siCtrl (lane 2), siVRK2#1 (lane 3), or siVRK2#2 (lane 4) transfected HeLa
cells. (C) DNA accumulation and (D) 24hr viral yield assays were completed in siCtrl
(light grey bars), siVRK2#1 (grey bars), and siVRK2#2 (dark grey bars) transfected
HeLa cells for WT and ΔB1 infected cells. The WT/HeLa siCtrl sample was set to 1 for
DNA accumulation. (E) Endogenous VRK2 was depleted in human A549 cells by
transfection of cells with siVRK2#1. Immunoblot analysis of siCtrl and siVRK2#1
transfected A549 cell lysates for detection of tubulin loading control and human VRK2
protein. (F) DNA accumulation and (G) viral yield assays were completed in siCtrl (light
grey bars) and siVRK2#1 (grey bars) transfected CV1 cells for WT (left two columns)
and ΔB1 (right two columns) infected cells. The WT/A549 siCtrl sample was set to 1 for
DNA accumulation. Standard deviation is denoted by error bars and * p-value < 0.005,
** < 0.001 (black lines drawn between compared columns).
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depleted HeLa cells. (Fig 4.7D). Next, endogenous VRK2 was depleted in A549 cells
using siVRK2#1. Depletion of VRK2 in A549 cells resulted in <20% remaining
endogenous VRK2 as assayed using immunoblot (Fig 4.7E). WT virus relative DNA
accumulation (Fig 4.7F) and viral yield (Fig 4.7G) were not significantly altered by
reduction of endogenous VRK2 from A549 cells. Yet, we observed a significant decrease
for ΔB1 DNA accumulation (Fig 4.7F) and viral yield (Fig 4.7G) in the VRK2 depleted
A549 cells. This outcome mirrored the attenuation of ΔB1 in HAP1 VRK2KO cells (Fig
4.4D and F). These data indicate that HAP1 and A549 are cell lines in which ΔB1 can
attain elevated levels of DNA accumulation, enabling us to quantify a significant
attenuation during the absence or depletion of VRK2. Moreover, the sufficiency of VRK2
to compensate for B1 during ΔB1 infection appears to be cell type dependent, as
suggested by the differing magnitude of the results in HeLa cells versus HAP1 and A549
cells
4.5. BAF depletion in HAP1 cells lacking VRK2 results in a small increase in ΔB1
DNA replication.
Our next goal was to explore the mechanism through which VRK2 complements
for the lack of the B1 viral kinase in ΔB1. Based on in vitro studies confirming VRK2
ability to phosphorylate BAF (98), we hypothesized that, like B1, VRK2 may regulate
BAF antiviral function in cells; therefore, BAF depletion would rescue ΔB1 growth in
VRK2KO cells. To test this prediction, we transduced HAP1 control and VRK2KO cells
to express a BAF-specific shRNA. We then measured viral DNA accumulation during
WT virus and ΔB1 infection in these transduced VRK2KO cells. We found that in cells
infected with WT virus, DNA replication was not affected by BAF depletion, consistent
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Fig 4.8. VRK2 rescues ΔB1 DNA replication primarily through a BAF independent
mechanism. ORFV life cycle occurs independent of either VRK1 or VRK2
expression from HAP1 cells. (A) DNA accumulation was measured at 24hpi for WT
(left two columns) and ΔB1 (right two columns) in control or BAF depleted cells HAP1
VRK2KO cells. The WT/HAP1 VRK2KO shCtrl sample was set to 1. (B) Immunoblot
analysis of HAP1 control (lane 1), VRK1KO (lane 2), and VRK2KO (lane 3) cell lysates
using αtubulin and αBAF primary antibodies as shown. (C) HAP1 control, VRK1KO,
and VRK2KO cells were infected with parapoxvirus, orf virus (ORFV) at MOI =1 for
four days. Cell and virus were harvested and titrated on primary ovine fetal turbinate
(Oftu) cells and quantified by the Spearman-Karber’s tissue culture infectious dose 50

88

method (TCID50/mL). Viral titer values are an average of 2 replicates and error bars
indicate standard deviation between replicates. (D) Working model of B1 and VRK
regulated vaccinia virus life cycle stages based on this study and previous reports.. We
identified a B1-VRK2 shared function in BAF regulation and a BAF-independent
mechanism, both affecting vaccinia DNA replication. B1 was also previously shown to
contribute to vaccinia morphogenesis.

with other cell lines (69, 81, 83). In comparison, when measuring ΔB1 DNA
accumulation in the VRK2KO shCtrl cells and BAF depleted cells, a 3.5 fold rescue is
observed (Fig 4.8A). This increase from 4% to 12% DNA accumulation as compared to
WT infection of VRK2KO shCtrl cells is modest, but is similar to earlier results for ΔB1
DNA accumulation in BAF depleted CV1 cells (Fig 3.4C). We therefore posit that
VRK2 enhances ΔB1 DNA replication partially through a BAF dependent mechanism,
but also to a significant degree through a BAF independent mechanism.
To examine whether loss of VRK2 impacts BAF expression levels or
phosphorylation status, we then performed immunoblot analysis of BAF in HAP1
control, VRK1KO, and VRK2KO cells (Fig 4.8B). The antibody employed detects both
phosphorylated BAF (grey arrow), which migrates more slowly in the gel, and the more
rapidly migrating unphosphorylated form of BAF (black arrow). In control HAP1 cells,
both forms are detected at similar levels. In VRK1KO cells there is a clear loss of the
upper band representing phosphorylated BAF. This data is consistent with numerous
other studies that VRK1 plays an important part in modifying BAF phospho-status in the
nucleus (89, 94, 98, 144). Interestingly, in VRK2KO cell lysates there is no apparent loss
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of the upper form of BAF. This lack of a measurable impact of VRK2 on BAF
phosphorylation indicates that VRK1 is the dominant BAF kinase in HAP1 cells when
measured in whole cell lysates and leads us to speculate that VRK2 mediated
complementation for B1 occurs via a BAF independent mechanism.
4.6. The viral life cycle of ORF virus, naturally lacking the B1 kinase, is not affected
by the absence of either cellular VRK1 or VRK2.
Our observation that VRK2 can partly complement during infection with ΔB1
raised the question of whether other viruses lacking a B1 homolog may depend on VRK1
or VRK2 for replication. The orf virus (ORFV) is a Poxviridae family member; however,
it is classified under the Parapoxvirus genus (1) and lacks a B1-like kinase (130). To
explore the role of VRK1 and VRK2 during ORFV infection we performed a viral
growth assay in HAP1 control, VRK1KO, and VRK2KO cells. Interestingly, no
significant difference was observed for ORFV viral titer between the control HAP1 cells
and either VRK1KO or VRK2KO HAP1 cells (Fig 4.8C). These results indicate that
VRK1 or VRK2 are not required for the viral life cycle of ORFV and that this pathogen
has evolved alternative mechanisms to replicate without B1. Consistent with this
reasoning, ORFV infection of CV1-B1myc cells did not exhibit enhanced viral fitness
when compared to control CV1 cells (data not shown). This suggests that ORFV may not
rely on cellular VRK1 or VRK2, possibly due to a divergence in evolution from
Orthopoxviruses. Alternatively, it is plausible that the ORFV is capable of utilizing
either VRK1 or VRK2 interchangeably in order to replicate its viral DNA. Future
production of a VRK1/VRK2 double knockout cell line will be needed to test this
possibility.
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4.7. Chapter 4 Summary
To this point we know that the vaccinia B1 kinase regulates the antiviral activity of BAF
and has additional substrates with no known associated function. To fill this gap in
knowledge of B1 roles, this chapter 1) identified cellular pathways differentially regulated
during B1 expression and 2) characterized cooperative activity between B1 and cellular
VRK homologs. Together, we identified potential regulatory roles of B1 on stress/immune
response, metabolism, signal transduction, proteolysis and vesicle transport. Mediation of
stress/immune response as well as signal transduction are known for B1 function, yet the
other pathways present novel pathways related to B1 regulation. Furthermore, we show in
this chapter the redundant function of VRK2 with the B1 kinase and discover that this
shared function between B1 and VRK2 is largely BAF independent (Fig 4.8D). Lastly, we
determined that the necessary role of B1 and the VRKs was specific for vaccinia virus but
not ORFV, supporting a model where Parapoxvirus divergence and absence of a B1 kinase
does not increase the requirement of both cellular VRKs.
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CHAPTER 5
VACCINIA B1 KINASE AND B12 PSEUDOKINASE ARE GENETICALLY AND
FUNCTIONALLY LINKED
5.1. Fitness gains observed following adaption of the ΔB1 virus correlate with an
indel mutation within the B12R gene.
The vaccinia virus B1 kinase is a critical positive regulator of vaccinia DNA
replication. Specifically, B1 inhibits the BAF antiviral factor, which can otherwise
restrict viral DNA replication and subsequent gene expression (69); however, much
remains unknown about how B1 may regulate other viral factors during infection. In a
recent study of B1 function, our laboratory generated a mutant vaccinia virus (ΔB1 virus)
in which the B1R gene was deleted by homologous recombination (127). As expected,
without this viral kinase, growth of the ΔB1 virus was severely impaired compared to
WT virus. Intriguingly, the fact that some progeny virus could be isolated following
infection with the ΔB1 virus suggested to us that it may be amenable for use in a screen
for second site suppressors using an experimental evolution protocol. If successful, this
approach could reveal novel genetic linkages between B1R and other viral genes.
The experimental evolution of ΔB1 was conducted by iterative passage of the
virus at a low multiplicity of infection (MOI) of 0.1 on non-complementing CV1 cells.
Each infection was allowed to proceed for three to four days prior to harvest. After each
passage the viral yield was determined by plaque assay titration on complementing, B1
expressing CV1 (CV1-B1myc) cells characterized previously (127). Virus titrations on
the CV1-B1myc cells allowed for accurate quantification of serially passaged ΔB1 virus,
while no visible plaques could form on the non-complementing CV1 cells. The process of
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Fig 5.1. Adaptation of ΔB1 virus. (A) ΔB1 virus was serially passaged in CV1 cells in
triplicate and named A1-A3 for adapted ΔB1 viruses. Virus harvested at each passage
was titrated on CV1-B1myc cells. (B) Fold DNA abundance was quantified using qPCR
and primers designed to vaccinia HA or B1 genes for total viral DNA or B1 specific
DNA. DNA was isolated from CV1 cells infected with WT, ΔB1, ΔB1-A1 passages 1-7,
ΔB1-A2 passages 1-7, or ΔB1-A3 passages 1-7 viruses at a MOI of 3 and harvested 24h
post infection. (C) Plaque assay of CV1 control or B1myc expressing cells infected with
WT, ΔB1 and ΔB1-A1 virus from passages 1-7 at 200 PFU/well. Cells were fixed 72h
post infection.

93

harvesting, titration on CV1-B1myc cells, and reinfection of CV1 cells at low MOI was
carried out for seven passage rounds. Virus yield at each passage was graphed for the A1,
A2, and A3 lineages of adapted ΔB1 virus (Fig 5.1A). During these serial passages, the
yield of the ΔB1 virus showed a notable 10-fold increase in titer between passage rounds
3 and 5, suggesting the emergence of a rescued virus in all three, independent replicates.
Using quantitative PCR we verified that the B1R gene remained undetected in our serially
passaged viruses (Fig 5.1B), thus confirming that reintroduction of B1 is not responsible
for the rescue of the passaged ΔB1 virus.
Next, we predicted that the 10-fold increase in viral yield may be sufficient to
permit spread through non-complementing cells and allow plaque formation. To test this
prediction, we infected CV1 control cells and CV1-B1myc cells with 200 plaque forming
units (PFU) per well of WT, ΔB1, and each passage of adapted ΔB1 virus from lineage
A1, then fixed and stained the cells at 72h post infection. Starting at passage three, the
adapted cultures contained virus that formed plaques which were smaller than WT, but
clearly visible on non-complementing CV1 cells (Fig 5.1C, top row). As expected,
adapted ΔB1 virus plaque size was increased in cells expressing B1 in trans (Fig 5.1C,
bottom row). These data confirm the rescue of the adapted ΔB1 virus in noncomplementing CV1 cells, although the smaller plaque phenotype of the adapted ΔB1
virus suggests that it is less fit than the WT virus in this assay.
With three independently adapted ΔB1 viruses in hand, we sought to identify
significant genetic alterations within the adapted viruses as compared to the ΔB1 virus.
To this end, DNA isolated from the WT (Wiebe laboratory), ΔB1, and adapted ΔB1
viruses A1 and A3 (passage round 7) were subjected to 150 base pair paired end
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sequencing using a MiSeq V2 instrument. Following guided assembly, WT (Wiebe),
ΔB1, ΔB1-A1, and ΔB1-A3 sequences were compared to the WT Western Reserve
reference genome (NC_006998.1) in the NCBI database. One previously characterized
mechanism of virus adaptation involves the development of genomic ‘accordions’ in
which gene amplifications occur for a specific locus, permitting a dose dependent
compensation by a complementary gene (11, 12). However, the ΔB1-A1 and ΔB1-A3
virus sequence data lacked evidence of genomic accordions, which would have been
identified by large increases of sequence read counts for a particular region in the adapted
genomes compared to WT and ΔB1 controls. Instead we observed a consistent read count
depth across the entire genome for both adapted and control viruses. We also analyzed
the specific read calls at each nucleotide position in the complete genome for evidence of
single nucleotide polymorphisms (SNPs). For this analysis we made sequence
comparisons between WT (Wiebe) to WT WR (reference sequence), ΔB1 to WT
(Wiebe), and ΔB1mutB12 to ΔB1. From the genome analyses of ΔB1-A1 and ΔB1-A3
viruses, only one non-synonymous mutation was identified, which was found solely in
the ΔB1-A1 virus. This mutation identified in ΔB1-A1 is a G to A substitution expected
to cause a Gly115 to Asp mutation within the B12R coding region. Based on the read
depth for this specific nucleotide location, we determined that this point mutation is
present in 18% of the reads from the ΔB1-A1 virus (Fig 5.2A and Table 5.1). Finally, we
quantified reads containing insertion/deletion (indel) mutations across the entire genome
for ΔB1, ΔB1-A1, and ΔB1-A3 as compared to the changes in WT (Wiebe) from the WT
WR (reference sequence) genome. To present the locations of indels graphically,
comparisons of indel read counts are plotted along the y-axis for ΔB1 to WT (Fig 1B,
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Fig 5.2. Characterization of ΔB1 viruses serially passaged on CV1 cells and
identification of mutation within the B12R gene. (A) Experimental evolution depiction
with genome reference identification numbers. There were no single nucleotide
polymorphisms (SNPs) in >5% of the nucleotide read counts for the coding regions of
vaccinia WR reference compared to WiebeLab virus genome, and WiebeLab compared
to ΔB1 virus genome. (B) Deep sequencing data for WT (Wiebe), ΔB1, ΔB1-A1, and
ΔB1-A3 viruses was used to graph insertion/deletion mutations at each nucleotide site for
the entire vaccinia genome when comparing ΔB1, ΔB1-A1, and ΔB1-A3 viruses to the
change in indel mutations of the WT (Wiebe) compared to the WT WR (reference
sequence). (C) Graphed insertion/deletion mutations for ΔB1-A3 compared to WT WR
(reference sequence) for reads 170,015-175,094bp. The dotted line indicates indel
mutations that occur in 5% of the total reads at a single nucleotide. Indel mutations above
5% were considered significant mutations in the mixed ΔB1 adapted virus population.
Locations of encoded genes are labeled below, corresponding to the base pairs on the xaxis of the graph.
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Table 5.1. Sequnencing data from adapted ΔB1 viruses
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top), ΔB1-A1 to WT (middle), and ΔB1-A3 to WT (bottom) and the nucleotide numbers
of the reference genome along the x-axis. Strikingly, indel mutations were identified at
identical nucleotide positions in the ΔB1-A1 and ΔB1-A3 comparisons to WT (Fig 5.2B,
middle and bottom graph), but not for ΔB1 sequence comparison to WT (Fig 5.2B, top
graph). Narrowing the x-axis to focus on the region of interest, we graphed the total
number of indel mutations found between 170,015 and 175,094 base pairs for the ΔB1A3 alignment to the ΔB1 genome (Fig 5.2C). The genes labeled below the x-axis indicate
the genes encoded at the specific base pair regions. This graph depicts that the ΔB1-A3
virus population contains a significant spike in insertion and deletion mutations within
the B12R gene. This spike of indel mutations corresponds to adenine 689 in the B12R
gene, which is the start of an eight adenine sequence (Table 5.1). This single site of indel
mutations is present in approximately 48% and 65% of the reads for the ΔB1-A1 and
ΔB1-A3 virus, respectively (Table 5.1). Interestingly, either an insertion or deletion of an
adenine at this site alters the predicted reading frame of the gene and thereby introduces a
premature stop codon, resulting in a truncated B12 protein. In addition to the Illumina
sequencing of mixed viral populations, targeted Sanger sequencing of the B12 locus was
performed on 10 isolated plaques chosen from the three adapted cultures after two rounds
of plaque purification. As a result, we found that all ten isolated plaques contain either an
indel mutation at B12 nucleotide 689 or an indel at another earlier position in B12R
(Table 5.1). Together these results highlight the significant frequency of mutations within
the B12R gene, leading it to become our top candidate for a ΔB1 second site suppressor
mutation.
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The B12 protein is 283 amino acids in length and shares 36% amino acid identity
to the vaccinia B1 kinase (124, 125). Akin to the B1 kinase, the B12 protein is
homologous to the cellular vaccinia related kinases (VRKs). Furthermore, the viral B12R
gene is expressed early in infection, like the B1 kinase, but differs from the B1 kinase in
that it lacks catalytic activity (114, 124). Proteins that possess sequence and structural
similarity to active kinases, but lack phosphotransferase activity due to alterations in key
catalytic residues are abundant in all forms of life and are commonly referred to as
pseudokinases. Although B12 is a pseudokinase and B1 paralog, the function of B12
during infection remains an enigma to date, as previous studies revealed no phenotypic
defect for a mutant vaccinia virus missing 83% of the B12 gene (114, 115).
5.2. The ΔB1mutB12 virus exhibits rescued DNA replication and viral yield in
multiple cell lines.
As described above, the adapted ΔB1 virus (hereafter referred to as the
ΔB1mutB12 virus) exhibited a visible plaque phenotype not observed for the ΔB1 virus.
To investigate the extent of the ΔB1mutB12 rescued phenotype, we measured both DNA
accumulation and viral yield during a single round of vaccinia virus replication in
noncomplementing cells. Following synchronous infections at a MOI of 3, viral genome
replication was measured by qPCR. Compared to the ΔB1 virus, the ΔB1mutB12-A1
(light green bars) and the ΔB1mutB12-A3 (dark green bars) viruses exhibit increased
DNA accumulation at 24h, exceeding ΔB1 (red bars) levels by >5-fold in monkey CV1
cells (Fig 5.3A) and >18-fold in human HeLa cells (Fig 5.3B). Increases were also
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Fig 5.3. Rescued DNA replication block for ΔB1mutB12 virus in multiple cells. (A)
CV1, (B) HeLa, (C) A549, and (D) L929 cells infected with WT (black), ΔB1 (red),
ΔB1mutB12-A1 (light green), ΔB1mutB12-A3 (dark green) at a MOI of 3 were
harvested 24h post infection for qPCR of relative DNA accumulation.
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Fig 5.4. Rescued viral yield for ΔB1mutB12 virus in multiple cells. (A) CV1, (B)
HeLa, (C) A549, and (D) L929 cells infected with WT (black), ΔB1 (red), ΔB1mutB12A1 (light green), ΔB1mutB12-A3 (dark green) at a MOI of 3 were harvested 24h post
infection for titration on CV1-B1myc cells for viral yield.
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observed in human A549 cells (Fig 5.3C) and mouse L929 cells (Fig 5.3D), although to a
lesser degree.
Regarding viral progeny, the ΔB1mutB12-A1 (light green bars) and ΔB1mutB12A3 (dark green bars) exhibit rescued viral yield phenotypes in multiple cell lines when
compared to the ΔB1 (red bars) virus. Specifically, the viral yields for ΔB1mutB12-A1
and -A3 viruses compared to ΔB1 levels were increased >6-fold in monkey CV1 cells
(Fig 5.4A), >50-fold in human HeLa cells (Fig 5.4B), >6-fold in human A549 cells (Fig
5.4C), and >12-fold in mouse L929 cells (Fig 5.4D). Notably, despite a >50-fold rescue
over the ΔB1 viral yield, the ΔB1mutB12-A1 and -A3 viruses remained at 11-fold (pvalue = 0.0056) and 13-fold (p-value = 0.0051) lower levels than WT yields in HeLa
cells (Fig 5.4B). Similarly, the ΔB1mutB12-A1 virus was 28-fold (p-value = 0.0474)
lower than WT viral yield in L929 cells (Fig 5.4D), despite showing a >12-fold increase
from ΔB1 levels. These results demonstrate a rescued viral yield phenotype for
ΔB1mutB12-A1 and -A3 over ΔB1 levels in all cell lines, while remaining attenuated
compared to WT virus.
To examine ΔB1mutB12-A3 virus yield at earlier time points, CV1 cells infected
with WT (black line), ΔB1 (red line) or ΔB1mutB12-A3 (green line) virus were harvested
early during infection to monitor input DNA (3hpi) and initial DNA replication (7hpi),
while later time points were selected for the completion of DNA replication (16hpi) and
the completion of vaccinia virus replicative cycle (24hpi). DNA accumulation at each
time point demonstrated that the ΔB1mutB12-A3 virus replicated its genome at a rate
similar to WT (Fig 5.5A). Next, virus samples were titrated on CV1-B1myc
complementing cells to quantify viral yield at each time point. At early time points the
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Fig 5.5. Viral growth kinetics of ΔB1mutB12 is similar to WT virus. (A) WT (black),
ΔB1 (red), or ΔB1mutB12-A3 (green) infections of CV1 cells were performed at a MOI
of 3 and harvested at 3, 7, 16, or 24h post infection for relative DNA accumulation or (B)
viral yield quantification on CV1-B1myc cells. (C) A multi-step viral yield assay was
completed by infecting CV1 cells at a MOI of 0.01 with WT (black), ΔB1 (red) or
ΔB1mutB12-A3 (green) and harvested at 48h post infection for titration on CV1-B1myc
cells.
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ΔB1mutB12 viral yield levels were identical to WT levels. Similar to the 24h only data
(Fig 5.4A), the ΔB1mutB12-A3 virus exhibited an almost 3-fold reduction in viral yield
as compared to WT virus at late time points, although these differences were not
statistically different (Fig 5.5B, 16 and 24hpi). Therefore, the WT virus and ΔB1mutB12
virus have only modest growth difference with respects to DNA accumulation and viral
yield output in CV1 cells under these conditions.
The similar growth profiles of WT and ΔB1mutB12 viruses in CV1 cells at a
MOI of 3 led us to question whether the same was true at lower concentrations of virus.
For this next assay, cells were infected with a low MOI of 0.01 and allowed to propagate,
spreading cell-to-cell, for 48h before harvest and titration on CV1-B1myc cells. From
these infections, ΔB1mutB12 (green bar) viral yield was >180-fold higher than ΔB1 (red
bar) virus (Fig 5.5C). Interestingly, the ΔB1mutB12-A3 (green bars) virus was attenuated
12-fold (p-value = 0.09) as compared to the WT (black bars) virus viral yield (Fig 5.5C).
In summary, the ΔB1mutB12 virus exhibits a rescued DNA accumulation phenotype
compared to ΔB1 in multiple species cell lines. The viral yield of the ΔB1mutB12 virus
also indicates a recovered growth phenotype as compared to ΔB1 levels for all cell lines
tested. Yet, the extent of ΔB1mutB12 attenuation compared to WT viral yield differed
depending on the cell line and amount of virus used for infection.
5.3. The B12ΔA690 protein is truncated and accumulates to lower levels than the
wild-type B12 protein.
The sequencing data for the ΔB1mutB12 viruses revealed a prevalent indel
mutation within the 3’ end of the B12R gene that leads to a frame shift. This frameshift
introduces a premature stop codon into the mRNA, which is predicted to translate into a
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protein missing about 45 amino acids from the C-terminus, about 16% of the total
polypeptide. Studies on VRK1, a cellular homolog of B12 determined that removal of
18% of the protein from the C-terminus produces a protein that cannot be purified from
E. coli (145) suggesting that this region is necessary for protein folding and/or stability.
The only nonsynonymous point mutation in greater than 5% of the read counts also
occurred within the B12R gene and encoded a glycine (G) to aspartate (D) change at
amino acid 215 (Table 5.1). Interestingly, the temperature sensitive (ts) B1 mutant virus,
ts25, has a lesion within the B1R gene that results in glycine at amino acid 227 to change
to aspartate. This glycine aligns with the mutated glycine in the B12 protein sequence of
the ΔB1 adapted virus. Analysis of the ts25 virus growth supports that the lesion in B1R
results in a catalytic null, labile B1 protein (73). Based on these supporting information
and B12 sequence analysis, we hypothesized that the indel mutation within the B12R
gene will lead to a truncated protein with reduced protein accumulation, and B12 amino
acid G to D mutation would reduce B12 protein stability similarly resulting in decreased
protein abundance. To test this hypotheses, we PCR amplified the wild-type B12R
vaccinia gene from the WT vaccinia virus and generated two B12R mutants. The first
B12R mutant was a single adenine deletion at nucleotide 690, corresponding to the site of
the indel in ΔB1mutB12. The second B12R mutant contained a SNP at nucleotide G215
to A for representation of the point mutant in the ΔB1mutB12-A1 virus, Next, we cloned
the vaccinia virus B12R gene or the B12R mutants with a HA epitope tag sequence at the
5’ end of the gene into the pJS4 vaccinia expression vector. CV1 cells were transfected
with pJS4-HA-B12wt, pJS4-HA-B12ΔA690, or pJS4-HA-B12 G-A plasmid DNA,
synchronously infected with WT virus at a MOI of 3 and harvested 24h post infection to
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Fig 5.6. Adapted virus B12ΔA690 mutant is truncated and less abundant than wildtype B12 protein. (A) CV1 cells were transfected with pJS4-HA-B12wt, pJS4-HAB12ΔA690 or pJS4-HA-B12 G-A plasmid and infected 6h post transfection with WT
virus at a MOI of 3. 24h post infection cells were harvested for immunoblot analysis. The
HA-B12Δ690 represents the indel mutation and HA-B12 G-A represents the point
mutation within the ΔB1mutB12 virus B12R gene. (B) B12 proteins were expressed from
the pJS4 vector during WT infection (representative immunoblot in Fig 1A). Protein
abundance was averaged for HA-B12wt and HA-B12ΔA690 or for (C) HA-B12wt and
HA-B12 G-A from five independent experiments.
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allow for saturation of late gene expression. Following immunoblot analysis, the tubulin
control shows equal loading of protein, while the HA blot shows HA-B12ΔA690 protein
band has a smaller molecular weight as shown by a faster migrating band than the HAB12wt and HA-B12 G-A protein bands (Fig 5.6A). As predicted, the HA-B12ΔA690
protein has reduced protein abundance, almost 2 fold lower than HA-B12wt protein (Fig
5.6B). However, the HA-B12 G-A mutant protein was not significantly lower than HAB12wt protein abundance and averages at 90% of the wild-type protein (Fig 5.6C).
Together, these results support the hypothesis that deletion of the adenine at nucleotide
position 690 within the B12R gene results in a truncated protein and reduced protein
levels as compared to the wild-type B12 protein. While similar protein levels between
HA-B12wt and HA-B12 G-A supports that the mutant protein is not inherently less
stable, the population of ΔB1 adapted viruses containing this mutation suggests that this
residue or region may be critical for B12 function.
5.4. Loss of B12 through depletion rescues the ΔB1 and ts2 growth phenotype, but
not other viruses with restricted DNA replication phenotypes.
The results thus far confirm that HA-B12ΔA690 is both truncated and may be less
stable than the HA-B12wt protein. We posited two possible scenarios to explain how the
enhanced replication of ΔB1mut12 may be mediated by the truncation and reduced
abundance of B12. Either a proviral activity of B12 is increased in ΔB1mutB12 due to
the absence of a regulatory domain lost after truncation, or wild-type B12 is capable of a
repressive activity that is no longer present in the ΔB1mutB12 virus. To distinguish
between these gain of function versus loss of function scenarios for the B12R indel
mutation, we decided to test how ΔB1 growth was impacted by B12 depletion mediated
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Fig 5.7. Depletion of B12 or B13 mRNA impact on neighboring gene expression. (A)
Depiction of B12R and B13R general regions targeted by siRNA for mRNA depletion
and probe/primer set binding of cDNA to quantify relative early gene expression using
qPCR. (B) CV1 cells were transfected with siRNA for 24h then infected with WT
(black), ΔB1 (red), or ΔB1mutB12-A3 (green) at a MOI of 3 and harvested 4h post
infection for mRNA isolation. The cDNA generated from harvested mRNA samples was
used with probe/primer sets in panel (A) to quantify early gene expression for B12R (B)
and B13R using either the probe/primers B13R.1 set (C) or B13R.2 set (D).
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by siRNA targeting of B12 mRNA. First, as controls, B12 mRNA levels for WT (black
bars), ΔB1 (red bars), and ΔB1mutB12 (green bars) were quantified at 4h post infection
in CV1 cells. Purified RNA was reverse transcribed to cDNA for qPCR quantitation of
relative B12 mRNA levels using a specific primer and probe set (Fig 5.7A). Each virus
expressed similar levels of relative B12 mRNA (Fig 5.7B, siCtrl). Second, we determined
the level of B12 depletion using siRNA targeting B12 mRNA. Transfection of CV1 cells
with siB12 prior to infection reduced relative B12 mRNA to <28% for each virus as
compared to control cells (Fig 5.7B). We also verified that downstream B13R gene
expression was not altered for the ΔB1mutB12 virus or during B12 mRNA depletion (Fig
5.7C and D) using two different B13 primer/probe sets (Fig 5.7A). We further validated
that these primer probe sets were specific for B13 by demonstrating that they were
sensitive to siRNAs specific to B13 (Fig 5.7C and D).
Upon successful B12 depletion using siRNA, we addressed the question of
whether B12 loss of function rescues the ΔB1 growth phenotype. To test the rescue of
ΔB1 plaque formation by depletion of B12, a plaque assay was carried out on CV1 siCtrl
and siB12 (four different siRNAs targeting the B12 mRNA) treated cells during WT,
ΔB1, and ΔB1mutB12 virus infections at 200 PFU/well (Fig 5.8A). We observed that
WT and ΔB1mutB12 viruses can form plaques on CV1 siCtrl cells and similarly on CV1
siB12 cells. Strikingly, the ΔB1 virus that is unable to form plaques on CV1 siCtrl cells
was able to form plaques in CV1 siB12 cells that were of a similar size as those present in
the wells infected with ΔB1mutB12. To quantify this rescue in viral yield, CV1 cells
were infected with WT, ΔB1, or ΔB1mutB12 virus at a low MOI of 0.01 for a multi-step
growth assay. Infected cells were harvested at 7h and 48h post infection. At 7h post
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Fig 5.8. Depletion of B12 rescues ΔB1 virus growth in CV1 cells. (A) 200PFU/well
WT, ΔB1, or ΔB1mutB12-A3 infections were carried out on CV1 cells 24h following
transfection with siCtrl or siB12. Cells were fixed 72h post infection. (B) Multi-step viral
yield assay was conducted in siCtrl or siB12 CV1 cells for WT (black), ΔB1 (red), and
ΔB1mutB12-A3 (green) infections at a MOI of 0.01. Cells were harvested at 7h or 48h
post infection and titration on CV1-B1myc cells. (C) Growth assays on siCtrl or siB12
transfected CV1 cells were completed for WT (black), ΔB1 (red), and ΔB1mutB12
(green) viruses at a MOI of 3 for relative DNA accumulation and (D) viral yield titration
on CV1-B1myc cells.

infection, each virus shows similar amounts of viral yield in CV1 siCtrl-treated cells and
CV1 siB12-treated cells (Fig 5.8B). This measurement at 7h post infection is indicative
of input virus. At 48h post infection, WT (black bars) and ΔB1mutB12 (green bars)
yields remain constant between control and B12 depletion (Fig 5.8B). By comparison, the
ΔB1 (red bar) virus increases 40-fold in the CV1 siB12 cells as compared to CV1 siCtrl
cells (Fig 5.8B).
Next, we quantified the rescue of DNA accumulation and viral yield following
B12 depletion during ΔB1 infection using a one-step viral growth assay. Both WT and
ΔB1mutB12 DNA accumulation levels are not significantly increased during infection of
CV1 siB12 cells as compared to CV1 siCtrl cells (Fig 5.8C). However, DNA
accumulation of ΔB1 increases 5.4-fold in CV1 siB12 cells compared to CV1 siCtrl cells.
Similarly, the viral yield for WT and ΔB1mutB12 viruses remains constant between CV1
siCtrl and siB12 infected cells while ΔB1 yields an increase of about 9-fold in CV1 siB12
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cells as compared to siCtrl treated cells (Fig 5.8D). In summary, the replication assays of
ΔB1 virus during B12 depletion indicate that the loss of B12 function rescues the ΔB1
phenotype. This siRNA study also refutes the gain of function scenario outlined earlier.
Specifically, if the indel mutation within B12R resulted in a gain of function, then the
depletion of the B12 mutant during ΔB1mutB12 infections should have restored the
attenuated ΔB1 phenotype during these infections, but it did not (Fig 5.8C and D,
compare siB12 ΔB1mutB12 to siCtrl ΔB1). Together, these data are consistent with the
model that the B12R indel mutation in ΔB1mutB12 causes a loss of B12 function, leading
us to infer that full length B12 is a repressor of ΔB1 growth.
It was interesting that siB12 treatment does not impact WT growth, but is only
apparent in the absence of the B1 kinase, indicating that the B12 repressive function may
not be active in the presence of B1. To explore this possibility further, we examined
whether B12 depletion would increase DNA accumulation of other replication deficient
vaccinia viruses, such as those with lesions in the D5 primase/helicase or E9 DNA
polymerase. We posited that if B12 inhibition is directly linked to a B1 mediated
pathway of promoting DNA replication, then depleting B12 will only rescue B1 mutant
or deletion viruses (Fig 5.9A). Alternatively, depletion of B12 may also rescue growth of
other replicative deficient viruses such as D5 or E9 mutant viruses, which would indicate
that B12 inhibits DNA replication via a more general mechanism of action (Fig 5.9A). In
order to determine which model fits B12 repressive function, we depleted B12 during
infection with WT or mutant viruses and assayed for DNA accumulation. Viruses used
for this assay included WT, ΔB1, a temperature sensitive B1 mutant (ts2) virus (68), a
temperature sensitive D5 primase/helicase mutant (ts24) virus (131), and a temperature
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Fig 5.9. Rescue of DNA replication block using siB12 is specific for viruses lacking a
functional B1. (A) Diagram of hypothesis that B12 is either a general inhibitor of DNA
replication or specific to B1 kinase mutant viruses. (B) CV1 cells treated with siCtrl or
siB12 were infected with WT (black), ΔB1 (red), ts2 B1 mutant (pink), ts24 D5 mutant
(blue), or ts42 E9 mutant (purple) at a MOI of 3 and harvested 24h post infection for
quantification of relative DNA accumulation. Infections were carried out at 31.5˚C, 37˚C
or 39.7˚C to provide permissive, semi-nonpermissive and nonpermissive temperatures
respectively for the temperature sensitive mutant viruses.
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sensitive E9 DNA polymerase mutant (ts42) virus (132). Infections were performed at
permissive temperature (31.5˚C), semi-permissive temperature (37˚C), and
nonpermissive temperature (39.7˚C). DNA accumulation was quantified using qPCR
during a synchronous infection of siCtrl or siB12 treated CV1 cells. The 24h DNA
accumulation for WT virus remains constant at all three temperatures, independent of
siB12 pre-treatment of cells (Fig 5.9B, black bars). The ΔB1 virus DNA accumulation
was attenuated compared to WT in siCtrl cells as previously published (127). Pretreatment with siB12 rescues the ΔB1 DNA accumulation 58-fold, 5-fold, and >9-fold as
compared to the siCtrl at 31.5˚C, 37˚C, and 39.7˚C respectively (Fig 5.9B, red bars). The
temperature sensitive ts2 B1 mutant virus follows a similar trend to the ΔB1 virus.
Specifically, at non-permissive temperatures the siB12 treated cells have increased DNA
accumulation 2-fold at 37˚C and >4-fold at 39.7˚C as compared to siCtrl cells for the ts2
virus (Fig 5.9B, pink bars). At permissive temperature the ts2 virus has similar DNA
accumulation as the WT virus as expected. Importantly, the rescue in DNA accumulation
observed for ΔB1 at all temperatures and for ts2 at non-permissive temperatures was not
observed for the other two viruses with restricted DNA accumulation. Explicitly, the ts24
(blue bars) and ts42 (purple bars) viruses have similar restricted DNA accumulation at
37˚C and 39.7˚C temperatures for CV1 siCtrl cells compared to CV1 siB12 cells (Fig
5.9B). In summary, these data demonstrate that the depletion of B12 specifically rescues
B1 mutant/deletion viruses, while B12 depletion does not enhance DNA replication for
temperature sensitive D5 (ts24) and E9 (ts42) mutant viruses.
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5.5. Reconstitution of B12 in CV1 cells represses ΔB1 and ΔB1mutB12 replication.
At this point we have shown that siRNA-directed loss of B12 rescues the ΔB1 and
ts2 virus growth, specifically by increasing DNA replication. This supports a model in
which B12 carries out a repressive function on DNA replication in the absence of a
functional B1 kinase. To complement our above B12 depletion studies, we next
hypothesized that expression of B12 from the cellular genome would be sufficient to
inhibit replication of viruses lacking B1. To test this hypothesis, we began by generating
cells stably expressing a HA-tagged or untagged codon optimized B12 (GeneArt). Codon
optimization for mammalian cells allows for enhanced expression of the gene by
mammalian cells and in our system codon optimized B12 is resistant to the siB12 used to
deplete B12 mRNA expressed by the virus. Expression of HA-B12 was confirmed using
immunoblot analysis of whole cell lysates from both control and HA-B12 lentivirus
transduced and selected CV1 cells (Fig 5.10A).
To test the repressive activity of reconstituted B12, we transfected control or HAB12 expressing CV1 cells with siCtrl or siB12 for 24h and then infected cells with WT,
ΔB1, or ΔB1mutB12 virus at a MOI of 3. The cells were harvested at 24h post infection
and relative DNA accumulation of each vaccinia virus was quantified using qPCR. Using
a combination of siB12 treatment during a ΔB1 infection and separately using the
ΔB1mutB12 virus allows us to test B12 repressive activity via restoration on two
different systems in which the viral B12 has been inactivated. First, we compared results
from cells treated with the control siRNA. In cells transfected with siCtrl, the DNA
accumulation for the WT virus is not altered by reconstitution of HA-B12 (Fig 5.10C,
siCtrl, black solid and striped bars). In contrast, the ΔB1 virus exhibited a 2.7-fold
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Fig 5.10. B12 reconstitution during infection with B1 and B12 naïve viruses
repressed vaccinia replication. (A) Immunoblot analysis of control or HA-B12
(GeneArt) lentivirus transduced CV1 cells was completed to detect tubulin (loading
control) and HA (HA-tagged B12). (B) CV1 control cells or cells stably expressing B12
or HA-tagged B12 were infected with WT or ΔB1mutB12-A3 at 300PFU/well and fixed
72h post infection. (C) 24h relative DNA accumulation quantification was completed for
CV1 control or HA-B12 expressing cells transfected with siCtrl or siB12 and infected
with WT (black), ΔB1 (red), or ΔB1mutB12-A3 (green) at a MOI of 3.

117

reduction in relative DNA accumulation in CV1-HA-B12 cells as compared to CV1-Ctrl
cells (Fig 5.10C, siCtrl, red solid and striped bars). Similarly, the relative DNA
accumulation for ΔB1mutB12 virus was 2.3-fold lower in HA-B12 expressing cells than
control cells (Fig 5.10C, siCtrl, green solid and striped bars).
Next, we compared cells in which viral B12 was depleted. In siB12 transfected
cells, the WT virus DNA accumulation was not altered by HA-B12 expression in cells
(Fig 5.10C, siB12, black solid and striped bars). Consistent with our model of B12
repressive activity during vaccinia virus infection in the absence of a functional B1
kinase, the DNA accumulation for the ΔB1 virus was 3.4-fold lower in HA-B12
expressing cells than control cells under siB12 conditions (Fig 5.10C, siB12, red solid
and striped bars). Lastly, the ΔB1mutB12 replication in HA-B12 expressing cells was
reduced 2.8-fold relative to control cells for siB12 transfected cells (Fig 5.10C, siB12,
green solid and striped bars). Importantly, B12 expression from the cell was sufficient to
inhibit DNA replication for both the ΔB1/siB12 and ΔB1mutB12 systems. These data
further support a model in which B12 can downregulate vaccinia virus DNA
accumulation in the absence of a functional B1 kinase.
Previously we demonstrated that depletion of B12 during a ΔB1 infection
allows the virus to carry out productive infection as measured by the formation of plaques
on CV1 cells (Fig 5.8A). To determine how reconstitution of wild-type B12 affects
vaccinia productive infection, we carried out a plaque assay of either WT or ΔB1mutB12
infected control, B12 expressing, or HA-B12 expressing CV1 cells. Cells were fixed
three days post infection. The WT virus plaque number and size was unchanged by the
expression of B12 or HA-B12 in cells as compared to the control CV1 cells (Fig 5.10B,
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top row). Strikingly, after infection with the ΔB1mutB12 virus there was a consistent
reduction in number and in size of plaques in both the B12 and HA-B12 expressing cells
compared to control CV1 cells (Fig 5.10B, bottom row). Thus, the addition of the wildtype B12 decreases ΔB1mutB12 productive infection, providing additional evidence that
B12 can impair poxvirus replication in the absence of B1.
5.6. Chapter 5 Summary
These studies in chapter 5 extend our understanding of B1 roles to promote DNA
replication by identifying viral factors that can contribute to vaccinia DNA replication in
the absence of the essential B1 kinase. Using experimental evolution of the B1 deletion
vaccinia virus we identified two significant mutations in only the B12R gene out of the
entire viral genome that rescued the viral fitness of ΔB1. We characterized the
B12ΔA690 mutant as a truncated protein, reduced 2-fold in abundance and the B12 G-A
mutant to have similar protein levels as the wild-type B12. Significantly. we also
determined that B12 loss rescued the replicative defect in the absence of the B1 kinase
(Fig 5.11). Furthermore, the role of B12 to repress DNA replication is not a dominant
phenotype when a functional B1 kinase is expressed (Fig 5.11).
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Fig 5.11. Model of B1-B12 signaling during vaccinia virus replication. The
contributes of this chapter to our working model includes the discovery that vaccinia B12
pseudokinase restricts vaccinia DNA replication and is regulated by vaccinia B1 kinase.
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CHAPTER 6
B12 MEDIATES RESTRICTION OF VACCINIA DNA REPLICATION VIA
INTERACTIONS WITH NUCLEAR FACTORS
6.1. B12 is predominantly nuclear and solubilizes separate from chromatin-bound
proteins.
To provide insight into the function of the B12 protein, we examined the
subcellular localization of transiently expressed HA-tagged B12 (GenScript) in CV1
cells. One day after transfection, cells were fixed, incubated with αHA primary antibody
with corresponding secondary antibody and stained with DAPI for immunofluorescence
imaging of cells. The HA-B12 expressing cells show a clear nuclear localization as
compared to control cells (Fig 6.1A, top row). By comparison, the B1 kinase localizes to
the cytoplasm (Fig 6.1A, bottom row), as published previously (127). Next, we tested
whether B1 expression in cells could alter B12 subcellular localization by examining
transiently expressed HA-B12 in cells expressing the myc-tagged B1 protein. The top
panels show that HA-B12 still exhibits a nuclear localization in cells expressing the B1
kinase (Fig 6.1B, top row). Additionally, the B1 kinase does not have altered localization
in the presence of HA-B12 expression and nuclear localization (Fig 6.1B, bottom row).
Therefore, B1 expression does not detectably redirect B12 localization in this assay.
Although B12 localized to the nucleus in uninfected cells, it is possible that B12
localization is different during vaccinia infection. To address this question, homologous
recombination within the nonessential viral TK locus was used to generate a WT/HAB12 recombinant virus expressing the transgene under an early and leaky late viral
promoter (Fig 6.1C). This inducible system also allows for increased HA-B12 late
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Fig 6.1. B12 exhibits a nuclear localization in uninfected and infected cells. (A) CV1
cells with or without HA-B12 (GenScript) mRNA transfection were used for
immunofluorescence detection of HA-tagged B12 (red, top row). CV1 control and CV1B1myc expressing cells were incubated with αmyc for B1myc detection (red, bottom
row). All cells were stained with DAPI nuclear stain (blue). (B) B1myc expressing CV1
cells were also transfected with HA-B12 (GenScript) mRNA and separately incubated
with a primary antibody to detect HA-tagged B12 (αHA, top red image) or myc-tagged
B1 (αmyc, bottom red image) and DAPI (blue) nuclear stain. (C) Plasmid schematic of
HA-B12 forms cloned into pJS4 vector under an early/late promoter and a leaky
tetracycline repressor. (D) CV1 cells were infected with WT or WT/HA-B12 virus at a
MOI of 5 and fixed at 4hpi or (E) 7hpi for immunofluorescence analysis of HA-B12
detection (red), I3 ssDNA binding protein (green) and DAPI nuclear stain (blue).

expression, occurring outside of the virion core, during doxycycline treatment which
restricts tetracycline (tet) repressor binding to the tet operator (Fig 6.1C). To assess HAB12 localization during infection, CV1 cells were infected with WT or WT/HA-B12
virus at a MOI of 5 and fixed at either 4 or 7hpi, chosen to coincide with times of peak
early gene expression and DNA replication. Interestingly, virus expressed HA-B12
exhibited a predominantly nuclear localization at 4 and 7hpi, (Fig 6.1D and E, αHA
panel) similar to that observed in uninfected cells. Furthermore, HA-B12 nuclear
localization was distinct from the viral, cytoplasmic replication factories as indicated by
puncta formation of vaccinia I3 single-stranded DNA binding protein (Fig 6.1D and E,
αI3 and αHA/αI3 panels). To further characterize HA-B12 nuclear localization, we
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examined B12 solubility in two separate assays. First using an immunofluorescence
based approach, we utilized a protocol in which cells are briefly treated with detergent
prior to fixation to separate highly soluble proteins from those more strongly tethered to
nucleic acids or cytoskeletal elements in the cell (133, 134, 146-150). Cells transiently
expressing HA-B12 or HA-GFP were either fixed then permeabilized or first
prepermeabilized (0.1% Triton X-100), followed by fixing cells and a second
permeabilization (0.2% Triton X-100) step. In CV1 cells fixed prior to permeabilization,
the control cells (top row) had low background after αHA incubation, the HA-B12
(middle row) had a nuclear localization, and HA-GFP expressing cells (bottom row)
showed diffuse localization of that protein (Fig 6.2A). For CV1 cells that were
prepermeabilized, the αHA columns for control cells (top row) had low background, HAB12 expressing cells (middle row) continued to exhibit bright, nuclear localization, while
HA-GFP expressing cells (bottom row) exhibited only background levels of green
fluorescence similar to the control cells (Fig 6.2B). In summary, pre-permeabilization of
cells was sufficient to solubilize HA-GFP from cells while HA-B12 was retained in the
nucleus under the same conditions. Together, these data suggest that B12 not only
localizes to the nucleus of uninfected or infected cells, but also interacts with unknown
binding partners there.
For comparison to the immunofluorescence based solubilization assay, we also
examined the B12 fractionation profile following sequential treatment with a
commercially optimized panel of extraction buffers. Following fractionation of control
CV1 and CV1-HA-B12 cells, western blot analysis was performed using equal
proportions of each fraction (Fig 6.2C). In addition to HA-B12, we examined the
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Fig 6.2. B12 nuclear localization is distinct from chromatin bound proteins. (A) CV1
cells were transfected with no mRNA, HA-GFP mRNA, or HA-B12 (GenScript) mRNA.
Cells were either fixed then permeabilized to detect HA-tagged proteins or (B)
prepermeabilized, fixed and then permeabilized again for detection of HA-tagged
proteins remaining in cells following washes to remove unbound protein. The DAPI
nuclear stain (blue) and αHA antibody (green) for detection of HA-GFP and HA-B12
were used. (C) Subcellular fractionation of CV1 control or HA-B12 (GeneArt) stably
expressing cells was completed to separate cells into cytoplasmic extract (Cyto.),
membrane extract (Memb.), soluble nuclear extract (Nuc.), chromatin-bound extract
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(Fig 6.2 continued) (Chrom.), and cytoskeleton extract (Cytoskel.). Lamin A/C, GAPDH
and BAF protein detection were used as fractionation controls and HA was used to detect
HA-tagged B12 protein.

abundance of GAPDH, lamin A/C, and BAF in each fraction. As expected, GAPDH was
most enriched in the cytoplasm with some also detected in the membrane fraction, but not
in the other fractions. Lamin A/C was enriched in fractions expected to contain nuclear
components and cytoskeleton. Previous studies have demonstrated that BAF is present
both in the nucleus, where it binds chromatin, and free in the cytoplasm as summarized in
a recent review article (151). Our results here are consistent with those data and show
BAF to be primarily present in a soluble form in the cytoplasmic fraction, and in a
chromatin-bound fraction. Interestingly, the HA-B12 protein was found primarily in the
soluble nuclear fraction. Detectable HA-B12 was also present in the cytoplasmic,
membrane and chromatin-bound extracts albeit at much lower levels. Together in concert
with the immunofluorescence assays, these studies indicate that B12 localizes
predominantly to the nucleus where it fractionates distinctly from BAF and likely other
chromatin associated proteins.
6.2. Wild-type B12 predominant nuclear localization correlates with B12 repressive
function.
To this point we have shown that B12 predominantly localizes to the nucleus even
during infection with the WT virus. However, it is unclear if nuclear localization is
necessary for B12 repressive activity on vaccinia DNA replication. To characterize the
connection between B12 nuclear localization and repressive activity we took two
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different approaches. The first approach was to test if B12 remained nuclear in infected
cells lacking the B1 kinase. Our current data support a regulatory function of the B1
kinase to defuse B12 repressive activity (Fig 5.9). Therefore, it is possible that in the
absence of the B1 kinase during infection, the B12 protein may carry out an abnormal
function, inconsistent with the phenotype during WT infection. For this experiment, CV1
cells were transfected with in vitro synthesized HA-B12 (GenScript), infected 24h post
transfection with WT, ΔB1, or ΔB1mutB12 at a MOI of 5, and fixed for
immunofluorescence analysis at 7h post infection. Primary antibodies for I3 singlestranded DNA binding protein (green) and HA epitope (red) were used to visualize
replication factories and HA-B12 respectively. During WT and ΔB1mutB12 infections
replication factories are visible at 7h post infection and are highlighted with white arrow
heads (Fig 6.3A, left and right columns), while the ΔB1 virus does not form replication
factories (Fig 6.3A, middle columns) consistent with a replicative block as shown
previously (Fig 3.2B and D). HA-B12 is predominantly nuclear in WT infected cells (Fig
6.3B, left columns) as shown with the WT/HA-B12 recombinant virus (Fig 6.1D and E).
Consistent with this phenotype, HA-B12 is also predominantly nuclear in ΔB1 and
ΔB1mutB12 infected cells (Fig 6.3B, middle and right columns). However, a striking
reduction in replication factories was observed in ΔB1mutB12 infected cells expressing
HA-B12 (Fig 6.3B, right columns), which was rescued in cells expressing both HA-B12
and B1myc (Fig 6.3C). It is important to note that HA-B12 protein may have localized to
the nucleus before viral infection. Despite this possibility, the ΔB1mutB12 virus still
exhibited an attenuated phenotype as visualized by a reduction in replication factories for
this experiment. One additional limitation of this experiment was the variability in HA-
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Fig 6.3. Wild-type B12 is nuclear during infection and mutant B12 proteins are
diffuse. (A) CV1 cells control or (B) transfected with HA-B12 (GenScript) mRNA and
(C) stable B1myc expressing cells were used for immunofluorescence detection of HAtagged B12 (red) during infection with WT, ΔB1, or, ΔB1mutB12 virus at an MOI of 5
and assayed for I3 (green) representing replication factories. (D) CV1 cells were
transfected with pJS4-HA-B12wt, (E) pJS4-HA-B12ΔA690 or (F) pJS4-HA-B12 G-A
plasmid and infected with WT virus at a MOI of 5 and fixed at 24h post infection for
immunofluorescence analysis of HA-B12 form (red), I3 (green), or nucleic acid stain
DAPI (blue).

B12 mRNA quality. This was inferred by differences observed in HA-B12 intensity when
assayed in immunofluorescence assays and inconsistent results in repression assays
where HA-B12 mRNA transfection was carried out to determine B12 repressive function
on I3 puncta formation during ΔB1mutB12 infection. Therefore, an alternative method of
HA-B12 expression may be necessary to clearly conclude that B12 is absent from
replication factories in the cytoplasm.
The second approach was to discern if the adapted virus mutations of B12R
altered B12 predominant nuclear localization. As we are unable to visualize B12
localization at replication factories or in the cytoplasm during infection with replicative
deficient B1 deletion viruses, it is possible that B12 nuclear localization is important for
its repressive function. The B12 protein is small enough to diffuse into the nucleus and
our data supports a B12 interaction with a host, nuclear factor to restrict diffusion of B12
out of the nucleus (Fig 6.2A and B). Therefore, we predicted that ΔB1 adapted virus
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mutations, ΔA690 and G215-to-A215, within B12R may alter B12 predominant nuclear
localization if B12 mutants lack a nuclear interacting partner. To determine the
localization of the mutant B12 proteins, CV1 cells were transfected with pJS4-HAB12wt, pJS4-HA-B12ΔA690, or pJS4-HA-B12 G-A plasmid DNA for expression of an
HA-tagged B12 protein under a late viral promoter. At 6h post transfection, cells were
infected with WT virus at a MOI of 5 and fixed 16h post infection for
immunofluorescence analysis. The HA-B12wt protein is predominantly nuclear with
some diffusion into the cytoplasm (6.3D), identical to the WT/HA-B12 recombinant virus
phenotype (Fig 6.1D and E). A striking change to diffuse cellular localization was
visualized for both the HA-B12ΔA690 (Fig 6.3E) and HA-B12 G-A (Fig 6.3F) mutant
proteins. These two approaches support a correlation between B12 predominant nuclear
localization and B12-mediated repressive activity. Due to incomplete repression of the
ΔB1mutB12 virus in HA-B12 add back experiments, it seems unlikely that undetectable
levels of HA-B12 in the cytoplasm are sufficient for repression of viral replication in the
absence of a function B1 kinase.
6.3. The ΔB1mutB12 virus is less sensitive to BAF antiviral activity than the ΔB1
virus correlating with altered BAF regulation.
The vaccinia virus B1 kinase regulates the antiviral protein BAF via
phosphorylation of its N-terminus, which inactivates BAF binding to dsDNA (98) and
repression of vaccinia virus DNA replication (69). To investigate whether a link exists
between BAF and the rescued growth phenotype of ΔB1mutB12, we measured both
phosphorylated BAF levels during ΔB1mutB12 infection and DNA replication of the
ΔB1mutB12 virus in cells overexpressing BAF. First for immunoblot analysis of BAF,
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CV1 cells were infected with WT, ΔB1, and ΔB1mutB12 viruses at a MOI of 10.
Infected cells were harvested at 6h post infection along with an uninfected control
sample, lysed in the presence of phosphatase and protease inhibitors and subjected to
immunoblot analysis. BAF specific antibodies recognizing either total BAF (phosphoBAF upper band and unphosphorylated BAF lower band) or only phosphorylated BAF
were used to detect protein levels under each condition. The total BAF levels were
similar between uninfected and each infected sample in multiple experiments (Fig 6.4A,
top row). Regarding phosphorylated BAF levels, lysates from WT infected cells
contained increased levels of modified BAF as compared to the uninfected control (Fig
6.4A, αPhospho BAF, compare lanes 1 and 2). In contrast, the ΔB1 infected cells show a
consistent reduction in phospho-BAF levels as compared to both uninfected and WT
infected cells (Fig 6.4A, αPhospho BAF, compare lane 3 with lanes 1 and 2).
Surprisingly, the ΔB1mutB12-A1 and ΔB1mutB12-A3 viruses had phospho-BAF
amounts that were repeatedly higher than the ΔB1 infected cells (Fig 6.4A, αPhospho
BAF, compare lanes 4 and 5 with lane 3), but not to the same level as those in WT
infected lysates. Consistent with this representative immunoblot, infection with
ΔB1mutB12-A1 or ΔB1mutB12-A3 virus clearly correlates with elevated phosphorylated
BAF as compared to ΔB1 infected cells in multiple biological replicates (Fig 6.4B-E).
This suggests that the absence of a functional B12 protein during ΔB1 infection correlates
with increased BAF phosphorylation and consequently may affect BAF’s antiviral
activity.
The intermediate level of BAF modification in ΔB1mutB12 lysates compared to
WT and ΔB1 infected lysates may impact BAF’s capacity to block viral DNA replication.
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Fig 6.4. ΔB1mutB12 virus infection enhances BAF phosphorylation as compared to
ΔB1 virus infection. (A) Immunoblot analysis of total BAF protein (top panel) or
phosphorylated BAF (bottom panel) in CV1 cells uninfected or infected with WT, ΔB1,
ΔB1mutB12-A1, or ΔB1mutB12-A3 at a MOI of 10. Cells were collected at 6h post
infection. (B) Immunoblot analysis in three biological replicates were used to quantify
total BAF protein and phosphorylated BAF in CV1 cells uninfected (grey) or infected
with WT (black), ΔB1 (red), ΔB1mutB12-A1 (light green), or ΔB1mutB12-A3 (dark
green). Protein levels were determined by chemiluminescence quantification using
ImageLab on chemidoc images and raw values were used to calculate phospho-BAF over
total BAF levels for biological replicate experiment 1, experiment 2 (C), and experiment
3 (D). (E) The phospho-BAF levels relative to total BAF levels were averaged for all
three experiments.

If true, one would predict that the ΔB1mutB12 virus may remain sensitive to BAF levels,
but to a lesser degree than the ΔB1 virus. To test this model, cells stably overexpressing
3XFlag-tagged BAF protein (~10-12 fold increased BAF protein as compared to
endogenous BAF levels) or control cells were infected with WT, ΔB1, or ΔB1mutB12A3 virus at a MOI of 3 and levels of DNA accumulation measured. The DNA
accumulation for WT, ΔB1, and ΔB1mutB12-A3 infected cells was reduced by 1.3-fold,
26-fold, and 7.5-fold respectively in Flag-BAF cells as compared to control CV1 cells
(Fig 6.5A). This data demonstrates a significant attenuation of both ΔB1 and ΔB1mutB12
DNA accumulation, but not WT virus, when BAF levels are increased. Furthermore, the
viral yield of WT, ΔB1, and ΔB1mutB12-A3 viruses were 5.8-fold, >51-fold and >10-
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Fig 6.5. The ΔB1mutB12 virus restriction of BAF antiviral activity is greater than
the ΔB1 virus. (A) Control or CV1 cells expressing 3XFlag-tagged BAF in excess were
infected with WT (black), ΔB1 (red), or ΔB1mutB12 (green) at a MOI of 3 and harvested
at 24h post infection for analysis of relative DNA accumulation or (B) viral yield titration
on CV1-B1myc cells.
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fold reduced in Flag-BAF cells than control CV1 cells (Fig 6.5B). It is interesting to note
that in the presence of increased BAF, the ΔB1mutB12 DNA accumulation and viral
yield levels are 19-fold and 45-fold higher respectively than the ΔB1 virus (Figs 6.5A and
B, compare green bars to red bars from cells expressing Flag-BAF). Combined, these
assays demonstrate a correlation between loss of B12 function and increased
phosphorylated BAF levels, and support the conclusion that ΔB1mutB12 virus represents
an intermediate sensitivity to BAF’s antiviral activity as compared to the ΔB1 and WT
viruses.
6.4. B12-mediated regulation of BAF phosphorylation activity is through an indirect
mechanism.
The B12 protein is known to be catalytically inactive (112). Therefore, mediation
of BAF phosphorylation levels may occur through a direct binding and sequestering from
a host kinase or through indirect regulation of a kinase or pseudokinase to act on the BAF
protein. In order to dissect a direct versus an indirect mechanism of B12-mediated
regulation of BAF phosphorylation levels, we tested B12 interaction with BAF in two
different assays. To begin, we used immunoprecipitation of αHA in HA-B12 expressing
cells and immunoblot of endogenous or FLAG-tagged BAF. From this assay we did not
show a significant enrichment of BAF bound to HA-B12 as compared to background
binding to HA conjugated beads incubated with FLAG-BAF cell lysate (data not shown).
For the reciprocal αFLAG immunoprecipitation, no HA-B12 was detected (data not
shown). Under these lysis conditions, a B12-BAF interaction is not strongly supported.
It is possible that the lysis conditions are too stringent to preserve the interaction
between B12 and BAF. Therefore, we postulated that if BAF interaction with B12
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tethered the pseudokinase to the nucleus we could observed a requirement of BAF for
B12 nuclear retention. To test this theory, we stably depleted BAF to ~14% endogenous
BAF levels using a lentiviral system packaging a shRNA for a non-specific/Ctrl target or
BAF targeted depletion (Fig 6.6A). CV1-shCtrl and –shBAF cells were transfected with
HA-B12 in vitro synthesized mRNA and either fixed at 24h post transfection (Fig 6.6B)
or permeabilized first followed by fixing of cells (Fig 6.6C) and immunofluorescence
analysis. Consistent with the tethered phenotype of B12 localization even following prepermeabilization (Fig 6.2A and B), both CV1-shCtrl (Fig 6.6B) and CV1-shBAF (Fig
6.6C) cells retained nuclear B12 following pre-permeabilization. Therefore, under
conditions in which B12 is retained in the nucleus due to a predicted interaction with a
host factor, depletion of BAF does not impact B12 nuclear retention. The
immunoprecipitation and immunofluorescence data do not support a B12-BAF
interaction.
6.5. B12 localizes to the chromatin during mitosis.
We have now shown that B12 regulates BAF phosphorylation, likely through an
indirect mechanism. The nuclear localized BAF is diffuse in non-dividing cells and
interacts with inner nuclear membrane proteins and DNA during mitosis (89, 152, 153).
In order to understand the role of B12-mediated regulation of BAF we asked if B12
expression could modulate nuclear inner membrane proteins and if B12, similar to BAF,
localized to the chromatin in dividing cells. First, to determine the impact of HA-B12
expression on the integrity of the nuclear membrane, we used immunofluorescence
analysis of emerin nuclear membrane protein and the nuclear pore complex proteins
which are imbedded in the nuclear membrane. CV1 cells were transfected with either
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Fig 6.6. B12 nuclear localization is not disrupted by BAF depletion. (A) CV1 cells
were transduced with shCtrl or BAF for stable depletion and harvested for immunoblot
analysis of tubulin and total BAF. (B) CV1 control or shBAF transduced cells transfected
with no mRNA or HA-B12 (GenScript) mRNA. Cells were either fixed then
permeabilized to detect HA-tagged proteins or (C) prepermeabilized, fixed and then
permeabilized again for detection of HA-tagged proteins remaining in cells following
washes to remove unbound protein. The DAPI nuclear stain (blue) and αHA antibody
(green) for detection of HA-B12 were used.
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HA-GFP or HA-B12 mRNA. 24h post transfection the cells were fixed, permeabilized
and incubated with HA, emerin, and nuclear pore complex (NPC) primary antibodies and
corresponding secondary antibodies. The HA antibody has low background in the control
well where no mRNA was added, diffuse HA-GFP detection throughout the cells, and
nuclear localization of HA-B12 (Fig 6.7A, left panels). Both emerin and NPC were
unaltered by HA-GFP or HA-B12 expression and remained localized to the nuclear
membrane and nuclear space in all conditions (Fig 6.7A, middle and right panels).
Therefore, the expression of HA-B12 in cells does not disrupt the nuclear membrane
shape or integrity of cells not going through mitosis. Next, we asked if B12 localized to
the chromatin during mitosis as we have shown diffuse localization in non-dividing cells.
For this immunofluorescence assay, CV1 cells were transfected with HA-B12 mRNA and
fixed 24h post transfection. DAPI nuclear stain and HA primary antibodies were used to
visualize DNA and HA-B12 respectively. Control cells not expressing HA-B12 had very
low background when incubated with the HA primary antibody and corresponding
fluorescent secondary antibody (data not shown). During prophase, HA-B12 is diffuse
within the nucleus corresponding to the DAPI stain (Fig 6.7B, Prophase). The nuclear
envelop disassembles at the end of prophase, yet HA-B12 maintains colocalization with
the chromatin from prometaphase to telophase (Fig 6.7B). BAF has been shown to
localize to the chromatin during late anaphase and telophase to contribute to the exit of
mitosis and reformation of the nuclear envelop (89, 94, 154). Interestingly, we did not
observe dysregulation of emerin localization during telophase (Fig 6.7C), which we
would expect if BAF interaction with emerin was disrupted. Nonetheless, obtaining
higher resolution images may be required to confirm that emerin disruption is not
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Fig 6.7. B12 is constitutively colocalized to cellular chromatin during mitosis. (A)
CV1 cells were transfected with no mRNA, HA-GFP mRNA, or HA-B12 (GenScript)
mRNA and fixed for immunofluorescence analysis of HA (red), emerin, nuclear pore
complex (NPC), and DAPI (blue). (B) HA-B12 mRNA transfected CV1 cells were fixed
for immunofluorescence analysis of nucleic acid stain DAPI (left column) and HA (right
column) of HA-B12 protein throughout mitosis, or (C) emerin during late anaphase and
telophase. Yellow arrowheads indicate the cell corresponding to the listed cell division
stage. Mitotic cells were manually selected from wide field images containing many
cells.

occurring in B12 expressing cells. Therefore, the B12-mediated regulation of BAF
phosphorylation levels may result in BAF retention on the chromosomes as observed
during VRK1 depletion (94). Further characterization of B12 impact on inner nuclear
membrane proteins is needed, preferably using high resolution imaging of protein
localization throughout mitosis and telophase.
6.6. B12 pseudokinase interacts with host VRK1.
In order to provide insight into potential cellular proteins interacting with B12 in
the nucleus we decided to optimize for HA-tagged B12 immunoprecipitation during
infection coupled with mass spectrometry analysis of B12-bound proteins. In an effort to
increase HA-B12 expression in infected cells we chose to use the WT/HA-B12
recombinant virus which expresses HA-B12 under an early/late, inducible promoter (Fig
6.1C). First, we wanted to determine the relative levels of B12 proteins expressed by the
WT/HA-B12 recombinant virus as compared to the WT virus and from the WT/HA-B12
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virus utilizing doxycycline to induce higher expression B12 levels. Many early vaccinia
proteins are expressed at low levels and antibodies specific to these viral proteins are not
sensitive enough to detect the protein at such low abundances. For this reason, we used
whole cell proteomics to determine relative B12 quantities for WT, WT/HA-B12, and
WT/HA-B12 with doxycycline at 7h post infection. CV1 cells were infected with virus at
a MOI of 10, harvested using RIPA buffer, and subjected to whole cell mass
spectrometry. WT/HA-B12 recombinant virus expressed B12 at levels 3.4-fold more
abundance than WT levels (Fig 6.8A). Addition of doxycycline during WT/HA-B12
infection increased B12 levels by 18-fold as compared to WT infection with doxycycline
treatment and 4-fold as compared to WT/HA-B12 without doxycycline (Fig 6.8A).
Using this inducible, WT/HA-B12 recombinant virus for increased expression of
the HA-B12 protein during infection, we asked if immunoprecipitation of B12 pulled
down any unique bands. CV1 cells were infected with WT, WT/HA-B12 or WT/HA-B12
with 50ng/ml doxycycline treatment at a MOI of 5 and harvested at 7h post infection. The
7h time point was selected to correspond with the start of peak vaccinia DNA replication.
This experiment was carried out in duplicate with one set of samples being used for a
silver stain of total protein bound to the immunoprecipitated HA-B12 and the other set of
samples for an immunoblot. The silver stain of the WT, WT/HA-B12 and WT/HA-B12
plus doxycycline treatment eluent samples showed a unique ~50kDa band for the
WT/HA-B12 viruses with and without doxycycline treatment that was not in the WT
sample. Intriguingly, the host VRK1 protein is 50kDa in size and localizes to the nuclear
compartment. Therefore, in addition to assaying for the HA-B12 protein in the
immunoblot we also assayed for VRK1 protein. Similar to the whole cell proteomics
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Fig 6.8. B12 immunoprecipitation identified VRK1 interaction and VRK1 is
proviral during ΔB1mutB12 infection. (A) CV1 cells were infected with WT (black
bar), WT/HA-B12, or WT/HA-B12 with 50ng/ml doxycycline treatment (blue bars). B12
normalized total spectra were graphed. (B) Cells were also harvested for
immunoprecipitation of HA-B12 and immunoblot of HA for HA-B12 or cellular VRK1.
(C) HAP1 control or VRK1 knockout cells were infected with WT (black), ΔB1 (red), or
ΔB1mutB12 (green) at MOI of 3 and harvested 24h post infection for DNA accumulation
quantification.

data, the input HA-B12 protein levels are 5-fold higher in doxycycline treated cells
infected with WT/HA-B12 than untreated cells (Fig 6.8B, compare αHA lanes 2 and 3).
Slightly greater HA-B12 protein levels are immunoprecipitated from WT/HA-B12 with
doxycycline lysates than without doxycycline treatment (Fig 6.8B, compare lanes 6 and
7). Protein levels of cellular VRK1 are similar for infected cells for input samples (Fig
6.8B, αVRK1 lanes 1-3). Enrichment of VRK1 protein was detected only in HA-B12
protein containing lysates and not for the WT infected control lysates, indicating a B12VRK1 interaction (Fig 6.8B, compare lanes 6 and 7 to lane 5). Importantly, this
interaction can be detected from lysates during WT/HA-B12 infection without
doxycycline.
6.7. VRK1 has pro-viral activity in the absence of the B1 kinase and B12
pseudokinase.
With the discovery of a nuclear factor that interacts with the viral B12
pseudokinase, we asked if the function of VRK1 is upstream or downstream of B12
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signaling to repress vaccinia DNA replication. We hypothesized that if the rescued DNA
replication and viral yield of the ΔB1mutB12 virus was VRK1 dependent then we would
observe a reduction in viral growth in VRK1 knockout cells. On the opposing side, if
VRK1 participated in a function upstream of B12 repressive activity, then we would
predict reduced viral DNA replication for the ΔB1 virus and not for the ΔB1mutB12
virus in the absence of VRK1. To test these hypotheses, we carried out a one-step viral
yield assay in HAP1 control and VRK1KO cells during WT, ΔB1 or ΔB1mutB12
infection at a MOI of 3. Cells were harvested 24h post infection. Neither WT nor
ΔB1mutB12 viral DNA accumulation was affected by VRK1 absence at 7 and 24h post
infection (Fig 6.8C). Intriguingly, the ΔB1mutB12 virus had ~2-fold lower relative DNA
accumulation in VRK1 knockout cells than in control cells at both 7 and 24h time points
(Fig 6.8C). This data supports VRK1 working downstream of B12, mediating a pro-viral
function in the absence of both the viral B1 kinase and B12 pseudokinase.
6.8. Chapter 6 Summary
These data summarized in this chapter addressed questions pertaining to B12 molecular
mechanism in both infected and uninfected cells. In brief, we discovered B12 localizes
predominantly to the nucleus of infected and uninfected cells (Fig 6.1). This nuclear
presence is due to a tight interaction with a nuclear factor, likely distinct from a direct
B12-DNA interaction (Fig 6.2) and B12 nuclear localization is likely necessary for its
repressive function (Fig 6.3). An intriguingly observation that links B12 to the antiviral
protein BAF was the correlation between the presence of the wild-type B12 protein and
reduced phosphorylated BAF levels (Fig 6.4). The B12 protein seems to move between a
diffuse nuclear localization in non-dividing cells and localize constitutively to the
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chromatin throughout mitosis (Fig 6.7). Furthermore, we identified a B12-VRK1
interaction and determined that the rescue of the ΔB1mutB12 virus is dependent on
VRK1 in the HAP1 cells (Fig 6.8). Together, this chapter of data contributes the
discovery of an indirect, B12-mediated restriction of BAF phosphorylation. In our model
of BAF antiviral effect on vaccinia DNA replication, more dephosphorylated BAF would
increase BAF antiviral activity (Fig 6.9). Additionally, VRK1 is also a part of B12
mediated regulation of vaccinia DNA replication (Fig 6.9). Although, VRK1 seems to
play a proviral function in the absence of B1 and B12.

Fig 6.9. Working model of B1/B12/BAF signaling during vaccinia infection. The B1
kinase participates in restriction of BAF’s antiviral function against vaccinia DNA
replication in the cytoplasm, while also repressing B12 negative regulation of vaccinia
DNA replication through an unknown mechanism that is partly mediated via BAF
regulation. Direct interactions and/or signaling through additional factors may be
required for B1-B12 signaling and B12-BAF signaling, and are depicted using gold lines.
B1-BAF interaction and BAF binding to dsDNA are direct interactions and denoted in
black lines. VRK1 contributes to a proviral function that is restricted by the B12
pseudokinase.
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CHAPTER 7
DISCUSSION
The sequence identity between the poxvirus B1 protein and the eukaryotic VRKs
is striking; approaching 40% within their respective catalytic domains (72). While genes
encoding protein kinases are present in other DNA viruses (65), none exhibit this level of
sequence identity to any host kinase. Viral mimicry of host signaling components is
often an indication of which cellular pathways are manipulated during the course of
infection. Thus, our working hypothesis is that B1 and VRKs share substrates important
to poxviral replication. This avenue of study has been fruitful in the past, leading to the
identification of BAF as a target of both VRKs and B1 (98) and revealing a novel
function for BAF in antiviral defense (69). In chapters 3 and 4, we characterize a B1expressing cell line and B1-deletion virus, which provide new insights into the function
and regulation of this critical viral protein. We then explore the impact of B1 deletion on
viral DNA replication in various cell types, focusing our efforts on the question of
whether the cellular VRK proteins can complement for the loss of B1 when they are
expressed at endogenous levels by the cell.
7.1. The severe replicative deficiency of ΔB1 revealed a BAF-independent function
for the B1 kinase.
Previous biochemical and genetic studies of the vaccinia B1 kinase utilizing
temperature sensitive viruses uncovered a pivotal role for this protein during genome
replication (75). Furthermore, earlier efforts to delete the B1 gene using homologous
recombination were unsuccessful (73), indicating that the fitness cost of B1 deletion is
severe. In this study, we have revisited the goal of constructing a B1 knockout virus,
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relying on a complementing cell line for B1 expression during the isolation of the new
virus. The stable expression of B1 in these cells also presented us with an opportunity to
characterize B1 in the absence of other viral proteins. We did not observe any difference
in growth rate or morphology of cells stably expressing B1, suggesting that expression of
this viral kinase is not toxic to CV1 cells. We also found that B1 was present throughout
the cytoplasm in uninfected cells, consistent with the fact that it does not possess a
sequence predicted to direct localization to the nucleus or other organelles. Interestingly,
in infected cells B1 colocalizes with I3, the viral ssDNA binding protein and wellestablished marker of viral replication factories. This recapitulates previous evidence that
B1 is present at viral factories (113); however, as B1 is expressed by the cell in our assay,
this new data suggests that B1 is actively recruited to sites of vaccinia DNA replication.
If this is indeed the case, we speculate that recruitment is driven by the ability of B1 to
interact with another protein, such as the viral H5 protein rather than viral DNA; B1 has
been previously demonstrated to interact with H5 in multiple assays (86, 155), but B1
does not have any domains predicted to directly bind to DNA. Recruitment of B1 to viral
factories may enhance its ability to phosphorylate important target proteins, such as the
fraction of cellular BAF that is nearest to viral DNA and thus the most imminent threat to
the virus. Importantly however, we found that BAF phosphorylation increases in B1expressing cells in a manner independent of infection. This extends previous in vitro data
indicating that other viral proteins are not needed for B1 phosphorylation of BAF (98),
but it remains possible that phosphorylation of other B1 substrates depends more heavily
on B1 localization to factories.
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Our characterization of the B1 deletion virus included direct comparison with the
Cts2 virus in multiple assays. As with Cts2, in CV1 cells the ΔB1 virus exhibits a
marked loss in viral progeny and impairment of viral DNA replication, although in both
regards the phenotype of the ΔB1 virus was more severe than Cts2. A significant
advantage of studying the ΔB1 virus is that the phenotype is also robust at 37˚C, allowing
us to examine B1 function in cell types that cannot tolerate higher temperatures needed
for the Cts2 phenotype. Depletion of BAF rescued replication of both Cts2 and the ΔB1
viruses, reaffirming the B1-BAF signaling axis; although the increase observed during
the ΔB1 infection was notably reduced as compared to Cts2. This observation either
demonstrates that BAF remains a potent antiviral even after depletion or suggests that
other important B1 signaling pathways are being disrupted in the complete absence of
this kinase.
Positing that the ΔB1 virus may exhibit some host tropism, due to either cell type
specific complementing kinases or downstream targets, we next examined the ability of
this mutant virus to carry out DNA replication and produce new virus in a variety of cell
lines. As a result of these studies it was clear that B1 is vital for production of new
infectious virus in all cell types. However, in regard to DNA accumulation, the cell lines
could be grouped into two categories. In BSC40, CV1, L929, and HeLa cells there was a
severe decrease in DNA replication; even when assayed late in infection the viral DNA
from a ΔB1 infection was 10% or less of the WT virus. In contrast, in HAP1 and A549
cells gross DNA accumulation was slower than WT, but was significant and by 24hr
approached WT levels.
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Together, chapter 3 data emphasizes the importance of utilizing both temperature
sensitive mutant viruses, such as Cts2, and single gene deletion viruses, ΔB1, in order to
provide insight into protein function. Herein, we added evidence to support a BAFindependent function of the B1 kinase to promote vaccinia DNA replication (Fig 3.6).
7.2. B1 is a viral mimic of host VRK2 as shown by partial complementation of B1
function by endogenously expressed VRK2.
The B1 kinase was shown to have a promiscuous phosphorylation activity in vitro, which
was in contrast to its cellular homolog VRK1 (98). To understand how B1 expression in
cells changes the cellular environment to promote vaccinia replication upon infection, we
postulated that transcriptome analysis of B1 expressing cells would reveal insights into
which cellular pathways B1 modulates. Not surprisingly, B1 expression in cells
downregulated transcription of genes involved in immune and stress responses (Fig 7.1).

Fig 7.1. Biological processes transcriptionally regulated by B1 expression. B1
expression in cells transcriptionally regulates stress/immune response, metabolism, signal
transduction, proteolysis, and vesicle transport in uninfected cells.
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An interesting finding from this data was B1 association with modulation of transport
signaling of the endoplasmic reticulum (ER) and Golgi apparatus (Fig 7.1).
Vaccinia replication factories are thought to form near ER membranes, and utilize
the membrane to partition the replication factory environment from the cytoplasm (156,
157). Furthermore, envelopment of mature virions following morphogenesis contains
membranes originating from endosomes (158) or the trans Golgi organelle (29, 30) and
utilizes retrograde transport from the early endosomes to the trans Golgi network for
membrane wrapping (159). Therefore, a role of B1 to support replication and
envelopment of the virus by modulating trafficking of proteins and vesicles is an
intriguing idea. From the analysis of changes in specific gene expression profiles, we
identified a role for B1 to upregulate expression of the sperm acrosome associated 6
gene, which is shown to be important for fusion of sperm with an egg during fertilization
(136). It is possible that vaccinia virus utilities this same protein to facilitate envelopment
of the mature virion or for budding from the cell. However, confirmation of
transcriptional regulation during infection is required before addressing questions of
possible utility by the virus during replication.
As referenced above, we characterized in chapter 4 a moderate replicative defect
of ΔB1 in HAP1 and A549 cell lines. To address the question of viral mimicry of host
kinases, we next hypothesized that cellular VRK activity may allow for genome
replication in HAP1 and A549 cell lines. To test this theory, we acquired HAP1 cell
lines altered at either the VRK1 or VRK2 gene using CRISPR/Cas9 mediated gene
editing. Immunoblot analysis using antibodies specific for each VRK failed to detect
VRK1 or VRK2 in the cell line in which that gene had been edited, thus validating these
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as single knockouts for either VRK1 or VRK2. We also monitored the rate of cell
growth for both the knockout and control cells and found they were very similar. This
was a surprising observation, as previous studies have demonstrated that depletion of
VRK1 can severely impair growth of MCF10a and MDA-MB-231 cells, while also
causing mitotic defects linked to reduced BAF phosphorylation (94). Indeed,
immunoblot of BAF levels present in VRK1KO cells reveal a clear reduction in the
slower migrating phosphorylated form of BAF as compared to control HAP1 cell,
consistent with a decrease in BAF phosphorylation in these cells. Future investigation
will be needed to determine why HAP1 cells tolerate the loss of VRK1 during mitosis.
Possible mechanisms include the activity of VRK2 or other kinases in the cell, which
may substitute for VRK1 in these cells.
Using these HAP1 cell lines, we next compared relative DNA accumulation,
protein expression and productive viral yield during infection with the WT and ΔB1
viruses. These studies indicated that loss of VRK1 in HAP1 cells has no effect on the
WT virus and only a minimal impact during ΔB1 infection. In comparison, loss of VRK2
had no significant effect during WT infection, but had a striking effect on the ΔB1 life
cycle. Specifically, while early gene expression in ΔB1 infected cells is unchanged, no
DNA accumulation nor late gene expression is observed in VRK2KO cells. This robust
block in DNA replication culminates in an additional 10-fold inhibition of virus
production as compared to the ΔB1 infected HAP1 control cells. Importantly, VRK2
depletion in A549 cells also decreases ΔB1 DNA replication and viral yield while having
no impact on WT infection, which supports the model that VRK2 functionally overlaps
with B1 in these cell lines.
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The seminal observation made by Boyle and Traktman that VRK1 can rescue
Cts2 replication if expressed from the viral genome laid the groundwork for the discovery
of BAF phosphorylation, which is now understood to be a regulator of that protein’s
antiviral defense and mitotic function. Interestingly, here we show that loss of VRK2
does not result in a discernable change in BAF phosphorylation in HAP1 cells and BAF
depletion has only a very modest effect on DNA replication in ΔB1 infected VRK2KO
cells. Together, these data are consistent with the working model depicted in Fig 4.8D).
We suggest that VRK2 complements for the loss of B1 via a novel mechanism, likely
involving phosphorylation of an important substrate other than BAF. While previous
studies from our lab indicate that B1 is needed for a step late in the viral life cycle in
U2OS cells (77), the data presented here provide a clear indication that B1 is needed at
the stage of DNA replication not only to inactivate BAF but also for other reasons in
some cells. Furthermore, the functions of B1 cannot be rescued completely by VRKs
during vaccinia virus life cycle.
7.3. Experimental evolution of ΔB1 exposed a DNA replication restrictive function
for proposed non-functional vaccinia B12 pseudokinase.
A growing body of evidence indicates that vaccinia kinases modulate multiple
signaling pathways, although which of these are consequential for viral fitness is less well
understood (160-165). A primary function of B1 is to inactivate the host defense activity
of BAF and allow DNA replication to proceed (69). Notably, in chapter 3 we describe an
incomplete rescue of a B1 deletion virus following shRNA-mediated depletion of BAF,
suggesting that additional important functions for B1 exist. To expand our current
understanding of B1 driven signaling we subjected the B1 deletion virus to experimental
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evolution. When coupled with whole genome sequencing, this allowed us to identify a
vaccinia mutation correlating with marked suppression of the fitness defect caused by the
deletion of the B1R gene. Experiments using this approach to investigate mechanisms of
poxvirus adaption after deletion of other genes have been performed previously,
revealing that these pathogens can undergo rapid genetic expansions to form an
‘accordion’ of copies of a compensating gene to enhance virus production (11, 12).
Other adaptation studies have demonstrated that alterations in a small number of amino
acids may be sufficient to detectably compensate for the loss of a gene (10, 166). In
contrast to these examples exploiting gain of function mutations to improve the fitness of
a mutant virus, the data presented here indicate that a divergent mechanism involving the
rapid disruption of a suppressor gene, B12R, is sufficient for enhancement of ΔB1 virus
replication.
The initial evidence of a link between B1 and the mutation of B12R was quite
compelling, as greater than 48% of the read counts included an indel at the identical
nucleotide site in two independently adapted ΔB1 viruses. The evidence that B12
mutation is linked to viral adaptation was further supported through targeted Sanger
sequencing of DNA isolated from individual plaques from all three adapted viral stocks.
A fascinating aspect of the major indel mutation is its location in a homopolymeric run of
eight adenines. Indeed, each of the less prevalent indel sites mapped via Sanger
sequencing was also within a homopolymeric run of 4-5 nucleotides. Such sites of
repeated sequence may cause polymerase stuttering and favor indel introduction, perhaps
contributing to how quickly the virus was able to adapt in our assay (167-170). Thus,
independent of our goal to discover novel interactions between B1 and other vaccinia
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Fig 7.2. Vaccinia B12 pseudokinase has homology to vaccinia B1 kinase and cellular
vaccinia-related kinases. (A) Vaccinia B1, B12, VRK1, and VRK2 proteins have a
conserved αC4 helix, which distinguishes these proteins from related casein kinases. (B)
Amino acid length and sequence identity of B1, VRKs and casein kinases as compared to
vaccinia B12 pseudokinase.
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genes, this study is insightful as an experimental model of reductive evolution during
poxvirus adaptation. Indeed, rigorous sequence comparisons of gene maps within
members of the Orthopoxvirus genus have led to the theory that gene loss has played a
defining role in adapting family members to specific hosts (9). Notably, these
bioinformatics analyses predicted that indels introduced at simple sequence repeats
within viral ORFs are likely a common molecular mechanism for gene fragmentation (9).
Our data now provide strong experimental evidence that indel introduction can indeed
occur rapidly at homopolymeric sequence repeats during viral replication, causing gene
loss. Of further significance, it is clear that reductive evolution can lead to substantial
fitness gains for these pathogens and may be a stronger selective pressure on viruses than
previously appreciated.
Upon discovering the frame-shifting indel present within the B12R gene we
compared the amino acid sequence identity with other casein kinases, including a small
group that contained a unique αC4 helix (Fig 7.2A). Similar to previous comparisons, the
vaccinia B12 is most similar to vaccinia B1, yet also exhibits 32% shared identity with
the cellular VRK1 (Fig 7.2B). As stated before, B12 is a catalytic-null protein (114).
Specifically, the three critical domains required for phosphotranserase activity form a
catalytic pocket as highlighted in yellow on the VRK1 crystal structure (Fig 7.3A). Both
B1 and VRK1 have these domains required for ATP binding, phosphotransfer, and
catalysis conserved (Fig 7.3B). However, B12 is missing or has amino acid changes at
each of these specified domains (Fig 7.3B). Therefore, it is unlikely that B12 is
complementing the absence of B1 via a canonical phosphotransferase mechanism. Thus
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Fig 7.3. Domains required for B1 and VRK1 catalytic activity are missing in the B12
amino acid sequence. (A) The crystal structure of VRK1 with highlighted domains
required for catalysis (1-3) the kinase pocket. (B) Amino acid residues required for
catalytic activity are present in B1 and VRK1, but absent from B12 sequence.
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speculated that a non-canonical mechanism of phosphotransferase activity could be
enhanced by the indel mutation observed in the adapted virus B12R.
Alternatively, a loss of function could also result from the frameshift induced by
the indel within B12R. To support this hypothesis, VRK1 truncation studies determined
that removal of the most C-terminal alpha helix results in an insoluble protein when
expressed in E. coli (145), which is highlight in blue (Fig 7.4A, VRK1). Using a
modeling website, we constructed the predicted three-dimensional structure of vaccinia
B1 and B12 in order to map the adenine indel (red) and SNP (pink) onto the B12 protein
with reference to the C-terminal αhelix (blue) in figure 7.4A and B. These models
illustrate a further truncation of the B12 protein beyond the C-terminal alpha helix,
suggesting if B12 has similar structural requirements as VRK1 we could expect this
protein to be unfolded. Furthermore, the SNP is located in a loop structure, known to
have increased flexibility than structured beta sheets and alpha helices. It is possible that
this mutation affects the nearby alpha helix, however functional studies are required to
make this conclusion. With these two possible outcomes in mind, we were curious to
learn how the adapted virus mutations altered B12 protein function.
We posited that the truncation of B12 may enhance viral fitness either via a loss
of B12 function or a gain of function, the latter scenario possible if the truncation
removed a theoretical autoinhibitory domain from the protein. Experiments employing
siRNA to deplete B12 led to three important observations, allowing these two
possibilities to be distinguished. First, in the presence of siB12, the replication of ΔB1
virus DNA and yield of progeny virus increased to levels very similar to that observed
with the adapted ΔB1mutB12 virus in most cell lines tested. This outcome supports the

157

Fig 7.4. B12 predicted three-dimensional structure. (A) Crystal structure of VRK1
with highlighted helix (blue) corresponding to the truncated, insoluble protein and
predicted vaccinia B1 kinase with the same C-terminal helix highlighted as VRK1. (B-D)
B12 predicted vaccinia B12 psuedokinase with C-terminal helix highlighted (blue) and
helices removed during B12 mutations from ΔB1mutB12 viruses (red). (D) The point
mutation in B12 from the ΔB1mutB12 virus is highlighted (pink).
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loss of B12 function scenario. Second, while siB12 treatment led to the same decrease in
B12 mRNA from the ΔB1 virus and the ΔB1mutB12 virus, there was no reduction in
DNA accumulation or viral yield from the ΔB1mutB12 virus with siB12 treatment
arguing against a gain of function mutation. Third, while siB12 enhanced the replication
of the temperature sensitive Cts2 B1 mutant virus, it did not affect the WT virus or other
mutant viruses that exhibited reduced DNA replication at less permissive temperatures
because of defects in the vaccinia polymerase or primase/helicase proteins. This third
point emphasizes that the repressive function of B12 is controlled by the B1 kinase.
Together, these assays demonstrate that loss of B12 can suppress the fitness defects of B1
mutant viruses, but does not enhance replication of viruses containing a wild-type B1R
gene.
These genetic data are consistent with a model in which the B12 pseudokinase is
capable of acting as a repressor of vaccinia replication in a B1-dependent manner. The
inference that B12 function is masked by B1 is also consistent with previous single gene
knockout studies of B12. Specifically, thorough examination of a virus lacking the
majority of the B12R gene revealed no detectable change in viral fitness in cell culture or
mouse pathology as compared to WT virus controls (114, 115). Those results led to B12
being designated as one of the nonessential genes of vaccinia, which is also supported by
the fact that although the B12R gene is present in all members of the Orthopoxvirus
genus, the closely related taterpoxvirus and variola virus have a nonsense or deletion
mutation, respectively, in their B12 homolog (167). However, our studies demonstrate
that while nonessential, B12 pseudokinase is not without function. Furthermore, our
work adds to a growing body of evidence indicating that poxvirus genes categorized as
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nonessential in tissue culture and in vivo studies based on single gene deletions should be
investigated in multigenic knockout backgrounds, especially if they belong to gene
families (171).
7.4. B12 nuclear localization and interactions contribute to the replicative defect of
ΔB1.
To understand the possible ramifications of our B1/B12 model we find it
informative to draw from virology as well as potentially analogous systems in the broader
scientific literature. For example, the signaling relationship exhibited by B1 and B12
demonstrates similarity to features of toxin-antitoxin (TA) systems common in bacteria
or poison-antidote modules more recently uncovered in higher organisms (172-180).
While TA systems proceed via diverse and often poorly understood molecular
mechanisms, they are generally comprised of two genes, one of which is capable of
decreasing the overall fitness of the organism and is referred to as the toxin. Critically
however, the toxin’s repressive activity is inhibited in cells expressing a cognate antitoxin
gene product. In some instances, the TA system is regulated by upstream signals that can
influence antitoxin stability and/or activity, thus potentially benefiting an organism by
slowing its growth in response to stress (172, 173, 175, 181). However, in other
examples, TA modules provide little or no known benefit for their host, instead behaving
as a type of ‘selfish’ genetic element, perhaps to ensure their conservation in an organism
by addicting the organism to an antidote against the TA encoded ‘poison’ protein (176,
177, 182). As described herein, some attributes of toxin-antidote genetic elements also
apply to the B1 and B12 pair. Consideration of parallels between B1/B12 signaling and
TA systems has implications beyond poxviruses; this viral kinase and pseudokinase
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exhibit high sequence similarity to a family of mammalian proteins known as the VRKs
(vaccinia related kinases) also containing kinase and pseudokinase domains (70, 72, 124).
Thus, it is conceivable that the mammalian VRK family members and possibly some of
the other numerous kinase-pseudokinase pairs in nature exhibit features of TA modules
as well.
Returning to our data of B12 repressive activity, we have begun to dissect the B12
mechanism of action. Due to the apparent antagonism of B12-mediated repression in the
presence of B1, we were interested in examining where B12 localized in cells with
respect to the B1 kinase. We hypothesized that B12 may be localized to the cytoplasm
where the B1 kinase is found in both uninfected and infected cells (113, 127). However,
we were somewhat surprised to find that B12 is found predominately in the cell nucleus,
even in cells expressing the B1 kinase in the cytoplasm and in vaccinia infected cells.
Solubilization studies suggest that B12 is tethered to an unknown partner protein in the
nucleus; it is tempting to hypothesize that identifying this partner may provide a clue as
to B12’s mechanism of action.
Our data support a nuclear function for B12 to restrict virus DNA replication.
However, we were curious if B12 would localize to viral DNA at cytoplasmic replication
factories in viruses lacking the B1 kinase. Strikingly, we observed B12 nuclear
localization in HA-B12 mRNA transfected cells infected with ΔB1mutB12 virus in
conjunction with reduced formation of replication factories. We next hypothesized that if
B12 nuclear localization was necessary for its repressor function, we would observe
disrupted nuclear localization with the mutant forms of B12 from the adapted ΔB1
viruses. The mutant B12 proteins, B12ΔA690 and B12 G-A, had a diffuse localization in
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infected cells. Therefore, all our data to this point indicate an indirect function of B12mediated restriction of virus DNA replication via mechanisms that initiate in the nucleus.
We can only speculate as to the function of B12 in the nucleus at this time. Other
poxviral proteins including C4 (183), C6 (184), C16 (185), B14 (186), K7 (187), N2
(188), F16 (116), and E3 (189) can be detected in the nucleus and have been found to
impact innate immune signaling in most cases. However, there is no precedent to date for
a nuclear poxviral protein affecting viral DNA replication. Intriguingly, the B12
connection to B1 may also partly incorporate BAF. This B1-regulated antiviral host
factor is prevalent in both the nucleus and cytoplasm (Fig 7.5A). For this reason, we
investigated how the presence of B12 affects the ability of BAF to act as a host defense
against vaccinia. Measurement of phosphorylated BAF levels in infected cells
demonstrated that WT virus led to a clear increase in BAF phosphorylation when
compared to ΔB1 infected cells, as has been previously published (127). Interestingly,
BAF phosphorylation in ΔB1mutB12 infected cells was greater than in ΔB1 infected
cells, albeit not to the same levels as during WT virus infection. Parallel studies of viral
yield in cells overexpressing BAF demonstrated that inhibition by BAF was strongest on
the ΔB1 virus and, while still observed during ΔB1mutB12 infection, BAF affected this
adapted virus to a lesser degree. These data suggest a model in which B12 functions via
a BAF dependent mechanism, albeit only in part. Specifically, our previously published
data that BAF-depletion only modestly rescues the ΔB1 phenotype (127) leads us to
propose that B12 is also working through a distinct and BAF-independent pathway (Fig
6.9). It is provocative to consider that this pathway may be executed or triggered by B12
from within the nucleus.
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Fig 7.5. Subcellular localization and working signaling model of vaccinia B1 kinase
and B12 pseudokinase. (A) The vaccinia virus B1 kinase is predominantly cytoplasmic
with BAF and VRK2 bound to the ER membrane. BAF also have a nuclear fraction with
cellular VRK1 and vaccinia B12 pseudokinase. (B) Vaccinia proteins (red) and cellular
kinases (blue) regulate the host BAF antiviral activity and vaccinia virus DNA
replication. B12 repressive function on DNA replication is mediated via a BAF
dependent and independent pathway. VRK1 was also shown to promote DNA replication
in the absence of the B1 kinase, but is restricted or modulated by the B12 protein.
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In order elucidate how B12 regulates BAF phosphorylation levels, we utilized
immunoprecipitation of HA-B12 to assay for an interaction between B12 and BAF. We
were surprised to observed no enrichment of BAF from HA-B12 eluents as compared to
background control. Therefore, our data does not support a direct interaction between
B12 and BAF. In cells, BAF is known to play important roles to mediate efficient exit
from mitosis and nuclear envelope reformation via interactions with inner nuclear
membrane proteins and chromosomes (89, 152, 153). It is possible that B12 regulates
BAF indirectly, through modulation of factors that regulate or interact with BAF. For this
reason, we chose to ask if B12 expression in cells results in changes to the nuclear
membrane structure. No changes were observed. However, BAF also interacts with inner
nuclear proteins and chromatin during late anaphase and telophase stages of mitosis. To
elucidate at what stage during the cell cycle B12 may impact BAF phosphorylation levels
the most we turned to the images of cells going through mitosis. Shockingly B12, despite
lacking a DNA binding domain, remains colocalized with the chromatin throughout all of
mitosis (Fig. 6.7B). The cellular paralog of B12, VRK1, is known to interact with
histones (93) and transcription factors (142, 190-192) on the chromatin but releases from
the chromatin during metaphase and anaphase (193). Alternatively, the AURKB is a
kinase regulator of mitosis that phosphorylates histone proteins (194). This kinase
similarly releases from the chromatin during anaphase of mitosis (193). Intriguingly,
BAF is shown to be diffuse and then bind to chromatin during anaphase and telophase
(154). The constitutive localization of B12 with the chromatin during mitosis is unclear,
and will require further study for functional validation.
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As a final step in these current studies to determine a function for the B12 protein,
we strove to identify host and viral protein interactors. We were able to identify a strong
interaction between B12 and the cellular VRK1 protein during infection (Fig 6.8B). The
VRK1 protein is known to phosphorylate BAF in the nucleus to regulate chromatin
condensation (89, 94, 98). This kinase is also known to regulate cell division at multiple
levels (93, 98, 142, 143), modulate Gogli fragmentation (140), and DNA damage
response (190, 195, 196). Furthermore, it is possible that VRK1 modulates B12 as an
upstream component of signaling and B12 regulation. Alternatively, VRK1 could
participate in a downstream function related to repression of vaccinia virus DNA
replication. By using the VRK1 knockout HAP1 cells, we discovered that VRK1 activity
contributes to the rescue of the ΔB1mutB12 virus replication. This data supports a
function of VRK1 downstream of B12, and suggests that B12 may be restrictive of
VRK1 activity which results in virus replicative deficiency in the absence of the B1
kinase. To speculate on the impact of this data, we predict that VRK1 may complement
for a B1 function for viral DNA replication. However, the B12 pseudokinase may restrict
VRK1 activity in a WT infection to mediate evasion of innate immunity or another yet to
be determined function.
7.5. Conclusion
The findings discussed in this PhD dissertation thesis can be summarized into
three major discoveries as summarized (Fig 7.5A and B). 1) VRK2 partially complements
the function of the vaccinia B1 kinase during infection. 2) The B1 kinase and vaccinia
B12 pseudokinase represent a digenic relationship of genetic and functional linkage. 3)
The B12 psuedokinase is a negative regulator of vaccinia DNA replication via BAF-
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independent and dependent pathways. These discoveries highlight the interconnectedness
of the cellular VRKs and the viral kinase/pseudokinase pair, providing insight into viral
mimicry and our ongoing question of how poxviruses lacking a B1 protein replicate.
As in the case of the B1-BAF axis where parallel study of VRK1 was insightful,
future study of VRK2 and B1 will likely yield clues regarding which other pathways are
modulated by the B1 kinase. Published research of VRK2 provides a list of candidate
signaling cascades which may be involved. For example, VRK2 has been reported to
modulate MAP kinase signaling pathways at the ER, in part via interaction with the KSR
scaffolding protein (197, 198). Additionally, VRK2 appears to act as an apoptosis
regulator in some studies, inhibiting cell death via interaction with Bcl-xL or by altering
BAX gene expression (95). An investigation of these pathways in conjunction with
structure / function studies of VRK2 are ongoing in our lab. Yet, the most promising link
between VRK2 and B1 seems to be a shared regulation of vaccinia B12. Future studies
will shed light on the molecular mechanisms underlying VRK2 and B1 shared functions,
providing greater insight into how host and viral signaling converge during poxviral
infection.
Our continued study of the vaccinia B1 kinase using the ΔB1 virus has yielded
numerous unexpected insights into poxvirus adaptation pathways and signal transduction
circuitry. Our results evince that B1 contributes to viral fitness via antagonism of BAF
and B12 proteins, and raise new questions regarding the underlying mechanism of action
for this pseudokinase and how it is governed by B1. The findings of B12-VRK1
interaction and VRK1 requirement for maintenance of the ΔB1mutB12 rescued
phenotype, distinguishes a dependence on VRK1 in the absence of B1 and B12.
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Fig 7.6. Working model of BAF regulation by cellular and viral kinases and
pseudokinase. Vaccinia B1 kinase and cellular VRK2 proteins phosphorylate BAF in the
cytoplasm to restrict BAF antiviral activity against vaccinia DNA replication. The
vaccinia B12 pseudokinase restricts host VRK1-mediated phosphorylation of BAF in the
nucleus. VRK1 inhibition retains BAF in the nucleus in an unphosphorylated form that
would otherwise traffic to the cytoplasm, dephosphorylated, and mediate antiviral activity
against viral DNA.
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To speculate briefly, B12 restriction of BAF phosphorylation could occur in order
to retain BAF in the nucleus (Fig 7.6). In the absence of B12, VRK1 contributes to the
phosphorylation of BAF and BAF cycling between the nucleus and the cytoplasm (Fig
7.6). However, if this model is correct we would expect VRK1 to inhibit vaccinia DNA
replication when both B1 and B12 are absent. Specifically, VRK1 phosphorylated BAF
would rapidly move from the nucleus to the cytoplasm where it is dephosphorylated and
ready to restrict vaccinia replication. Is this model flawed or simply incomplete? It is
possible that VRK1 signaling of other pathways buffers the negative impact of BAF
antiviral activity. Therefore, manipulation of pathways known to be regulated by VRK1
is of interest to identify which pathways are necessary for ΔB1mutB12 propagation.
Another interesting aspect of this research is the result that B1 requirement is in
part to neutralize B12 repressive activity during vaccinia replication. Future investigation
of whether the inhibitory action of B12 extends to other poxviruses including those
lacking a B1 kinase, and perhaps even other pathogens, will be particularly intriguing.
Finally of broader relevance, pseudokinase domains are prevalent in diverse eukaryotic
organisms (118, 199), however this is the first example of a function for a viral
pseudokinase. The study of B12 pseudokinase and paralog B1 kinase will likely be of
broad biological interest.
7.7. Future Directions
We recently discovered that vaccinia encodes a self-repressor, B12 pseudokinase,
that modulates host VRK1 to inhibit vaccinia DNA replication. The cellular factor,
VRK1, is known to promote proliferation and metastasis of some cancers (139, 200,
201), while mutations or deletions of VRK1 cause microcephaly among other

168

neurological deficiencies (141, 202, 203) and infertility (88, 92), respectively. We have
identified a novel system to study VRK1 roles during vaccinia virus replication by
elucidating the mechanism of action for a viral pseudokinase that modulates VRK1
function. At this time, we have not characterized the mechanism of how B12
pseudokinase modulates VRK1 activity to restrict virus DNA replication. However, this
gap in knowledge will provide insight not only to viral DNA replication, but also
generally to aspects of chromosomal maintenance in proliferating cancer cells, fetal
neuronal developmental, and particular signaling pathways regulated by VRK1.
Specifically, the findings from studying this system will contribute to our understanding
of how the viral pseudokinase regulates VRK1 and through which signaling pathways
VRK1 complements the essential mechanism of viral DNA replication. Furthermore,
unveiling novel methods of VRK1 regulation is translatable to treatment of certain
cancers and will enhance our understanding of VRK1 roles during infertility and
neurological development deficiencies. Our long-term goal is to identify B1-VRK
shared signaling pathways that are required for vaccinia virus efficient DNA replication.
In order to achieve this goal and fill the current gap in knowledge, our overall objective
is to elucidate the mechanism how B12 modulates VRK1 activity and determine how
VRK1 regulates vaccinia virus DNA replication in the absence of functional B1 and B12
proteins.
The central hypothesis is that VRK1 and B1 kinase have a shared function to
regulate vaccinia DNA replication. VRK1 and B1 are known to regulate a shared
substrate, BAF (98). Additionally, human VRK1 expressed by the virus can rescue the
growth deficiency of a B1 mutant virus (73), supporting an overlapping regulation of
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signaling pathways necessary for vaccinia DNA replication. Importantly, multiple lines
of evidence detailed in this thesis dissertation support a primarily BAF-independent
mechanism in which VRK1 complements vaccinia DNA replication when expressed
from its endogenous locus in the cell (chapters 3 and 6). Therefore, the rationale of
addressing this central hypothesis is to extend our understanding of vaccinia DNA
replication modulators and clarify our interpretation of how these viral and cellular
homologs regulate each other and participate in shared or divergent signaling pathways.
Aim 1: Determine how B12 modulates VRK1 signaling activity. We hypothesize that
B12 acts as an adaptor protein to VRK1 to regulate interactions with specific substrates
thus modulating VRK1 kinase activity.
Experiment 1: Does B12 restrict VRK1 catalytic activity in vitro? In vitro analysis of
VRK1 catalytic activity was completed with heat inactivated lysates and showed VRK1
auto-phosphorylation and BAF phosphorylation (98). We predict that addition of B12 to
this assay will show restriction of BAF phosphorylation typically mediated by VRK1,
and enhanced phosphorylation of novel VRK1 substrates.
Experiment 2: Does B12 inhibit VRK1-mediated phosphorylation of BAF in cell culture?
Based on our previous studies that B12 expression during ΔB1 infection leads to less
phospho-BAF (chapter 3 and 6) and the dependence on VRK1 for ΔB1mutB12 virus
rescued phenotype (chapter 6), we predict that B12 restricts VRK1-mediated
phosphorylation of BAF. Therefore, we expect VRK1 knockout cells or VRK1 depletion
will reduce phosphorylated BAF levels during a ΔB1mutB12 infection as compared to
cells expressing endogenous levels of VRK1.
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Experiment 3: Does B12 modulate VRK1 colocalization with chromatin during mitosis?
VRK1 is known to bind and phosphorylate histones (93), and similar to B12, colocalizes
with chromatin during prophase, prometaphase, and telophase stages of cell division (93,
193). However, our recent studies revealed that unlike VRK1, B12 remains localized to
the chromatin throughout mitosis (chapter 6). Intriguingly, we noticed two instances
where B12 expressing cells in late anaphase stages contained chromatin bridges, which
were not observed for GFP expressing control cells (data not shown). The presence of
chromatin bridges indicates compromised chromosomal integrity during segregation
(204-206). With these pieces of data in mind, we predict that B12 nuclear presence will
dysregulate VRK1 chromatin localization during mitosis.
Aim 2: Determine how VRK1 complements vaccinia virus DNA replication in the
absence of the B1-B12 digenic pair. Our hypothesis is that VRK1 phosphorylation of
key substrates, particularly those involved in DNA damage response and mitosis, allow
for both host and virus DNA replication.
Experiment 1: Is VRK1 catalytic activity required for rescued fitness of the ΔB1mutB12
virus? Almost all of VRK1 cellular functions require catalytic activity. The sole catalyticindependent function of VRK1 is during neuronal migration (141). Furthermore, B1
regulation of vaccinia virus DNA replication is kinase dependent (68, 73, 75). Based on
these data, we predict that catalytic activity is required to promote ΔB1mutB12 virus
replication. We will test this question using VRK1 kinase dead protein expression in
VRK1 knockout cells and assay for ΔB1mutB12 virus DNA replication as compared to
VRK1 knockout cells.
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Experiment 2: Does depletion of BAF rescue the attenuation of ΔB1mutB12 in VRK1
knockout cells? We have not directly tested this, however our indirect evidence indicates
that B12-VRK1 repression of B1 deletion vaccinia virus replication is only modestly
BAF dependent (chapters 3 and 6). For this reason, we predict that depletion of BAF will
only modestly rescue the growth defect of ΔB1mutB12 in VRK1 knockout cells.
Experiment 3: Does restriction of the DNA damage response negate the requirement of
VRK1 for ΔB1mutB12 replication? As mentioned above, there were two instances were
cells expressing B12 had chromatin bridges connecting the segregated chromosomes
during late anaphase (data not shown). It is therefore possible that changes to the cellular
DNA, including subtle changes less extreme than chromatin bridging in late anaphase,
activate the DNA damage response. Therefore, during infection both host and viral DNA
replication would be susceptible to DNA damage signaling. Therefore, we predict that
suppression of the DNA damage response during ΔB1mutB12 infection of VRK1
knockout cells will enhance viral DNA replication.
The findings of these proposed studies will impact our interpretation of virus
mimicry of host proteins and determine the extent of overlapping pathways for these
cellular and viral kinase homologs. The signaling mechanisms elucidated inform which
cellular pathways can be targeted by the virus using catalytically active and dead
proteins, articulating how viral pseudoenzymes modulate the host environment.
Furthermore, understanding how the cellular VRK1 is regulated by vaccinia B12
pseudokinase will determine the translation potential of B12 as a drug to target VRK1
and/or use as a tool for manipulation of VRK1 in different disease models.
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